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ABSTRACT 
Serine proteases are involved in a number of physiological processes and have proved 
to be a valuable therapeutic target in the treatment of disease states resulting when the 
above processes move beyond homeostasis. The investigation of low molecular weight 
compounds as irreversible and reversible inhibitors of serine proteases has been fueled 
by the possibility of rational drug design and their use as meehanistic probes of enzyme 
action. As introduced in Chapter one particular attention has been focused on 
mechanism-based inactivators as these elicit clinically desirable specific, efficient and 
irreversible inhibition. The synthesis and assay of funtionalised imide mechanism-
based inhibitors of the serine protease a-chymotrypsin is the subject of this thesis. 
N-[(Sulfonyl)oxy]succinimides of type 1.41 (L = S02R') are known mechanism-
based inhibitors of a-chymotrypsin operating via a Lossen rearrangement that unmasks 
an inactivating isocyanate species. Inhibitory activity has been found to be mediated by 
the nature of the R substituent and the R' substituent of the L group. Structure activity 
relationships were investigated by preparing a number of derivatives of type 1.41. The 
design of the derivatives prepared focused on modulating the R' substituent to interact 
with extended binding sites of a-chymotrypsin, a strategy that would enhance 
inhibitory activity. 
Chapter 2 describes the synthesis of 1.41 and 2.1. Retrosynthetic analysis identified a 
route involving N-hydroxyimides to be favoured. A synthesis of 1.41 and 2.1 via this 
key intermediate required reaction between hydroxylamine and succinic and glutaric 
acid derivatives respectively. These derivatives were prepared using literature methods 
employing Guareschi, Michael and malonate ester reactions. A systematic study of the 
synthesis of succinic acids found the optimum route to involve the Stobbe condensation 
however a short synthesis employing amide base alkylation of succinimide was 
undertaken and this methodology may prove to be the ideal general route. 
An aromatic series of derivatives, 1.4lf-h was therefore synthesised using the 
methodology above as were "dimeric" inhibitors 1.41m and n capable of releasing two 
equivalents of inactivating species during inhibition. Succinimides with 3-C phenyl 
substituent rather than the benzyl substituent of the derivatives above, were prepared 
and a series of N-[(sulfonyl)oxy]glutarimides 2.1a, c-e where the extent and type of 
substitution were varied were prepared. N-[(Acyl)oxy]imides 1.41r-o and 2.1b (L = 
C(O)R') may also inhibit a-chymotrypsin and these too were investigated. 
Chapter 3 discusses the assay of inhibitory activity of compounds of type 1.41 and 
2.1 against a-chymotrypsin. All the synthesised derivatives, excepting a series of 
N[(acyl)oxy]succinimides 1.41o-r, were found to be active to such a degree that all but 
one of the active compounds could not be assayed using sampling techniques. These 
potent inhibitors were then assayed using the progress curve method. Three compounds 
1.41g and hand 2.1c were of such potency that the rate at which they inhibited a-
chymotrypsin could not be measured even with the progress curve method. All three of 
these compounds possessed a benzyl substituent which was found to be a requiremnent 
for the exhibition of mechanism-based inhibition in the succinimide series. Compounds 
1.41g and 1.41h owed their potency to being able to interact favourably with the Sn' 
subsites of a-chymotrypsin by containing aromatic substitution. 
Chapter 4 discusses the use of Evan's oxazolidinone chemistry in the preparation of 
chiral succinates from which an enantiopure inhibitor of type 1.41 was prepared. 
Preliminary inhibition studies showed that (R)-l.4lf was less active than its racemate 
indicating more activity resided in the (S)-enantiomer. 
Chapter 5 discusses the design and synthesis of a potential novel imide mechanism-
based inhibitor thought to act by unmasking a quinone imine methide in the active site 
of a-chymotrypsin. Although the compound released reactivity on hydrolysis it was not 
found to inhibit a-chymotrypsin significantly. 
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INTRODUCTION 
1 - Introduction 2 __ -L______ ______________________________________________________ __ 
Proteases constitute a large family of enzymes characterised by their function which 
is the catalysis of the hydrolytic cleavage of peptide bonds in proteins and polypeptides 
(Scheme 1.1). 
R H ~ ,N"", 
"",Way 
H 0 
peptide bond 
Protease 
.. + 
Scheme 1.1. The protease catalysed hydrolysis of a peptide bond. 
Proteases are involved in almost every aspect of life. The functions of proteases1 
include hydrolysis of proteins and polypeptides for digestive and nutritional purposes, 
release of peptide hormones and neuromodulators from inactive precursors, activation 
of enzymes, for example clotting factors, and termination of biological responses by 
degradation of the message-transmitting peptide. 
Proteases have been classified into four classes each with their own distinct 
mechanism.2,3 This classification is based on the most significant functional group 
associated with the protease activity. Hence the serine, aspartic, cysteine proteases 
derive their names from the most prominent catalytic amino acid residue in the active 
site whereas the metallo proteases are named according to the associated prosthetic 
metal ion. Table 1.1 lists examples of proteases in each mechanistic category. 
The following section of this introduction deals with the mechanism of action of 
serine proteases and the different approaches to inhibiting these enzymes. 
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Protease 
Serine 
Metallo 
Aspartic 
Cysteine 
Representative Enzymes Normal Function 
-thrombin, plasma kallikrein -blood coagulation 
-trypsin, a-chymotrypsin, -digestion 
pancreatic elastase 
-enterokinase plasmin, -fibrinolysis, destruction of 
plasminogen activator blood clots 
-tissue kallikrein, post-protein 
cleaving enzyme -hormone metabolism 
-elastase, cathepsin G, 
tryptases, mast cell chymases -phagocytosis 
-acrosin -fertilization 
-ATP dependent proteases -protein turnover 
(intracellular) 
-angiotensin converting -blood pressure regulation 
enzyme, aminopeptidases, 
renal dipeptidases 
-collagenase 
-carboxypeptidase 
-macrophage elastase 
-enkephalinases 
-renin 
-HN protease 
-therrnolysin, pepsin 
-tissue remodelling 
-digestion 
-peptide metabolism, blood 
pressure regulation 
-analgesic 
-blood pressure regulation 
-HIV replication 
-digestion 
-cathepsins B, H, L, calcium -protein turnover, bone 
activated neutral proteases resorbtion 
-papain -digestion 
-picornavirus -viral replication 
TABLE 1.1. Examples of Proteases, Subdivided into Mechanistic Categories 
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1.1 SERINE PROTEASES AND THEIR 
MECHANISM OF PEPTIDE HYDROLYSIS 
More than 130 serine proteases have been classified to date. 4 Their different 
functions include digestion, processing of peptide prohormones, thrombolysis and 
fibrinolysis, fertilization and blastocyst implantation. 5,6 Even though the physiological 
functions of serine proteases are diverse, all employ a common catalytic mechanism. a-
Chymotrypsin,7,8 a serine protease from the mammalian pancreas involved in digestion, 
has been studied intensively and more information is available on its mode of catalysis 
than for almost any other enzyme.9 Its active site has been well characterized by X-ray 
crystallography and intermediates of the hydrolysis reaction it catalyses are known. It is 
therefore representative of the mechanism of the whole class of serine proteases. 
The proposed mechanism of peptide hydrolysis by a-chymotrypsin is illustrated in 
Scheme 1.2. The first step in the hydrolysis is the complementary approach of the 
enzyme and substrate that results in the non-covalent enzyme-substrate aggregate 
known as the Michaelis-Menten complex (1.1). The driving force for its formation 
depends on favourable binding interactions between the enzyme and substrate. The 
structure of serine proteases remains quite conserved but differences in key structural 
binding elements imparts specificity of action to a protease with regards to its substrate. 
Topographical studies of a-chymotrypsin, for example, have shown the presence of a 
hydrophobic pocket associated with the active-site which binds the amino acid a-C 
substituent on the carboxyl side of the peptide bond which is to be hydrolysed (the so-
called scissile bond). Hence a-chymotrypsin selectively cleaves peptides on the 
carboxyl side of the amino acid residues; phenylalanine, tyrosine and tryptophan as 
these have aromatic side chains able to interact favourably with this pocket. 
The driving force for hydrolysis is the catalytic triad consisting of Ser-195, His-57 
and Asp-102 (the numbers 102, 57 and 195 denote the position of the amino acid 
residues Asp, His, and Ser, respectively in the polypeptide chain of the enzyme). His-57 
and Asp-102 act as an electron sink and source in a charge relay system that enhances 
the nucleophilicity of Ser-195 (Step I, Scheme 1.2) and the incoming water molecule 
(Step II, Scheme 1.2). Catalysis is initiated by nucleophilic attack of the Ser-195 on the 
susceptible carbonyl carbon of the scissile peptide bond (depicted by the arrow) of the 
substrate to form a tetrahedral intermediate (1.2). The oxyanion of the tetrahedral 
adduct is stabilised by hydrogen-bonding to the backbone NH groups of Gly-193 and 
Ser-195 (see 1.2) which incorporate a binding element referred to as the oxyanion hole. 
The proton on the serine hydroxyl group is ultimately transferred, via His-57, to the 
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Scheme 1.2 Proposed mechanism of substrate hydrolysis by a-chymotrypsin 
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Scheme 1.2 (continued) Proposed mechanism of substrate hydrolysis by u-
chymotrypsin 
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nitrogen atom of the eventual amine product, thereby facilitating collapse of the 
tetrahedral intermediate to the acyl-enzyme ester (1.3a) and release of the C-terminal 
peptide fragment. The acyl-enzyme 1.3b is hydrolysed by the catalytic addition of 
water (Step II), facilitated by the charge relay system working in reverse via a second 
tetrahedral intermediate (1.4), to afford the N-terminal carboxylic acid fragment of the 
peptide, along with regenerated enzyme (1.5). 
ENZYME-SUBSTRA TE SPECIFICITY 
The active site of proteases consists of two domains: a catalytic site where the 
covalent bond-forming and bond-breaking reactions take place, and an extended 
binding domain where non-covalent interactions occur between the enzyme and the 
amino acid residues of the substrate extending from either side of the scissile bond to be 
cleaved. It is these binding sites which impart specificity of action to a protease with 
regards to its substrate, as discussed above for a-chymotrypsin, thus enabling the 
diversity of the physiological function that exists within a protease class. 10 
The terminology of Schecter and Bergeril has been widely adopted to describe the 
interactions between enzyme and substrate on binding. This nomenclature has been 
applied to identify all the relevant interactions between the amino acid side chains of a 
natural heptapeptide substrate and the specificity pockets of a-chymotrypsin (Figure 
1.1). The amino acid residues of the substrate (or the inhibitor) are designated PI, P2, 
etc, numbering from the carbonyl end of the scissile amide bond in the (left-hand) 
direction of the amino terminal. The corresponding subsites of the enzyme are termed 
Sl, S2, etc. The residues in the (right-hand) direction of the carboxy terminal from the 
scissile bond are designated PI', P2', etc, and the corresponding subsites SI', S2', etc. 
Binding of the substrate occurs through non-covalent interactions such as hydrogen-
bonds and hydrophobic forces. The most important of these interactions is that between 
the SI subsite of the enzyme and the PI residue of the substrate. This interaction is the 
primary determinant of substrate specificity, and consequently the point of cleavage. 
The specificities of a number of serine proteases is illustrated by their inhibition by a 
number of natural peptide aldehydes chymostatin (1.6),12 elastatinal (1.7),13 leupeptin 
(1.8).14 
As discussed above, the size, shape and hydrophobic nature of the primary 
specificity pocket S 1 of chymotrypsin-like enzymes is such that these enzymes cleave 
peptides on the carboxyl side of aromatic residues: phenyalanine, tyrosine, tryptophan. 
The PI residue of chymostatin is phenylalanine and hence it is a potent inhibitor of a-
chymotrypsin (Ki = O.25IlM).15 Elastatinal1.7 (PI is alanine) and leupeptin 1.8 (PI is 
~~.~~~l~~In~t~ro~d:u~~c~ti~on~ __________________________________________ ~8 
Figure 1.1 The interaction of an idealised heptapeptide substrate with a serine protease 
as described by Schecter and Berger terminology. 
arginine) both lack a suitable bulky hydrophobic Pl residue and are therefore poor 
inhibitors of a-chymotrypsin. The 1C50 value for both leupeptin A 1.8a and B 1.8b is 
1100llM14 while elastatinall.7 does not inhibit a-chymotrypsin.13a 
Elastases have shallow hydrophobic SI subsites which preferentially bind medium 
sized aliphatic amino acids: isoleucine, valine and alanine. These enzymes are inhibited 
by elastatinal1.7 which has a PI alanine residue. The more potent inhibition of porcine 
pancreatic elastase by elastatinal 1.7 (Ki = O.24IlM) 15 is consistent with its smaller S 1 
pocket16 relative to human leukocyte elastase (Ki = 50-80~LM for 1.7)15,17,18 which has 
a preference for valine at its PI position.19 Since the Sl subsite of these enzymes is 
quite small, enzyme substrate recognition is influenced, more so than other serine 
proteases, by interactions between secondary binding sites e.g. S2-P2 and S2'-P2' as well 
as the primary binding interaction Sl-Pl hence these enzymes have relatively long 
extended active sites (S5'-S3).20,21 
Trypsin has a negatively charged S 1 subsite due to the presence of the acidic amino 
acid Asp-189 in its active site and hence it prefers substrates with a complementary 
positive charge. Hence this enzyme is potently inhibited by leupeptin A 1.8a (ICso = 
218JlM)15 and leupeptin B 1.8b (ICso = 211~)IS (PI for both is arginine). Elastatinal 
1.7 and chymostatin 1.6 lack the required positively charged PI residue and are 
consequently poor inhibitors as exemplified by chymostatin 1.6 which does not inhibit 
trypsin. 12 
1.6 
1.8 
1.8aR= CH3 
1.8b R = CH3(CH2)2 
1.7 
:Figure 1.2 Natural peptide aldehyde reversible inhibitors of serine proteases 
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1.2 INHIBITION OF PROTEASE ENZYMES 
The activity of proteases is strictly regulated by endogenous protease inhibitors.3,22 
However, a number of disease states, e. g. emphysema, inflammation, tumor metastasis, 
muscular dystrophy and hypertension, appear to be caused, to some extent, by 
excessive proteolytic activity brought on by abnormally low levels of the endogenous 
protease inhibitors.5,23 Serine proteases, in particular, have been implicated in 
emphysema, adult respiratory distress syndrome, rheumatoid arthritis, pancreatitis, 
inflammation and digestive disorders.5,24 
The involvement of serine proteases ill a wide variety of physiological and 
pathological processes, coupled with their well studied mechanism of action, has made 
this class of enzyme an attractive target for the preparation of inhibitors. The rational 
design of drugs to specifically target key metabolic pathways under enzymatic control 
which have run amok, has been the main impetus for the development of enzyme 
inhibitors. These inhibition studies have also revealed information regarding substrate 
specificity and the catalytic mechanism of enzymes. 
Active site directed competitive inhibitors are classically categorized as either 
reversible or irreversible.25 There exists no definite time period for which an enzyme 
has to remain inactivated for the inhibitor to be classified as either reversible or 
irreversible. Therefore, there exists a continuum from inhibitors which form an enzyme-
inactivator complex that is stable only for a short time before undergoing rapid 
decomposition to those inhibitors that form an enzyme-in activator complex that is 
resistant to denaturation or even acid hydrolysis. A general distinction between the two 
exists in that reversible inhibitors closely resemble the normal substrate and act by 
competing with it to form a stable, non-covalent inhibitor-enzyme complex whereas 
irreversible inhibitors form a covalent or particularly strong inhibitor-enzyme 
association. Inactivation refers to an irreversible inhibition process. 
Most enzyme inhibitor drugs are non-covalent, reversible inhibitors. Optimum 
activity of these requires maintenance of a high inhibitor concentration at the active 
site. Because of drug metabolism and excretion, repetitive administration of the drug is 
required. Inactivation has the distinct advantage over reversible inhibition in that a 
prolonged effect is achieved translating into smaller and fewer doses. Conversely 
reversible drugs are more manageable clinically in that if the enzyme is totally 
inactivated a potentially dangerous period of days26 can pass before enzymic activity is 
regained through gene-encoded synthesis of new amounts of enzyme. 
11 
REVERSIBLE INHIBITION 
Peptides are a rational starting point in the design of inhibitors due to their high 
specificity and affinity for a target enzyme. A number of oligopeptides, for example 
1.9,27 have been shown to inhibit human neutrophil elastase (HNE) by binding in the 
active site in such a manner that hydrolysis does not occur though the modes of action 
are uncertain. 
Boc-(V alh-NH-(CH2)11 CH3 
1.9 Ki = O.21~M I HNE27 
Peptides, however, have poor pharmalogical profiles due to poor oral absorption and 
metabolic stability resulting in low in vivo potency. Peptidomimetics are small non-
peptide ligands which retain the attractive potency and selectivity of the parent peptides 
whilst displaying more favourable pharmacological properties. In contrast to non-serine 
proteases, peptidomimetics have received little attention as inhibitors of serine 
proteases. This may, in part, be attributed to the fact that reactions with the active site 
serine provide an attractive inhibition strategy unavailable to other classes of enzyme. 
Peptidoisoteres, a class of peptidomimetic, are based on replacement of the amide 
bond with units that are functionally equivalent but due to the decreased peptide 
character are more stable. Two peptidoisoteres, carbamates (e.g. 1.11)27 and carbazates 
(e. g. 1.12)28 have been studied as inhibitors of human neutrophil elastase (RNE). 
Carbamates ~re obtained from a peptide ester substrate, represented by structure 1.10, 
by reversal of the positions of the a-nitrogen and the a-carbon atoms (compare 1.11 
with 1.10) while replacement of the a-carbon with a nitrogen gives a carbazate 
(compare 1.12 with 1.10). 
1.10 
Y N-N 
N s-l( 'N 
MeO-Succ-(Ala)2-Pro-'/ i( ~~ 
o CH3 
~ 0 ~ 
/'.. ~ ... N OPh H3C02C N Val-Pro-N Y 
H H 0 
29 1.12 1C50 = 0.28J.lM I HNE 
12 
Concurrent with the discovery of a number of natural peptide aldehydes (see Figure 
1.2) as reversible inhibitors of serine proteases, synthetic aldehydes were reported as 
inhibitors of the cysteine protease papain. 30 Subsequently, peptide aldehydes have been 
developed as inhibitors of serine proteases. These react with Ser-195 to give a covalent 
tetrahedral adduct that mimics the the second tetrahedral intermediate (1.4) involved in 
serine protease catalysed peptide hydrolysis (Scheme 1.2). Optimization of the peptide 
backbones to match the target enzymes' natural substrates has resulted in very potent 
inhibitors as illustrated by the tetrapeptide 1.1331 whose carbobenzyloxy (Cbz) 
substituent mimics the desmosine residues in elastin the natural substrate of human 
leukocyte elastase. 
While peptide aldehydes have been shown to be potent reversible inhibitors the 
aldehyde functionality is relatively unstable. An approach taken to improve stability 
and potency has been the replacement of the aldehydic proton with a group possessing 
greater electron withdrawing ability,32 Examples of the resulting inhibitors are shown 
in Table 1.2. 
Trif1uoromethylketones,33-5 such as (1.15),36 have been found to be 10- to 100-fold 
more potent inhibitors of serine proteases than the corresponding aldehydes (compare 
1.15 and 1.13) and over 1000-fold more pbtent'than the methyl ketones (1.14)31 due to 
increased hydrogen-binding with the oxyanion hole leading to a more stable enzyme-
inhibitor adduct. 
Replacement of one of the fluorine atoms of 1.15 to give a difluoromethylketone 
decreases the electrophilicity of the scissile bond carbonyl and hence potency. However 
synthetic methodology has developed so that the hydrogen atom of a simple 
diflouoromethylketone can be replaced with an alkyl, keto, amide or ester group which 
have improved electronic properties. The replacement may also be tailored to interact 
with the S' subsites of the enzyme to give difluoromethylketone inhibitors which are 
more potent than the parent trifluoromethyl e.g. 1.16 is seven fold more active than 
1.15. 
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Compound Inhibitor Ki OlM)/HNE 
number 
1.13 
Cbz-val-pro-~~H 0.041 31 
H 0 
1.14 8.031 ~CH' Cbz-Val-Pro-N 
H 0 
1.15 0.001636 ~CF' Cbz-Val-Pro-N 
H 0 
1.16 CbZ-Val-Pro-~CF"T~Ph 0.0002337 
H 0 0 
1.17 
Cbz-val-Pro-~YOEt 0.000638 
H 0 
1.18 
Cbz-val-pro-NNH2 
0.001837 
H 0 
1.19 
Cbz-Val-Pro-~\J~ 0.001637 
H 0 
1.20 
CbZ-Val-pro-N) 
0.000631 
H 0 
Table 1.2 Reversible inhibitors of human neutrophil elastase (HNE) based on peptide 
aldehydes 
In addition to the trifiuoromethyl and difluoromethyl groups discussed above, 
ester,39-41 amide,37 and ket037,41,42 groups have been used to activate the carbonyl 
group in peptidyl aldehydes resulting in inhibitors 1.17-1.19 respectively. All three 
types are thought to operate with a mechanism which involves formation of a 
tetrahedral adduct with Ser-195. Peptidyl a-ketoheterocycles (e. g. 1.2031 ) not only 
react with Ser-195 but the heterocyclic ring can also participate in hydrogen-bonding 
with His-57 enhancing potency. 
Tailored peptides containing C-terminal a-amino- alkylboronic acid residues such as 
1.2143 and 1.2244 have been shown to be some of the most potent reversible inhibitors 
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of serine proteases45 including a-chymotrypsin (a-CT), a-lytic proteinase (ALP), 
thrombin and trypsin. These compounds contain a trigonal boron with a vacant 2p 
orbital which reacts with either Ser-195 (type 1) or His-57 (type 2). Type 1 boronic 
acids react with Ser-195 give a covalent tetrahedral adduct which mimics the second 
tetrahedral intermediate (1.4) involved in the hydrolysis of peptides (see Scheme 1.2) 
and are potent inhibitors. Type 2 acids however, lack the correct geometry to optimise 
binding with the enzyme's S 1 pocket and react with His-57 rather than Ser-195 and 
consequently are poor inhibitors.43b 
P1 
CH30-SuC-Ala-Ala-prO-NA B"OH 
, H OH 
1.21 
1.22a R = (L) PhCH2 
Ki = O.541lM / ALp43b 
Ki = O.16nM / a_CT43a 
1.22b R = i-Pr 
Ki = O.57nM / HLF3a 
IRREVERSIBLE INHIBITION 
P1 N~ "OH Ac-(D)-Phe-Pro- B 
H OH 
1.22 
PI = (L)-Arg 
44c Ki = O.04nM / Thrombin 
Ki = O.045nM / Trypsin 44c 
A class of irreversible inhibitor includes reactive compounds referred to as affinity 
labeling agents.25,46 These contain a reactive functional group, e.g. an a-halo ketone or 
isocyanate, and react directly with active site nucleophiles, generally via an SN2 
alkylation or acylation. These have been used extensively in vitro for mechanistic 
probing of enzyme active sites, however any potential clinical utility is undermined by 
their high and therefore indiscriminate reactivity within the biological environment, 
resulting in toxicity and side effects. Although clinically disadvantaged due to their 
high reactivity and associated poor stability, research has nonetheless been undertaken 
to develop these compounds as therapeutic agents by addressing these issues. In this 
regard, the incorporation of simple organofluorophosphonates 47 and 
organosulfonylfluorides48 and isocyanates49 into peptidomimetics has resulted in 
compounds with increased selectivity and stability such as 1.23,47d whose inhibitory 
activity against human neutrophil elastase (HNE) and porcine pancreatic elastase (PPE) 
is shown below. 
Although of lesser reactivity, esters react readily with serine proteases and 
consequently have undergone extensive development as substrates for kinetic assays. 
This provides an abundant pool of compounds suitable for the development of 
1 - Introduction 
X OPh Boc-Val-Pro-N P: 
H II OPh o 
1.23 
kob/[I] = 27 000 M-1s-1 , HNE47d 
kob/[I] = 11 000 M-1s-1 'PPE47d 
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therapeutic agents which can be realised by designing the esters such that they rapidly 
acylate the enzyme giving an inactive acyl-enzyme species which has a long lifetime if 
the deacylation reaction is slow. The most success has been achieved with aromatic 
pivaloates50,51 however acetylsalicylic acid, aspirin, has obtained "cult" status as an 
inactivator of prostaglandin synthase and cure of the common headache. 52 
1.24 
Stability may also be improved by masking the affinity label in a structure specific 
for a particular enzyme. Imidazole N-carboxamides (e. g. 1.25)53 have been modified 
by the attachment of enzyme recognition elements such as the n-hexyl group of 
1.25a53b and amino acid sequences (1.25b)53c to improve enzyme selectivity. 
Compounds 1.25 are examples of such "paracatalytic" inhibitors.54 Their mechanism of 
inactivation involves deprotonation at nitrogen and subsequent elimination of imidazole 
to give an alkylisocyanate which inhibits the enzyme. 
1.25 
1.25a R = C~ 13 
1.25b R amino acid sequence 
The design of compounds that contain latent reactivity towards enzymes, as 
illustrated by the above example, has lead to the realisation of a second class of 
irreversible inhibition with important clinical applications known as mechanism-based 
inactivators25 of which this thesis is concerned. 
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1.3 MECHANISM-BASED INACTIVATION 
Mechanism-based inactivators25 (also known as suicide inhibitors and kcat 
inhibitors) are reasonably unreactive compounds which contain a latent reactive 
functionality. A mechanism-based inactivator is recognized by the target enzyme as a 
natural substrate. During catalysis, the latent reactive functionality in the inactivator is 
unmasked by the normal catalytic machinery of the target enzyme. The reactive group 
(generally an electrophilic site) becomes covalently bound to the enzyme (due to 
reaction with a nucleophilic residue in the enzyme). This renders the active site 
irreversibly blocked and the enzyme inactivated. 
In contrast, to affinity labeling agents, mechanism-based inactivators are unreactive 
compounds and this is the key feature which makes them particularly amenable to the 
design of highly specific, low toxicity drugs. The potential for generating the reactive 
species exclusively within the active-site of the target enzyme imparts, in principle, a 
much higher degree of selectivity to mechanism-based inactivators than affinity labels. 
In the ideal case only the target enzyme would be capable of catalysing the appropriate 
conversion of the inactivator to the reactive species and only one inactivator molecule is 
needed per enzyme molecule for inactivation. This efficiency of inactivation is an 
important concept in drug design and is measured by the partition ratio.54 In the ideal 
case case the partition ratio is equal to zero (no metabolites are formed per inactivation 
event). If the partition ratio is greater than zero the product(s) resulting from turnover 
may be hydrolysed to give a toxic product or react with other biomolecules to produce a 
toxic effect. 
The design of mechanism-based inactivators for a target enzyme requires a 
knowledge of the enzyme mechanism and structure. As discussed earlier, the 
mechanism of serine protease catalyzed peptide hydrolysis has been extensively studied 
and consequently a large number of mechanism-based inactivators have been based on 
electrophilic heterocycles which are capable of being attacked by the nucleophilic 
active site serine hydroxyl of the serine protease. The resulting ring-opened acyl 
enzyme intermediate reacts further to unmask a species that ultimately inactivates the 
enzyme. Herein provides a brief review of heterocyclic mechanism-based in activators 
of serine proteases illustrating design features that have been employed to increase 
target enzyme specificity and more favourable in activator pharmacodynamics and 
kinetics. 
1 - Introduction 
BENZOXAZINONES, COUMARINS, N-NITROSOAMINES 
1.26 
x y 
~R 
UO~o 
H3COyyyO HCO~~L"N 
3 II 
1.27 
1.27a R, Y = H, X = Br 
kobi[I] = 170 M-1s-1 / a_CT58b 
1.27b R, Y, X = Br 
kobJ[I] = 3 000 M-1s-1 / a_CT58b 
1.27c R = PhCH2, Y = H, X = CI 
kobi[I] = >20 000 M-1s- 1 / a_CT58b 
° 
1.28 
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The earliest enzyme-activated inhibitors studied were halomethylbenzoxazinones 
(1.26)56 and N-nitrosoamines (1.28)57 and which were found to inhibit a-
chymotrypsin. The first "true" mechanism-based inhibitors reported were the 
halomethyl dihydrocoumarins (1.27) which were observed to inactivate a number of 
serine proteases particularly a-chymotrypsin (a-CT),58 as shown above, and human 
neutrophil elastase,59 porcine pancreatic elastase,60 and trypsin60 but less effectively. 
The inactivation results from unmasking of a quinone methide which alkylates the 
imidazole side chain of His-57. Substitution at the 3- and 4-positions permits 
interaction with the SI subsite increasing inhibitory potency and efficiency as observed 
by comparison of the kinetic constants of inhibition for 1.27b and 1.27c against 1.27a. 
The related functionalized 3,4-dihydroquinolinone 1.29 was found to be inactive 
probably because the cis-Iactam ring is not opened by the enzyme.61 However 
Wakselman et al62 have shown that the macrocyclic analogs represented by struture 
1.30 are mechanism-based inhibitors of serine proteases since the scissile amide bond 
has the necessary trans configuration. These macrocyclic peptides contain a latent 
quinone imine methide species that resides between PI-PI' mimics of which can be 
tailored to impart selective action against a particular target enzyme. 
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CI 
~Ph U~~O 
1.29 
inactive61 
ISOCOUMARINS 
y 
rYYx l/yo 
o 
1.31 
1.31aX = CI, Y = H 
kob/[I] = 3 900 M-1s-l / HNE64 
1.31b X, Y = CI 
kob/[I] = 8 900 M-1s-1 / HNE65 
1.30 
PI = (L)-Arg 
kubl[I] = 2300 M-1s-1 / urokinase62c 
y 
z~x l/yo 
o 
1.32 
1.32a X = OCH3, Y = H, Z= N02 
Alternate substrate68 
1.32b X = OCH3, Y = CI, Z::::: NH2 
kob/[I] = 10 000 M-1s-1 / HNE68 
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Isocoumarin derivatives 1.31 and 1.32 have been found to be mechanism-based 
inhibitors of serine proteases particularly of human neutrophil elastase (HNE).63 
Introduction of a second chlorine atom in the 4-position of the first generation inhibitor 
1.31a64 gives 1.31b65 which is more potent due to increased electrophilicity of the 
carbonyl group. Electrospray mass spectrometry studies of the inhibition of porcine 
pancreatic elastase by 1.31b66 and proton inventories67 suggests the mechanism of 
action involves an unmasked active site tethered acid chloride which, unless 
hydrolysed, forms a salt linkage with His-57 to inactivate enzyme. 
While 3-alkoxy-isocoumarins such as 1.32a are only alternate substrate inhibitors 
lacking reactivity on ring-opening,68,69 introduction of a chlorine atom at the 4-position 
gave inactivators, e. g. 1.32b, of human leukocyte elastase.67,68 The mechanism of 
inactivation was found by X-ray analysis of a porcine pancreatic elastase-1.32b 
complex69,70 to differ from that of the simple isocoumarins 1.31 in that an unmasked 
quinone imine methide irreversibly alkylates His-57. The specificity of 1.32 can be 
tailored by modifying the 3-alkoxy substituent such that 1.32b and 1.32c were found to 
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be more re,active towards human neutrophil elastase and a-chymotrypsin 
respectively.67,68 
HALOENOL LACTONES 
1.33 
1.33a R = Ph, X = Br 
kinact/[I] = 23 M-1s-1 / a-CT72 
1.34 
1.34a R = Ph, X = Br 
kinact/[I] = 73 000 M-1s-l / a-Crn 
1.34b R = i-Pr, X = Br 
(E)- kinact/[I] = 14500 M-1s-1 / HNE77 
(Z)- kinac/[I] = 37 500 M-1s-1 / HNE77 
1.34c R = Ph, X = I 
kinact![I] == 130 000 M-1s-l / a-CT72 
1.34d R = naphthyl, X = I 
kinacJ[I] == 292 000 M-1s-1 / a-CT72 
Both mono a-substituted 5- and 6-membered haloenollactones (1.33 and 1.34) have 
been found to be mechanism-based inhibitors of serine proteases.7 1,72 These com-
pounds were first proposed by Rand073 however it was a decade later that an efficient 
synthetic route was developed.74 The mechanism of action involves ring-opening 
followed by a tautomeric shift to reveal an a-halo ketone75 which, as indicated by 
reactivation studies and molecular mechanics analysis, irreversibly alkylates the His-57 
imidazole.75,76 
The potency and efficiency of inactivation is related to the lactone ring size, 
geometry, halogen and substitution. Six membered haloenollactones are more effective 
than five membered rings (compare 1.33a and 1.34a) which may result from the fact 
that the reactive a-halo ketone is on a longer tether and has better access to His-57. The 
olefin geometry has a relatively moderate effect with (Z)-enols being more potent than 
the corresponding (E)-enols [compare 1.34b (E) and (Z)] as does the halogen with iodo 
enol lactones being more potent than bromo enol lactones (compare 1.34a and c). 
Judicious modification of the a-substituent can impart selectivity of action. Haloenol 
lactones with aryl a-substitutents (1.34a, c, and d) target specifically a-chymotrypsin 72 
while those with an a-isopropyl substituent (1.34b) are selective for human neutrophil 
elastase (HNE).77 The most potent inhibitor in the monosubstituted series, 1.34d, is 
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also very efficient with a partition ratio equal to 1.7. As a strategy for increasing 
specificity haloenollactones have been incorporated into psuedo dipeptides.78,79 The 
trans peptidyl haloenol lactone 1.35,79 which contains a proline-valine peptide 
sequence typical of elastase substrates, has been found to be an effective in activator of 
a-chymotrypsin (a-CT) and human neutrophil elastase (HNE) with specificity superior 
to other mono substituted haloenollactones. 
~/o Dyn-nu 
, oloXvBro 
1.35 
kob/[I] ::: 8 000 M-1s-] / a-CT79 
kob/[I] ::: 1100 M-1s-I / HNE79 
The "benzo" lactones represented by structures 1.36-8 were proposed to act by 
unmasking a latent a-halo ketones as postulated for the halo enol lactones. The 
isobenzofuranone derivative 1.36 and the isocoumarin 1.37 are not effective substrates 
of serine proteases and hence the latent reactivity cannot be released. Although 
isobenzofuranones of type 1.38 are potent inhibitors, the observation of biphasic 
inactivation kinetics and the results of reactivation studies indicate that due to their poor 
stability the benzopyran-l,4-dione is responsible for inactivation via a non mechanism-
based acylation process.80 
o 
~~ ~ X R 
1.36 
Inactive80 
1.37 
Inactive80 
o 0;0 
Br CHBr-R 
1.38 
Acylating agent80 
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YNENOL LACTONES 
R h //R' A~~ o 0 
1.39 
1.39a R, R' = H 
inactive82 
1.39b R = PhCH2, R' = H 
kinacJ[I] 7 600 M-1 S -1 / HNE82 
1.39c R = PhCH2, R' = CH3 
kinact/[I] 2.4 M-1s-1 / HNE65 
R 
Y"l ~ #' OAO~ 
lAO 
1.40a R = PhCH2 
kinacJ[I] = 28 000 M-1s-1 / HNE82 
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Five and six membered ynenol lactones represented by structures 1.39 and 1.40 
respectively have been found to be mechanism based inhibitors similar to haloenol 
lactones of serine proteases.81 ,82 The chemical competence of the mechanism of action 
has been examined83 and involves unmasking of a reactive allene ketone which 
irreversibly alkylates the enzyme although the site remains unknown. Five and six 
membered and (E) and (Z) ynenol lactones are similarly equipotent. Substitution at the 
a-position is required for inhibition (compare 1.39b and 1.39a) however substitution of 
the acetylene reduces the rate of inactivation or eliminates it completely (compare 1.39c 
and 1.39b). This is thought to be because of decreased rate of conversion to the reactive 
allenone and/or active site geometries restricting alkylation. 
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SUCCINIMIDES 
R 
~4 
oANAo 
I 
OL 
1.41 
1.41a R = i-Pr, L S02CH3 
kobs/[I] = 3817 M-1s-1 / HLE87a 
1.41b R = i-Pr, L = S02trans-styryl 
kobs/[I] = >100 000 M-1s-1/ HLE87a 
1.41c R ::; i-Bu, L = PO(OCH2Ph) 
kobs/[I] ::; 6 180 M-1s-1 / HLE89 
Acylating agent89 
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The series of succinimide inhibitors represented by structure 1.41 are unique in that 
the reactive intermediate is generated through molecular rearrangement. 84,85 Proton 
NMR studies support a mechanism which proceeds with reaction of Ser-195 to give a 
ring-opened N-sulfonyloxycarboxamide which undergoes a Lossen rearrangement86 to 
generate a reactive isocyanate if the N-substituent is a good leaving group. The reactive 
isocyanate then acylates His-57 to form a doubly bound inactive enzyme-inhibitor 
adduct. SAR study of 1.41 undertaken by Groutas et a187 has shown selectivity can be 
obtained by modification of the C-3 substituent that is proposed to interact with the S 1 
binding site of the enzyme. Introduction of a trans styry I group as the N-substituent 
resulted in a dramatic increase in inhibitory activity due to proposed interaction with 
the extended Sn' binding sites (compare 1.41a and 1.41b). 
N-Phosphoryloxyimides are also known to undergo a Lossen rearrangement on 
treatment with nucleophiles88 and hence compounds of type 1.41c were also examined 
as mechanism-based inhibitors. However 31p NMR studies indicated these compounds 
were only potent acylating agents.89 N-(Sulfonyloxyphthalimides) 1.42 have also been 
found to inactivate serine proteases with a mechanism established by flourescence 
spectroscopy to involve the Lossen rearrangement.90,91 
1 - Introduction 
o 
R~ ~N-OL 
o 
1.42 
1.42a L = S02CH3' R = NH2 
kob/[I] = 110000 M-1s-1 / HLE91 
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Other heterocyclic compounds, e.g. 1.43-46, which contain the masked isocyanate 
have been investigated as potential mechanism-based inhibitors but have been found to 
be less potent than the succinimide based derivatives 1.41.92-95 Of particular note is the 
reversal of the trend in activity observed with the succinimide series in the 
dihydrouracil inhibitors 1.44.93 Here incorporation of a trans-styryl group results in 
less potent inhibition thought to reflect the increased steric demands of these six 
membered inhibitors. 
1.43 
1.43aX, Y, Z = C 
kob/[I] = 180 M-1s-l / HLE92 
1.43b X =N, Y, Z = C 
kob/[I] = 64 M-1s-1 / HLE92 
1.43c Y = N, X, Z = C 
kob/[I] = 58 M-1s-l / HLE92 
1.43d X, Z =N, Y = C 
kob/[I] 20 M-1s-l / HLE92 
Ph 0 
N~N-OS02R b~ 
o 
1.45 
R trans-styryl 
Alternate substrate94 
1.44 
1.44aR= CH3 
kob/[I] 3310 M-1s-1 / HLE93 
1.44b R = trans-styryl 
leab/[l] = 480 M-1s-1 / HLE93 
o 
~N-OS02CH3 
Ph N~ 
Ph 
1.46 
Acylating agent95 
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SACCHARIN 
Mechanism-based inhibition of serine proteases by saccharin derivatives was first 
reported by Blasta et aZ96 based on the premise that incorporation of a leaving group 
into known acylating agents,97 such as 1.47, would permit further inactivation.98 
Groutas et aZ99 arrived at the design of inhbitors of type 1.48 on consideration of a 
possible mechanism of inactivation based on the known chemistry of saccharin and its 
derivatives towards nucleophiles. 
o 
01-v-N02 
o 0 N02 
1.47 
1.48 
L = halogen 
AN =-N~ 
= -O~S"Ph 
o 
(L)-Leu-N-Cbz 
The potency of these compounds depends on the electron withdrawing properties of 
the leaving group and modification of the saccharin nucleus to act as an enzyme 
recognition element. Preliminary SAR studies undertaken by Hlasta et al99 identified 1-
phenyl mercapto tetrazole as a favourable leaving group while computer modelled 
"docking" studies of substituted saccharins with human leukocyte elastase predicted 
that substituents at the 4-position would interact with the Sl specificity pockets of 
serine proteases resulting in the design of compound 1.49.103 Judicious choice of the 4-
substituent may therefore enhance potency as was observed on incorporation of a 4-iso-
propyl substituent (compare 1.49a and 1.49b). The kinetic constant Ki* serves as a 
measure of inhibitory activity for the following saccharin derivatives. A low value 
corresponds to potent inhibition. All values quoted are for inhibition of human 
leukocyte elastase. 
1.49 
1.49aR==H 
1.49b R = i-Pr 
K/ == O.3nM, t1/2 = 45min107 
1.49c R = i-Pr, R' = OCH3 
K/ = O.27nM, t1/2 260min107 
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Further SAR study included replacement of the mercapto tetrazole with aryl 
ethers101 and phosphate esters, 102 a novel class of leaving group. Based on the results 
of Smith et al103 with related compounds, aryl carboxylates were examined as leaving 
groups resulting in the selection of 2,6-dichlorobenzoate (as in 1.50) based on its ability 
to confer superior in vitro activity and stability. 104 
1.50 
1.50a R' = H 
Ki* = O.03nM, t1/2 = 30min107 
1.50b R' == OCH3 
Ki* = O.023nM, t1/2 = 140min107 
Clinical development of these saccharin derivatives has met the same hurdles 
experienced with other mechanism-based inhibitors of serine proteases in that in vivo 
activity by oral administration has been difficult to achieve because of poor hydrolytic 
and metabolic stability.1 05 A probable cause of the low stability is the reactivity of 
compounds 1.48-50 towards esterases. 106 It has been hypothesised that these 
preferentially attack the carbonyl of the saccharin nucleus and hence increasing the 
electron density and/or the sterk hindrance around this carbonyl would reduce esterase 
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cleavage and therefore improve stability.107 Introduction of an alkoxy group at the 6-
position (1.49c and 1.50b) lead to a dramatic increase in stability, due to combined 
electronic and steric effects, and potency (Kt = O.OSnM) due to hydrogen bonding 
between the C-6 alkoxy group and Val-216 of human leukocyte elastase. 108 However, 
these compounds are very lipophilic with poor aqueous solubility and hence have poor 
in vivo activity. To improve bioavailability, compounds such as 1.51 with aqueous 
solubilizing substituents were prepared and though a decrease in stability was observed, 
1.51 displays both potent in vitro and in vivo activity,l09 
1.51 K/ = O.013nM, t1l2 = 36min109 
Compounds with a modified saccharin skeleton have also been examined for 
inhibitory activity against human leukocyte elastase. A class of inhibitors based on a 
tetrahydrosaccharin heterocycle was shown to have different SAR than the 
corresponding saccharin inhibitors with increased inhibitory activity being predicted by 
modelling and observed with less sterically demanding C-4 substituents. Compound 
1.52 was the most potent inhibitor in the series displaying similar activity to the bicyclo 
derivative 1.53,110 
1.52 1.53 
Kt = O.03nM llO Kt = O.SnMll0 
The biochemical rationale underlying the design of compound 1.54, a potential 
mechanism-based inhibitor of human leukocyte cathepsin G (Cath G),111 is based on 
the Gabriel-Colman rearrangement of either phthalimido- or saccharino-acetic esters or 
ketones. I 12 Preliminary kinetic studies support the proposed mechanism which involves 
Ser-195 induced ring-opening of the heterocycle and a prototropic shift of the resulting 
imide anion to a carbanion. Subsequent elimination of the leaving group (L) gives a 
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reactive imine that undergoes a Michael reaction with His-57 to give doubly bound 
inactive enzyme inhibitor. Compounds 1.55 and 1.56 have been found to be 
mechanism-based inhibitors ofthe same ilk.113,1l4 
1.54 
L ::= leaving group 
Z ::= activating group 
1.54a L ::= F, Z = S02Ph 
kob/[I] ::= 60 M-1s·1 / Cath Glll 
1.56 
1.55 
L ::= leaving group 
Z ::= activating group 
1.55a L ::= F, Z = S02Ph 
kobi[I] ::= 420 M-ls- l / HLEl13 
kobsl[I] ::= 100 M-1s-1 / HLE1l4 
Compounds of type 1.58, related to the saccharin example, have been found to be 
mechanism-based inhibitors of serine proteases. 115,1l6 The mechanism of action of 
these derivatives involves Ser-195 induced ring-opening of the heterocycle to give a 
reactive electrophilic species that irreversibly alkylates the enzyme. In addition to 
increasing the inhibitory activity by tailoring the R substituent and leaving group L to 
interact with the Sl and Sn' subsites respectively of the enzyme the design of L has 
considered the pathophysiology of disease states resulting from protease/anti-protease 
imbalance. 
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1.57 
1.57a R = PhCH2, L = ibuprofen 
kob/[I] = 45 M-1 s-1 / HLE1l5 
1.57b R = i-Pr 
L = OPO(OCH2Ph)2 
kinactiKI = 95000 M-1s-I / HLE116 
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Connective tissue diseases such as emphysema are associated with elevated levels of 
oxidants and are inflammatory in nature. 117 Incorporation of an anti-inflammatory 
agent such as ibuprofen for release into the surrounding milieu during the inhibition 
process provides a second therapeutic effect. However obtention of this "dual funetion" 
comes at a cost in potency as seen by comparison of 1.57a115 and 1.57b. 1l6 
Based on the knowledge of the chemistry of the compounds represented by structure 
1.58, these were proposed to be mechanism-based inhibitors of serine proteases. 118 
1.58 
1.58a RI = PhCH2, R2 = PhCH2 
L == OPO(OCH2Ph)2 
kinacl[l] == 6 000 000 M-1s-1 / HLE116 
A noteworthy feature of the design process of these compounds was the use of 
available X-ray crystal structures of human leukocyte elastase and inhibitor complexes 
to model the binding of 1.58 in the active site. These studies suggested that the 
heterocyclic ring may act as a highly effective peptidomimetic suitable for appending 
peptidyl and nonpeptidyl recognition elements allowing the optimization of binding 
interactions with the Sl sub site (through modification of Rt) and the S2-n subsites 
(modification of R2). The choice of a good leaving group, (L = halogen, S02R, 02CR, 
N-protected amino acids, phosphate esters),1l6,118,119 directly increases potency but L 
may also be choosen such that interaction with the Sn' sub sites can be achieved 
enhancing activity. 
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The optimisation of RI, R2 and L has lead to some of the most potent inhibitors of 
serine proteases for example compound 1.58a116 which mimics the preferred PI residue 
(valine) (Rl :::: CH(CH3h) and Pn and Pn' bulky residues of human leukocyte elastase 
[R2 = PhCH2, L:::: OP(O)(OCH2Ph)]. Due to the dense functionalisation present in 1.58 
this class of inhibitor could be considered to be general in nature as different serine 
proteases can be targeted by judicious modification of Rl, R2 and L. The high stability 
and efficiency (the partition ratio of compound 1.58a was found to be ca zero) of these 
inhibitors enhances their suitability as potential in vivo modifiers. 
CEPHALOSPORINS 
(<;?)n 
R S ~5)3 L 
a ~ 
R' 
1.59 
Inhibitors containing a ~-lactam nucleus are probably the most intensively studied 
mechanism-based inhibitors of serine proteases and are unique in that they have been 
used clinically for disease modification. The rationale underlying their design was 
based on elucidation of their mode of action as antibiotics which inhibited bacterial 
serine proteases 120 and ~-lactama.')es.l21 The first reported inhibitors were 
cephalosporins represented by structure 1.59.122 These form a tetrahedral intermediate 
on reaction with Ser-195 which collapses with loss of the C-3' leaving group to form a 
reactive imine tethered in the active site which unless hydrolysed, slowly but 
irreversibly alkylates His-57 to give one of three possible doubly bound inactive 
enzyme-inhibitor complexes depending on the nature of the C-7 substituent.123-126 
SAR study by the Merck groupI24,127-130 indicated activity was optimised by 
modification of the substitution at the 2-, and 7-positions: the C-2 substituent is thought 
to allow interaction with the Sn' sub sites while the C-7 substituent aetivates the lactam 
ring towards nucleophilic attack and if it has the correct orientation (a-isomer) is 
believed to bind in the enzyme's S1 specificity pocket. The oxidation state of the C-5 
sulfur atom is also important with sulfones being more active than sulfoxides or 
sulfides. Variations of the leaving group at the C-3' position did not significantly alter 
activity. Whereas 1.60 was found to be the most potent in vitro inhibitor 1.61 was more 
potent in vivo when administered intratracheally. The increased in vivo potency was 
thought to be due to the C-2 amide imparting aqueous stability and hence optimisation 
of both stability and potency lead to the synthesis of 1.62. This optimum compound still 
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lacked systemic activity due to poor stability in blood and a remedy was sought in the 
investigation of simple moncyclic ~-lactams.131 
CI O~ p ~P'~o~ 
o Ot-Bu 
H CO O~ P 3', S 
oH:&.OAC 
o NHt-Bu 
1.60 1.61 
kob/[I] = 161 000 M-1s- 1 / HLE128 kob/[I] = 2 200 M-1s-1 / HLE130 
1.62 
kob/[IJ = 3800 M-1s-1 / HLE 130 
MONO CYCLIC P-LACTAMS 
Two classes of azetidinones have been developed as mechanism based inhibitors of 
serine proteases such as elastase132 and thrombin)33 Human cytomegalovirus 
protease134 has also been targeted for potential treatment of herpes and inhibition 
studies coupled with X -ray crystallography have lead to the discovery that this enzyme 
ha'i a novel mechanism of hydrolysis which involves a catalytic triad of Ser-132, His-63 
and His-157. 135 The first class (I) represented by structure 1.63136 has an electron 
withdrawing group on the nitrogen and leaving group at the C-4 position: in the second 
class (II) (1.64)136 the nature of the substituents is reversed. The binding and 
mechanism of action were proposed131 ,137 to be the same as that described above for 
the cephalosporin derived inhibitors excepting that class II azetidinones only form a 
singly bound enzyme-inhibitor adduct which is functionally irreversible.138 The C-3 
substituent occupies the Sl subsite of the target enzyme while that of the nitrogen atom 
interacts with the Sn' subsites.136 
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1.63 1.64 
kob/[I] = 5 615 M-1s-l I HNE136 kob/[I] = 5 615 M-1s-1 I HNE136 
Structure-activity optimisation has lead to some of the most potent in activators of 
human neutrophil elastase reported. Azetidinone 1.65139 is only 2.5 times less reactive 
than the natural human neutrophil elastase inhibitor aI-proteinase inhibitor (kinact/KI = 
2 200 000 M-Is-I)140 and possesses improved stability relating to the N-carbamoyl 
group and the dialkyl substitution at C_3.139,141 Azetidinones related to 1.65 are among 
the few compounds reported to be orally active human neutrophil elastase 
inhibitors. 142,143 
1.65 
kob/[I] 867 000 M-1s- i I HNE139 
This thesis is concerned with the study of substituted succinimide and glutarimides 
which are potential mechanism-based inhibitors of the serine protease a-chymotrypsin. 
Through the employment of general synthetic routes to these compounds it is a goal to 
prepare a number of derivatives so that the relation between the extent and type of 
functionalisation and substitution and inhibitory activity can be determined on assay 
against a-chymotrypsin. 
CHAPTER 2 
SUBSTITUTED N-[(ACYL 
AND ALKYL ANF ARYL 
SULFONYL)OXY]IMIDES 
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2.1 SYNTHETIC STRATEGY 
A cornerstone of contemporary organic. synthesis is the principle of so-called 
retrosynthetic analysis. The application of retrosynthetic analysis involves the 
disconnection of larger target molecules into smaller molecules the chemist can 
recognise as freely available starting materials either from a commercial or synthetic 
source. There may exist several ways to disconnect a molecule on paper providing a 
"tree" of alternatives for its synthesis. The route chosen is a product of logical 
reasoning, based on the chemist's knowledge of reactivity and chemical reactions, and 
intuition. 
The potential mechanism-based inhibitors of serine proteases, 1.41, 2.1, and 2.2, 
contain two common structural elements: an imide skeleton essential for enzyme 
recognition and a reactive moiety essential for activity. Due to this similarity it could be 
perceived that each inhibitor be prepared using slight modifications of one central 
synthetic strategy using similar pools of precursors. In order to design such a strategy 
retrosynthetic analysis of 1.41 was undertaken, being representative of the other target 
inhibitors 2.1 and 2.2. 
R 3h4 
oANAO 
I 
OL 
1.41 
L=S02R' 
=C(O)R' 
Rn'R R" 3 4 
o ~ 0 
X 
2.2 
x = leaving group 
Rn'R R" 3 4 
o N 0 
I 
OL 
2.1 
L=S02R"' 
= C(O)R'" 
The aim of the following discussion is to present briefly those disconnections that 
exemplify the points and features that were considered in a desire to cultivate an 
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attractive and aesthetic general synthetic strategy. When considering the preliminary 
disconnections of a target molecule a commonly employed strategy is to disect the 
molecule in half. This often cultivates a shorter, more convergent synthesis than that 
which is obtained from a retrosynthetic analysis that whittles away at the molecule's 
skeleton. Following this principle, the two following retrosynthetic analyses were 
examined to the exclusion of others. 
FIRST RETROSYNTHETIC ANALYSIS OF 1.41 
R o~o 
I 
Br 
2.4 
~o 
+ OL 
1.41 
L::: S02R' 
::: C(O)R' 
Scheme 2.1 First retrosynthetic analysis of 1.41. 
The arbitrary first disconnection that appeared favourable was to cleave the bond 
between the nitrogen of the succinimide ring and the oxygen adjacent to the reactive 
group L (as shown by the wavy line in Scheme 2.1). This would lead to the silver 
alkylsulfonate and alkylcarboxylate salts and 2-substituted-N-bromosuccinimides 2.3 as 
reagents. The retrosynthetic analysis continues with the functional group 
interconversion (FGI) of 2.3 to the 2-substituted succinimides 2.4. These are readily 
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prepared from either the respective succinic acid or if the substituent is an alkyl group, 
from succinimide and the appropriate alkylhalide. 
SECOND RETROSYNTHETIC ANALYSIS OF 1.41 
The second strategy proposed for the synthesis of the target inhibitors is depicted by 
the retrosynthetic analysis shown in Scheme 2.2. This proceeds by cleaving the bond 
between the oxygen and the reactive moiety L which gives the 3-substituted-N-
hydroxysuccinimides 2.5, and alkylsulfonic and alkylcarboxylic acid derivatives as 
reagents. Disconnection of 2.5 proceeds by cleavage of the imide bonds, as indicated by 
the wavy lines, to give hydroxylamine and 2-substituted succinic acid derivatives 2.6 
and 2.7 as reagents. 
2.6 
2.6aX = Cl 
2.6b X=OH 
2.6c X = OR' 
2.5 
2.7 
1.41 
L= S02R' 
=C(O)R' 
R'S02X 
R'C(O)X 
Scheme 2.2 Second retrosynthetic analysis of target inhibitor 1.41 
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The above retrosynthetic analyses proposed two possible forward syntheses of the 
target inhibitor. The chemical competency of each of these syntheses was then 
investigated to identify the most favourable route to the target inhibitor 1.41. Of aid in 
this investigation was the substantial literature describing the synthesis of succinic and 
phthalic acid derivatives, however there existed little documentation, of which was 
disjointed, a..'l to the synthesis of substituted succinate derivatives. An aim of this thesis, 
therefore, was to make a systematic study of the preparation of these compounds. 
FIRST FORWARD SYNTHESIS OF 1.41 
2.8 
B 
A 
.. 0>00 
H 
2.9 2.4 
D 
R o~o 
I 
OL 
2.3 1.41 
L = S02R' 
L= C(O)R' 
Scheme 2.3 A, 1) NaNH2, Ih, -78 DC 2) PhCH2Br, Ih, -78 DC 
B, urea, 3h ca 200 DC 
C, HOBr or Br2 
D, AgOS02R' or Ag02CR', CH3CN, rt 
C 
The key 2-substituted succinimides 2.4 (Scheme 2.3) were prepared in two ways. In 
the case where the R substituent of 2.4 is alkyl, it may be obtained by NaNH2 mediated 
alkylation of succinimide.144 For example, 2-benzylsuccinimide 2.4 (R=PhCH2) was 
prepared in 12% yield using this methodology which is discussed later in this chapter. 
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When this reaction was not applicable, as in the case of aromatic succinimides, e.g. 2.4 
(R Ph), the 2-substituted succinimides were otherwise obtained by heating a mixture 
of the corresponding succinic acid 2.8 with two equivalents of urea for 3h at ca 200 °C 
(Step B, Scheme 2.3).1 45 Both 2-phenylsuccinimide 2.4 (R=Ph) and 2-
benzylsuccinimide 2.4 (R=PhCH2) were obtained in 65% yield in this manner. 
The remainder of this synthetic route (Steps C - D, Scheme 2.3) was examined using 
succinimide 2.9 as a model substrate. Due to the availability of N-bromosuccinimide 
the bromination reaction of Step C (Scheme 2.3) was not immediately investigated, 
however, it was anticipated that 2-substituted N-bromosuccinimides 2.3 could be 
prepared following well established literature procedures. 146 
The reaction of silver tosylate salts with alkylhalides to give alkyltosylates has been 
documented147 but to our knowledge this methodology has not been expanded to 
include a study of the reaction of halo-imides and silver sulfonate or acetate salts as a 
means of preparing compounds of type 1.41. Initial studies using commercially 
available N-bromosuccinimide (NBS) and silver (I) tosylate (prepared from reaction 
between sodium tosylate and silver nitrate)148 failed and hence the preparation of the 
target inhibitors 1.41 using the route displayed in Scheme 2.1 was abandoned. 
SECOND FORWARD SYNTHESIS OF 1.41 
The synthesis of the target inhibitor 1.41 was carried out according to the route 
shown in Scheme 2.4. 
2.6 
2.6a X = CI 
2.6bX OR 
2.6cX= OR' 
R o~ 
2.7 
A 
2.5 
Scheme 2.4 A, H2NOH B, R'S02X or R'C(O)X 
B 
1.41 
L= S02R' 
L= C(O)R' 
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The intermediate 3-substituted N-hydroxysuccinimides 2.5 were prepared from 2-
substituted succinic acid derivatives 2.6 and 2.7 by reaction with hydroxylamine. It is 
possible that on reaction of 2.6 and 2.7 with hydroxylamine (Step A, Scheme 2.4) 
mono- and di-acylation could occur at either the oxygen or nitrogen atom to give a 
mixture of products. 149 Jencks, however, has shown that acylation of the amino group 
of hydroxylamine does not usually require protection of the hydroxyl group.1 50 
However, as will be discussed, it proved more practical to utilise an O-protected form 
of hydroxylamine - O-benzyloxyamine - in many cases. The choice of whether to use 
hydroxylamine or O-benzyloxyamine was found to depend on the type of 2-substituted 
succinic acid derivative used. Hence reaction of 2.6 or 2.7 with either hydroxylamine or 
O-benzyloxyamine gave 3-substituted N-hydroxysuccinimides 2.5. Base mediated 
coupling of these with alkylsulfonic and alkylcarboxylic acid derivatives (in the 
presence of an acylation catalyst) (Step B of Scheme 2.4) then gave the desired 
compounds 1.41. 
A detailed discussion of the preparation of the succinimide inhibitors 1.41 according 
to Scheme t.4 follows, beginning with the synthesis of 2-substituted succinic acids 
which were prepared using three methods. 
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2.2 THE SYNTHESIS OF 2-SUBSTITUTED 
SUCCINIC ACIDS 
METHOD A: MALONATE ESTER ROUTE 
Monosubstituted succinic acids have been traditionally prepared using malonate ester 
condensation reactions of the type shown in Scheme 2.5. 151 A range of 2-substituted 
succinic acids can be obtained employing this methodology using different malonic 
esters as starting materials. 
A 
2.10 
C 
2.12 
.. 
Ph~02Et 
Et02C C02Et 
2.11 
2.13 
Scheme 2.5 A ethyl bromoacetate, NaOEt I EtOH, reflux 14.25h 
B KOH I EtOH, reflux 4h 
C 2.25h at 160-170 °C 
B 
Our initial goals were aimed at obtaining a good supply of 2-benzylsuccinic acid as 
the corresponding inhibitors of type 1.41 (R = PhCH2, L = S02R') have been found to 
be more specific for our target enzyme a-chymotrypsin (a-CT) than those with other 
substitution (compare the inhibitory activities of 1.41a and 1.41d towards a-
chymotrypsin which are shown below). 84 
R 
o~o 
J 
OL 
1.41 
1.41a R = i- Pr, L = S02CH3 
kob/[I] = 1 050 M-is·il a-CT84 
1.41d R = PhCH2, L = S02CH3 
kob/[I] = 9 000 M-ls·i; a-CT84 
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Halo enollactones 1.33a and 1.34a with an a-phenyl substituent have been found to 
be potent inhibitors of a-chymotrypsin (a-CT),n hence it was proposed that inhibitors 
of type 1.41 (R = Ph) may similarly be potential inhibitors. 
R 
~x o 0 
1.33 
1.33a R = Ph, X = Br 
kinac/[I] = 23 M-1 s -1 / a-Cr72 
1.34 
1.34a R = Ph, X = Br 
kinac/[I] = 73000 M-1s-1 / a-CT72 
The commercial availability of 2-phenylsuccinic acid provided a quick entry point 
into the synthesis of the corresponding inhibitors 1.41 (R = Ph, L = C(O)R', S02R') 
while 2-benzylsuccinic acid was prepared by a number of routes as detailed in this 
section. 
The initial preparation of 2-benzylsuccinic acid 2.13 was carried out as depicted in 
Scheme 2.5 following the directions of Cohen and Milovanovic.1 52 Diethyl 
benzylmalonate 2.10# was alkylated with ethyl bromo acetate in a reaction mediated by 
sodium ethoxide. Despite the long reaction course (14.25h) and attempts to remove 
unreacted starting material during work-up, the isolated product still contained 
unreacted starting material: the ratio of starting material to product was found to be 4:5 
by IH NMR analysis. This mixture was submitted to the subsequent hydrolysis (Step B, 
Scheme 2.5) to effect the synthesis of the triacid 2.12, however, a crude solid was 
isolated containing a substantial amount of benzyl malonic acid impurity which was 
due to hydrolysis of the diethyl benzylmalonate 2.10 that was present in the starting 
material. Decarboxylation (Step C, Scheme 2.5) was carried out by heating this crude 
solid for 2.25h at 160-170 oC. The desired 2-benzylsuccinic acid 2.13 was then 
obtained in an overall yield of 17% by what was a lengthy and messy work-up 
procedure (see experimental section for details). 
METHOD B: AMIDE BASE ALKYLATION OF SUCCINIMIDE 
A more general synthesis of 2-substituted succinic acids could involve first the 
construction of the essential basic succinic skeleton which is then modified by 
incorporation of the R substituent at a late stage. Taking into account the relatively poor 
yielding reactions of the above synthesis and difficulties with purification it was 
deemed advantageous, considering our desire to obtain a good supply of 2-
# We utilised commercial diethyl benzylmalonate. In our hands the literature procedure for preparing this 
compound153 resulted in difficult to separate mixtures. 
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benzyl succinic acid, that cleaner and more direct preparations of 2-alkylsuccinic acids 
be examined. 
Bryant and Hauser144 reported the potassium amide mediated benzylation of 
succinimide 2.9 to give 2-benzylsuccinimide 2.14 from which 2-benzylsuccinic acid 
2.13 can be obtained by acid hydrolysis (Scheme 2.6). The preparation of 2.14 was 
carried out in the reported low yield of 29% due to competing reactions. A substantial 
amount of higher C-alkylated product and a quantity of stilbene (generated from the 
self-condensation of benzyl chloride - a reaction which is quite facile under these 
conditions) were also obtained. 
o~o A 
H 
2.9 
Ph~ 
OAN~O 
H 
2.14 
B 
Scheme 2.6 A, 1) KNH2 or NaNH2, NH3(l) 2) PhCH2X (X = Br, CI), NH3(l) 
B, 6N HCI, reflux 1d 
2.13 
There is literature precedent that the yield of the key reaction (Step A) of Scheme 2.6 
may be optimised by changing the reaction conditions.144,154 The yield of the mono-
alkylated product appears to be dependent on the reaction temperature. Bryant and 
Hauser isolated only higher C-alkylated products when the preparation of 2.14 was 
carried out at higher temperatures in refluxing Et20 or toluene. Description of the 
apparatus used for the above authors' preparation of 2.14 in 29% yield indicated the 
reaction was carried outin refluxing ammonia (-33 OC) hence a higher yield (>29%) of 
monoalkylated product may be realised if lower temperatures are used i.e. the reaction 
is carried out at <-33 °C. 
Wolfe and Rodgers154b report improved yields for the benzylation of disodio 
glutarimide when potassium amide (65%) is replaced with sodium amide (80%). 
Greater success was also observed when a higher molar equivalency of amide base and 
longer alkylation periods were employed. The replacement of benzyl chloride with 
benzyl bromide may also result in a higher yielding reaction. This advantage may be 
offset in that the bromide may activate self condensation, producing greater amounts of 
stilbene, relative to the chloride. 
In consideration of the above the following procedure for the preparation of 2-
benzylsuccinimide was used. Succinimide 2.9 was added to a solution of sodium 
amide155 in liquid ammonia to give disodio succinimide which was benzylated on 
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addition of a solution of benzylbromide in ether to give pure 2-benzylsuccinimide 2.14 
in 12% yield. Acid hydrolysis of 2.14 with 6N Hel over a day period then gave 2-
benzylsuccinic acid 2.13 in quantatative yield. Although the yield of the monoalkylated 
product was low, the reaction provides a direct and short two step synthesis of 2-
alkyl succinic acids. This route is also versatile in that it allows the preparation of a 
number of different 2-alkylsuccinic acids by simply substituting the alkylating agent 
used. 
METHOD C: STOBBE CONDENSATION ROUTE 
The Stobbe condensation 156 has been employed as a general method for the 
preparation of 2-substituted succinic acid derivatives. 157 Groutas et a187a have reported 
the preparation of 2-alkylsuccinic acids by the route shown (Scheme 2.7) using a 
potassium t-butoxide (t-BuOK) mediated Stobbe condensation between the appropriate 
aldehyde and diethyl succinate followed by reductive hydrogenation and hydrolysis. 
Subsequently the preparation of 2-benzylsuccinic acid was undertaken using this route. 
Sodium ethoxide was used to mediate the condensation between benzaldehyde (2.15) 
and diethyl succinate (2.16) (Step A, Scheme 2.7) to give 2.17. Reductive 
hydrogenation of 2.17 gave the corresponding saturated 2-benzy lsuccinic acid 
monoethyl ester (2.18) as a yellow oil (60%). Hydrolysis of this ester was attempted a 
number of times by treatment with ethanolic NaOH as prescribed by literature 
procedures l52,157d however this was unsuccessful. Hence more vigorous reaction 
conditions were employed and 2-benzylsuccinic acid 2.13 was successfully obtained in 
82% yield (overall yield 37%) by refluxing 2.18 in ethanolic KOH for Sh. 
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° Ph~ + 1\ Et02C COzEt H 
2.15 2.16 
C 
2.18 
A 
.. 
Scheme 2.7 A NaOEt I EtOH, reflux 12h 
B. H2/1O% Pd-C I EtOAc 19h 
C. KOH I EtOH, reflux 5h 
SUMMARY 
2.17 
2.13 
43 
B 
.. 
The preparation of 2-substituted succinic acids by Method C (Scheme 2.7) as 
represented by the synthesis of 2-benzylsuccinic acid 2.13 gave the best overall yield 
(37% over three steps). The malonate ester route Method A (Scheme 2.5) gave 2.13 in 
an overall yield of 16% over three steps while 2.13 was prepared in an overall yield of 
12% in two steps using Method B (Scheme 2.6). On this basis, the method of choice 
for the preparation of 2-substituted succinic acids is Method C. However the short two 
step synthesis of Method B and its general nature make it more attractive excepting the 
low yielding alkylation reaction (Step B, Scheme 2.6). The chemistry and practice of 
this reaction was not as established as those in Method C, however there is literature 
precedent to suggest that optimisation of this reaction is possible and once undertaken 
Method B could provide the ideal route to the desired 2-alkylsuccinic acids. 
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2.3 THE SYNTHESIS OF 3-SUBSTITUTED-N-
HYDROXYSUCCINIMIDES 
The next step towards the preparation of the desired inhibitors 1.41 is the synthesis 
of the intermediate 3-substituted-N-hydroxysuccinimides 2.5 from the corresponding 2-
substituted succinic acid derivatives 2.6 and 2.7 (Scheme 2.8) by reaction with either 
hydroxylamine (conditions A) or O-benzyloxyamine (conditions C). The following 
discussion presents an investigation of the preparations of 3-alkyl-N-
hydroxysuccinimides from 2-alkylsuccinic acid derivatives in order of increasing 
utility. 
2.6 
2.6a X = CI 
2.6bX=OH 
2.6c X = OR' 
2.7 
Scheme 2.8 A H2NOH 
A 
B 
... 
B H2NOCH2Ph 
C H2, Pd catalyst 
D R'S02X or R'C(O)X 
DIESTER 
R o~o , 
OH 
2.5 
jc 
R o~o 
I 
OCH2Ph 
2.19 
R 
D 0);).0 .. 
I 
OL 
1.41 
L::::S02R' 
L:::: C(O)R' 
The use of dicarboxylic acid diesters of the type 2.6c in reactions with 0-
benzyloxyamine favours formation of monoacylated N-benzyloxyhydroxamic acids 
rather than the desired N-benzyloxyimides. N-Hydroxyphthalimide, however, has been 
obtained in a one step synthesis by acidification of the sa1t obtained from reaction of 
diethyl phthalate with hydroxylamine.I58 Reaction of diethyl 2-benzylsuccinate with an 
ethanolic hydroxylamine solution failed, however, to give the proposed salt and 
attempts to obtain 3-benzyl-N-hydroxysuccinimide 2.5 (R = PhCH2) using this 
methodology was abandoned. 
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DIACID 
It is possible to prepare imides from the diacid e.g. 2.6b and amine constituents 
under relatively harsh dehydrating conditions. For example 2-benzylsuccinimide 2.14 
was prepared by heating a mixture of 2-benzylsuccinic acid 2.13 and 2 equivalents of 
urea for 3h at 170-200 °C (Scheme 2.9). However, it was thought unlikely that a 
desirable preparation of 3-substituted N-hydroxysuccinnimides 2.5 could be realised by 
the reaction between the appropriate 2-alkylsuccinic acid and hydroxylamine 
hydrochloride despite the obvious attraction of the short one step synthesis. The 
observation that hydroxylamines form explosive mixtures at elevated temperatures also 
adds caution to such a synthesis. 149 
A 
.. 
2.13 2.14 
Scheme 2.9 A, urea, 3h at ca 170-200 °C 
A milder preparation of 3-alkyl-N-hydroxysuccinimides requires the use of activated 
acid derivatives such as acid chlorides, e.g. 2.6c, anhydrides e.g. 2.7 or by activating the 
diacid 2.6b in situ. A preparation of substituted N-benzyloxyglutarimides has been 
reported by the EDAC/HOBt mediated condensation of O-benzyloxyamine and the 
respective substituted glutaric acid.1 59 This methodology was successfully applied by 
us to the preparation of a 4,4-dialkyl-N-benzyloxyglutarimide (see Section 2.7 of this 
chapter) with the corresponding N-hydroxyglutarimide being obtained by the removal 
of the O-benzyl protecting group by catalytic hydrogenation. The preparation of 3-
benzyl-N-benzyloxysuccinimide was attempted using this methodology but was 
unsuccessful. 
DIACID CHLORIDE 
N-Hydroxyphthalimide has been prepared from reaction between the respective 
diacid chloride and hydroxylamine. 160 A route to 3-alkyl-N-hydroxysuccinimides based 
on this reaction first requires a reliable method for the preparation of substituted 
succinic diacid chlorides. In general, acid chlorides are obtained by the treatment of the 
parent acid with chlorinating agents for example succinyl dichloride has been obtained 
by reaction of succinic acid and PC15.161 The preparation of 2-benzylsuccinyl chloride 
was attempted by heating the acid with three molar equivalents of SOCh however the 
isolated white solid was identified by NMR, melting point and mass spectrometry to be 
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the respective anhydride. A milder preparation was employed using oxalyl chloride and 
DMF at room temperature but the anhydride was again obtained. Hence, in light of 
these perhaps not suprising results, it was not possible to design a synthesis of 3-
substituted N-hydroxysuccinimides from diacid chlorides as their preparation favoured 
activated ring closure to give the corresponding anhydride. 
MONO ETHYL ESTER DERIVATIVES 
The preparation of 3-alkyl-N-hydroxysuccinimides from 2-alkylsuccinic acid mono 
ethyl ester derivatives was also investigated on the basis of study of the 
functionalisation of the succinimide ring undertaken previously within the University of 
Canterbury Department of Chemistry162 it was observed that methyl hydrogen 
succinate 2.20 undergoes coupling to O-benzyloxyamine under standard DCCIHOBt 
conditions to give methyl N-benzyloxysuccinamate 2.21. Treatment of 2.21 with either 
Et3N or iso-propyl amine gave N-benzyloxysuccinmide 2.22 which on catalytic 
hydrogenation gave 2.23. 
A 1\ B • .. 
H3COl C COlH H3COl C CONHOCHlPh 
2.20 2.21 
oJ:;\o C O~O .. 
I I 
OCHlPh OH 
2.22 2.23 
Scheme 2.10 A, HCl.H2NOCH2Ph, Et3N, DCC, HOBt, CH2Cb, overnight 0-5 °C-rt 
B, Et3N, CH2Cl2, rt 2h 
C, H2, 10% Pd-C, THF, 3h 
Consequently possible preparations of substituted N-hydroxysuccinimides were 
investigated by applying this methodology to substituted succinic acid mono ethyl 
esters. Of the two esters available, ethyl 3-benzylidenesuccinate 2.17 and ethyl 3-
benzylsuccinate 2.18, obtained in the course of preparing 2-benzylsuccinic acid using 
Stobbe condensation chemistry (see Scheme 2.7) a route to 3-benzyl-N-
hydroxysuccinimide 2.26 was investigated from 2.18. The synthesis of 3-benzyl-N-
hydroxysuccinimide 2.26 from 2.18 in five steps is shown below Scheme 2.11. 
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° 1\ Ph--1 + 
H 
Et02C C02Et 
A Ph~ 
Et02C C02H 
.. 
2.15 2.16 2.17 
Phh C .. Phh 
Et02C C02H H02C CONHOCH2Ph 
2.18 2.24 
Ph~ E 
.. 
o N 0 
I 
Ph~ 
o N 0 
I 
OCH2Ph OH 
2.25 2.26 
Scheme 2.11 A, NaOEt, EtOH, reflux 12h 
B, H2, 10% Pd-C, EtOAc, 19h 
B 
D 
C, HCl.H2NOCH2Ph, Et3N, DCC, HOBt, CH2Ch, overnight 0-5 °C-rt 
D, p-TsOH, DCE, reflux 13h 
E, H2, 10% Pd-C, THF, overnight 
47 
The mono ethyl ester 2.18 was prepared as discussed previously by reductive 
hydrogenation of the Stobbe condensation product 2.17 in 46% yield (Steps A and B of 
Scheme 2.11). Coupling of O-benzyloxyamine hydrochloride to 2.18 using standard 
DCC / HOBt conditions gave a 2: 1 mixture, by 1 H NMR, of the ring opened N-
benzyloxy hydroxamic acid derivative 2.24 and the ring closed N-
benzy loxysuccinimide 2.25. 
To complete conversion to the ring closed product 2.25 a solution of a sample of the 
isolated mixture of 2.24 and 2.25 in CH2Ch was treated with triethylamine employing 
the conditions used for the cyclisation of the model compound methyl N-
benzyloxysuccinamate 2.21 discussed above (Scheme 2.10). Proton NMR analysis of 
the isolated product indicated no further cyclisation had taken place implying that 
harsher conditions were required. 
To this end a neat synthetic sample of the mixturc obtained from the coupling of 2.18 
and O-benzyloxyarnine hydrochloride was heated for 2h at 160 °C. The isolated product 
was found by IH NMR to contain a 2:3 mixture of ring-opened 2.24 and ring-closed 
2.25 implying that some further cyclisation had ocurred. The harsh conditions used 
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were deemed to be destructive considering that incomplete cyclisation took place and 
therefore a milder alternative was sought. 
Park et al163 have prepared a series of N-CBz-a-aminoglutarimides and 
succinimides from the N-protected glutamic and aspartic acids respectively. The 
ultimate step in the four step synthesis they employed involved cyclisation of methyl N-
Cbz-a-aminoglutaramates and succinanamates by refluxing with 0.5 equivalent of p-
TsOH in 
toluene for 8h in 65-82% yields. Consequently we tried these cyclisation conditions 
only to find that the reaction mixture decomposed. However, on changing the solvent 
from toluene to 1,2-dichloroethane (DCE) and refluxing for 13h we isolated the desired 
ring-closed product 2.25 in 85% yield over the two steps (C and D of Scheme 2.11). 
The desired 3-benzyl-N-hydroxysuccinimide 2.26 was then obtained by hydrogenolysis 
of 2.25 in 72% yield (Step E , Scheme 2.11). 
ANHYDRIDE 
The synthesis of 3-alkylN-hydroxysuccinimides was carried out via an anhydride 
using modifications of procedures adopted by Groutas et al.85 ,87 
A 
2.13 
B 
.. 
2.28 
R' =H, CH2Ph 
Scheme 2.12 A, AC20, reflux 
.. 
Ph~ 
oJ.-..oAo 
2.27 
Ph~ 
OJ.-.N~O 
I 
OR' 
C [ 2.25 R' CH2Ph 
2.26R' = H 
B, H2NOR' (R' = H or CH2Ph), toluene or xylene, reflux 
C, H2, 10% Pd-C, 1: 1 MeOHlEtOH, EtOAc, or THF 
B 
2-Benzylsuccinic acid 2.13, prepared as discussed earlier in this chapter, was 
refluxed with excess acetic anhydride to give the anhydride 2.27 in 90% yields. 
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However, it was found that the reaction of 2-benzylsuccinic anhydride 2.27 with 0-
benzyloxyamine was low yielding using the conditions described by Groutas et al.85 
A review of the literature preparations149,164 of the model compounds N-
benzyloxysuccinimide and N-benzyloxyphthalimide suggested that this reaction 
proceeds by initial attack of O-benzyloxyamine with concomitant ring-opening to give 
the intermediate which then undergoes ring closure with elimination of water to give the 
N-benzyloxyimide. Depending on the reaction conditions (reaction time, temperature) 
employed, either the ring opened intermediate or ring closed product can be obtained. 
For example, N-benzyloxysuccinimide has been prepared from O-benzyloxyamine and 
succinic anhydride in refluxing benzene with a reaction time of O.Sh but N-
benzyloxysuccinamic acid was obtained employing a reaction time equal only to the 
time required to mix the reagents.164 
To ensure formation of the desired N-hydroxysuccinimides we sought to employ 
longer reaction times than those used in literature preparations. Additional 
improvements on the existing literature procedures were sought by employing 
azeotropic removal of water from the reaction mixture to drive formation of the ring-
closed N-benzyloxyimide and substituting the higher boiling xylenes (bp165 137-144 
OC) for toluene (bp165 111 OC). On increasing the reaction time and employing the 
azeotropic removal of water during the reaction we observed an increase in yield for the 
preparation of 3-benzyl-N-benzyloxysuccinimide (78% cf 60%). On substituting 
xylenes for toulene there was no observed improvement in yield, however, the work-up 
of these reactions which involved evaporation of the reaction solvent proved more 
difficult. 
The original conditions employed by Groutas84 for the hydrogenolysis of 2.25 used a 
1: 1 MeOHlEtOH solvent system, desirable because of the high solubility of H2 in both 
MeOH and BtOH. Considering that both are nucleophilic it could be possible that 
formation of ring-opened derivatives of type 2.28 could occur during the hydrogenation 
reaction. Hence the work-up procedure includes evaporation of the solvent and then 
reflux of a toluene solution of the resulting residue with azeotropic removal of water to 
promote formation of the ring closed product. Substitution of 1: 1 MeOHlEtOH (61 % 
yield) with the non-nucleophilic solvent THF (72%) resulted in higher yields and 
simplified work-up procedures. 
3-Phenyl-N-hydroxysuccinimide was also prepared using the reactions described 
above (Scheme 2.13). 
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Scheme 2.13 A, AcCI, reflux 
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B, H2NOR' (R' = H, CH2Ph) 
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.. 
Commercially available 2-phenylsuccinic acid (2.29) was refluxed with an excess of 
acetyl chloride to give 2-phenylsuccinic anhydride (2.30) in 69% yield after 
recrystallisation from toluene/petroleum ether.166 Addition of O-benzyloxyamine to a 
refluxing solution of 2.30 in toluene followed by reflux with azeotropic removal of 
water for 7 hours gave 3-phenyl-N -benzyloxysuccinimide (2.31) in 70% yield. 
Hydrogenolysis of 2.31 in THF with 10% Pd-C for 4.5 hours gave 3-phenylN-
hydroxysuccinimide (2.32) with 52% mass recovery after radial chromatography. 
Despite this purification, inspection of the 1 H NMR spectrum still showed impurities. 
Similar results have been observed on the hydrogenolysis of O-benzyl hydroxamates 
similar to 2.31. 167 Despite using different types of palladium catalyst Pd-C (5%, 10% as 
above, 20%), Pd black, 10% Pd-SrC03164 and varying the reaction pressure (l0-50psi) 
the desired products were not obtained cleanly the corresponding amide being a major 
impurity. The catalyst 5% PdlBaS04 proved to be more effective in the hydrogenation 
of the described O-benzyl hydroxamates to the desired hydroxamic acids and hence 
prompted its use to effect a clean synthesis of 2.32. 
Hydrogenolysis at 50psi of 3-phenyl-N-benzyloxysuccinimide 2.31 in MeOH with 
5% Pd/BaS04 for 8 hours gave 3-phenyl-N-hydroxysuccinimide 2.32 in 37% yield 
(17% overall) and good purity after chromatography. Although a greatly reduced yield 
was observed with this catalyst, the 1 H NMR spectrum of the crude product showed 
less impurities than that of the reaction using 10% Pd-C as catalyst. 
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The O-protected form of hydroxylamine, O-benzyloxyamine, has been preferred in 
the above preparations of 2-substituted N-hydroxysuccinimides to reduce the risk of 
side reactions. Jencks 150 has shown that acylation of the amino group of hydroxylamine 
does not usually require protection of the hydroxyl group and hence shorter syntheses of 
substituted N-hydroxysuccinimides may be perceived from reaction of the anhydrides 
and hydroxylamine. 
The model compounds N-hydroxysuccinimide and N-hydroxyphthalimide have been 
obtained by reaction of the respective anhydride with hydroxylamine.168,169 N-
Hydroxyphthalimide has been obtained by simply heating a mixture of hydroxylamine 
hydrochloride, phthalic anhydride and Na2C03 in H20 for one hour.169 These reaction 
conditions have also been used by Groutas in the preparation of 3-alkylthio-N 
hydroxysuccinimides.87f 
Both 3-benzyl- and 3-phenyl-N-hydroxysuccinimide (2.26 and 2.32) were prepared 
in this manner. Hence 2.26 was prepared in 51 % yield by refluxing a solution of the 2-
benzylsuccinic anhydride 2.27, hydroxylamine hydrochloride (2 equiv.) and anhydrous 
potassium carbonate (1 equiv.) for two hours and 2.32 by refluxing a solution of 2.30, 
hydroxylamine hydrochloride and anhydrous sodium carbonate for five hours (82% 
yield). 
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2.4 THE DESIGN AND SYNTHESIS OF 3-
SUBSTITUTED N-[(ACYL AND ALKYL AND ARYL 
SULFONYL) OXY]SUCCINIMIDES 
The ultimate step in the synthesis of the target inhibitors 1.41 was the coupling of 
alkylcarboxylic and alkylsulfonic acid derivatives to the 3-substituted N-
hydroxysuccinimides 2.5 (Scheme 2.14). 
~ ol~o 
X X 
R R 
2.6 
.. o):;Ao A 0);).0 .. R .. 
o):;Ao I I OH OL 
2.5 1.41 
2.7 L== SOzR' 
L == C(O)R' 
Scheme 2.14 A, R'S02X or R'C(O)X 
The object of this thesis was to examine the effect the L group of 1.41 had on 
inhibitory activity. The design of these derivatives is discussed later but aspects 
included the incorporation of favourable substitution capable of harnessing the binding 
energy available through interaction with the Sn and Sn' subsites of a-chymotrypsin and 
increasing the number of equivalents of reactive species released during inhibition. 
The preparation of the N-[(sulfonyl)oxy]succinimide derivatives 1.41 (L == S02R') in 
Table 2.1 was undertaken according to literature procedures for N-hydroxyphthalimide 
or succinimide substrates,85,87,91,170 which prescribe the treatment of 2.5 with base 
followed by the alkylcarboxylic and alkylsulfonic acid derivative. A variety of bases 
have been used for this reaction including aqueous sodium bicarbonate and hydroxide, 
and pyridine (two equivalents have been normally employed) or triethylamine if organic 
solvents (benzene, dichloromethane, chloroform, toluene) have been used. Different 
reaction times and temperatures have also been used with a continuum ranging from 
20min at 0-5 °C followed by the same period at room temperature to room temperature 
overnight to ultimately 40°C overnight. 
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R 
o~o 
I 
OH 
2.26 R = PhCH2 
2.32 R = Ph 
A 
B 
C 
.. 
R o~o 
I 
OL 
1.41 
L=S02R' 
Conditions A Sulfonylation at 0-5 DC 
B Sulfonylation at rt 
C Sulfonylation at 50 DC 
Compound R L 
number 
1.41d PhCH2 S02CH3 
e Ph S02CH3 
f PhCH2 S02 ~Ph 
g PhCH2 
S02-{ > 
h PhCH2 
S02-G-CH3 
i Ph 
S02-G-CH3 
j PhCH2 
S02-{ ~ > 
k PhCH2 N02 
S02-{ ~ 
I PhCH2 CH3 ~ S02 C02Et 
rn PhCH2 o Ph S020-N~ 
S02-{ ~ 0 
n PhCH2 £(Ph 
o N 0 
S02-{ > < )t-S026 
Table 2.1 N-[(sulfonyl)oxy]succinimide inhibitors of type 1.41 
Conditions 
B 
A 
A 
B 
A 
A 
A 
A 
C 
A 
C 
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To effect the sulfonylation of 2.5 three distinct procedures were employed. The 
mildest (Method A) involved treating an organic solution of 2.5 with either two 
equivalents of pyridine or a slight excess of triethylamine followed by the appropriate 
sulfonyl chloride for 0.5h at 0-5 °C and then allowing the reaction mixture to rise to 
room temperature normally overnight. A second procedure (Method B) was a slight 
modification of the first with the reaction being carried out at room temperature. 
Dichloromethane was generally used as the reaction solvent except when solubility 
problems were encountered requiring a third procedure (Method C) in which toluene 
replaced dichloromethane and the reaction was carried out at an elevated temperature of 
40-50°C. 
When 2.26 was the substrate there was no noticeable difference in the nearly 
quantatative yields observed between reactions mediated with pyridine or triethylamine 
however when the latter was employed triethylamine hydrochloride deposited from the 
reaction mixture requiring a filtration step in the work-up procedure. However treatment 
of a solution of 3-phenyl-N-hydroxysuccinimide 2.32 in toluene with pyridine followed 
by methanesulfonyl chloride using the conditions of Method B (24 hours at room 
temperature) failed to give the desired compound 1.41e (R = Ph, L S02CH3) in 
anything greater than ca 5-10% by 1 H NMR. Similar results were obtained using the 
same reagents and employing the conditions of Method C with the temperature raised 
to 50 °C for two hours. These results prompted a change in base. Employing Method 
A, a solution of 2.32 in dichloromethane was treated with Hunigs base (N,N-
diisopropylethylamine) followed by methanesulfonyl chloride which gave 1.41e in 98% 
yield and high purity. 
The Mitsunobu reaction 172 was also investigated as a method for the esterification of 
compounds of this type, using N-hydroxysuccinimide as a model. A solution of N-
hydroxysuccinimide, triphenylphosphine, diethylazodicarboxylate and methane sulfonic 
acid was stirred at room temperature for 24 hours. Although similar compounds have 
been prepared in this way, N-[(methanesulfonyl)oxy]succinimide was not obtained. 173 
It has been found that the potency of the inhibitors 1.41 can be enhanced by 
judicious choice of the R' substituent of the reactive moiety L. Substitution of the R' 
group with improved electron withdrawing capabilites relative to the simple analogues 
1.41d and 1.41e will result in increased inhibitory activity. In addition the R' substituent 
may be modified to allow interaction with the secondary Sn' subsites of the serine 
protease improving enzyme-inhibitor recognition and hence inhibitory activity. For 
example Groutas et al87a observed a dramatic ten-fold increase enhancement of activity 
against human leukocyte elastase on replacement of R' methyl substituent (1.41a) with a 
trans-styryl group (1.41b). 
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R o~o 
I 
OL 
1.41 
1.41a R :;::: i- Pr, L :;::: S02CH3 
kobi[I] :;::: 3 817 M-1s-l / HLE87a 
1.41h R:;::: i-Pr, L :;::: S02transstyryl 
k /[1] > 100 000 M-1s-1 / HLE87a obs 
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This result prompted the synthesis of derivatives of type 1.41 with R' aromatic 
substituents that may utilise the potential increased binding energy available by 
interaction with the Sn' subsites (for a definition see Section 1.1, Chapter 1). Hence 
benzene sulfonyl chloride was coupled to 2.26 and p-toluenesulfony lchloride coupled to 
both 2.26 and 2.32 to give inhibitors 1.41g-i respectively. The more sterically 
demanding 2-napthalenesulfonyl chloride was coupled to 2.26 to give an inhibitor 1.41j 
which extended further into the Su' subsites. To study the increased electron 
withdrawing effects within this aromatic series 3-nitrobenzenesulfonyl chloride, 
obtained from the available sodium sulfonate by reaction with PCIs/POC13,174 was 
coupled to 2.26 to give 1.41k. 
Chapter 2 - SubstitutedN-[(acyl and alkyl and aryl sulf()llyl)oxy]c!....i_m_id_e_s ______ 56 
Ph o~o 
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I ~Ph 
0802 
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1.41j 
1.41h 
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Figure 2.1 Aromatic series of succinimide inhibitors 1.41 
The stereoselective synthesis of the 3-amino-3-alkyl-N-benzyloxysuccinimide 2.33 
permitted the preparation via the N-hydroxysuccinimide intermediate 2.34 of imide 
containing psuedo peptides 2.35,175 which were found to be inhibitors of serine 
proteases with extension in the N direction.1 76 An aim was to expand this work 
completed within the University of Canterbury Department of Chemistry to the 
incorporation of an inhibitor of type 1.41 into a complete psuedo peptide sequence 2.36. 
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OCH2 Ph 
2.33 
PI:::: PhCHz 
2.34 
PI:::: PhCHz 
2.36 
PI:::: PhCHz 
2.35 
PI ::::PhCH2 
Figure 2.2 Synthetic Strategy for preparation of "extended" inhibitors 
The strategy employed for the preparation of "extended" inhibitors of type 2.36 
involved the synthesis of an alkylsulfonyl chloride with substitution similar to that of a 
natural amino acid hence containing structural features able to improve enzyme-
inhibitor recognition and the functionality to permit further extension by the proposed 
coupling of other amino acids. Coupling of such a designed sulfonyl chloride to the 
peptidic N-hydroxysuccinimide 2.34 using the reaction conditions described above 
would give a peptidyl inhibitor of type 2.36. Compound 1.411 was targeted as an initial 
step towards this goaL 
The synthesis of the sulfonyl chloride 2.40176 designed as a Pn' alanine mimic and 
the subsequent coupling reaction to give the corresponding inhibitor 1.411 extending in 
the C-direction is shown in Scheme 2.15. 
Commercially available 2-bromo-propionic acid (2.37), the starting point of the 
above scheme, was esterified with SOCl2 and BtOH to give ethyl 2-bromopropionate 
(2.38) in 30% yield. The potassium sulfonate salt 2.39 was obtained from the 
Strecker178 reaction between an ethanolic solution of 2.38 and aqueous K2S03. 
Activation with PCls and POCl3 gave the sulfonyl chloride 2.40 in 11 % yield which on 
pyridine mediated coupling to 2.26 gave lAll in 28% yield after purification by flash 
Si02 chromatography. 
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Scheme 2.15 A, 1) SOCh, reflux 2) BtOH, 0-5 DC-rt 
B, K2S03, 12% v/v BtOH, reflux 
C, PC15, POCh, overnight 70 DC 
D, 2.26, pyridine, CH2Ch, I8h 50 DC 
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D 
• 
Inhibitors such as 1.411 interact with a-chymotrypsin in the manner that one 
molecule of 1.411 yields one molecule of inactivating species. Increased inactivation 
may be realised if on interaction with a-chymotrypsin an inhibitor yielded two 
equivalents of inactivating species. Of mechanistic interest, therefore, was the activity 
of the two so-called 'dimeric' inhibitors 1.41m and 1.41n prepared from the coupling of 
the commercially available disulfonyl chlorides and 2.26. It is proposed that the 
stoichiometry of inactivation will be different from the monomeric inhibitors, e.g. 
1.41d, resulting in two molecules of enzyme being inhibited for one molecule of 
inhibitor resulting in a more rapid inactivation. 
Ph~ 
OAN~O 
I 
OH 
2.26 1.41m 
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Ph~ 
OJ.-..N~O 
I 
OR 
2.26 
Ph~ °VPh 
OJ.-..N~~S020--N 
I - 0 
OS02 ~ A 
1.41n 
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The biochemical rationale underlying the design of N-sulfonyloxy succinimide 
mechanism based inhibitors discussed above was based on the knowledge that these 
derivatives are known to undergo spontaneous Lossen rearrangements on reaction with 
nucleophiles to produce aliphatic isocyanates. These are known affinity label 
inactivators of serine proteases reacting with His-57. The Lossen rearrangement was 
first observed in amide systems88 and has also been observed in N-
[(acyl)oxy]phthalimide derivatives179 and hence we proposed that N-acyloxy imides 
1.41(R = Ph, PhCH2, L = C(O)R') may be potential mechanism based inhibitors 
operating with the same mechanism of action as their sulfonylated counterparts 1.41 (R 
= Ph, PhCH2, L = S02R'). 
Inhibitors of type 1.41 (R = Ph, PhCH2, L = C(O)R') , see Table 2.2, were prepared 
by the base mediated coupling of either acetic anhdride with N,N-dimethyl-4-
aminopyridine (DMAP) as a reaction catalyst, or acetyl chloride to 2.26 and 2.32 to 
give the acetyl derivatives 1.410 and 1.41p. Reaction of cinnamic acid with 2.26 
mediated by triethylamine and catalysed by DMAP gave the proposed "dual" inhibitor 
1.41q which in addition to inhibiting a-chymotrypsin will release cinnamic acid, a 
known anti-oxidant, to combat the high level of free radicals associated with the disease 
states resulting from unregulated a-chymotrypsin activity. To enhance inhibitory 
activity through interaction with the enzyme's Sn' subsites the extended inhibitor 1.41r 
was prepared by DCCIHOBt mediated coupling of 2.26 to N-benzyloxycarbonyl-(L)-
phenylalanine (N-CBz-(L)-Phe). 
The syntheses of 1.410-r by these methods gave crude products which required 
further purification either by acid and base washing and crystallisation or 
chromatography. Hence a cleaner acylation procedure was sought. Procopiou et al180 
have published results describing the use of trimethylsilyl trifluoromethanesulfonate 
(TMSOTf) as a catalyst in what are fast and efficient acylations of a variety of alcohols. 
Applying this methodology initially to the synthesis of 1.410 a faster and cleaner 
reaction in higher yield was observed requiring less equivalents of acylating agent and 
catalyst. Specifically, reaction of 2.26 with AC20 (1.5 equiv.) and TMSOTf (0.02 
equiv.) gave 1.410 as a white crystalline solid in 86% yield, whereas under the original 
conditions, reaction of 2.28 and AC20 (2 equiv.), Et3N (1.1 equiv.) and DMAP (0.1 
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A 
R B R 
0):).0 C 0):).0 D I I 
OH E OL 
2.26 R = PhCH2 1.41 
2.32 R =Ph L=C(O)R' 
Conditions A Et3N or i-PrNEt and DMAP catalysed acylation 
B Et3N or i-PrNEt acylation 
Compound 
number 
1.410 
P 
q 
r 
C TMSOTf acetylation 
D TMSOTf acylation with in situ mixed anhydride 
E DCC, HOBt mediated acid coupling 
R L Conditions 
PhCH2 Ac A,C 
Ph Ac B 
PhCH2 C~Ph A,D 
II 
0 
PhCH2 Ph, E _ 0 
CANJlO ........... Ph 
II H 0 
Table 2.2 Inhibitors of type 1.41 (R = Ph, PhCH2, L = C(O)R') 
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equiv.) gave 1.410 as a brown residue in 79% yield after purification by acid and base 
washing. 
Procopiou's method requires the use of anhydrides as acylating agents. The synthesis 
of 1.41q and 1.41r would therefore require a supply of trans-cinnamic acid anhydride 
and N-Cbz-(L)-phe acid anhydride both of which are not commercially available and 
difficult to prepare. The use of mixed anhydrides generated in situ as acylating agents 
was investigated as a solution to this problem hence the synthesis of 1.41p was 
attempted using this methodology (Scheme 2.16). 
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2.41 
Scheme 2.16 AN-methyl morpholine, CIC(O)OEt, 0 °C 
B 2.26, TMSOTf, overnight, 0-5 °C-rt 
B 
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1.41q 
Trans -cinnamic acid (2 equiv.) was treated with ethyl chloroformate (2 equiv.) and 
N -methyl morpholine (2 equiv.) at 0 °C to generate the mixed ahydride 2.41. Reaction 
of this with 2.26 and TMSOTf (0.02 equiv.) gave a brown residue that was found to 
contain 2.41 and the desired product 1.41q in a 1: 1 ratio, by 1 H NMR. It was proposed 
a cleaner reaction may be observed if the equivalency of the mixed anhydride and 
therefore that of trans-cinnamic acid and N-methyl morpho line used be lowered. 
Subsequently the reaction was repeated with only 1.05 equivalents of acid and base and 
pure 1.41q as a white solid in 86% yield. 
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2.7 DESIGN AND SYNTHESIS OF SUBSTITUTED 
N-[(ACETYL AND METHANESULFONYL)OXY] 
GLUTARIMIDES 
In order to study the effect ring size has on inhibitory activity a number of previously 
unknown substituted N-[(acyl and alkylsulfonyl)oxy]glutarimides represented by 
structure 2.1 were prepared which are represented in Table 2.3. 
Compound R 
number 
2.1a Ph 
2.1b Ph 
2.1c PhCH2 
2.1d H 
2.1e H 
2.lf H 
R' 
H 
H 
H 
Ph 
RlC).'R " 
3 4 
o N 0 
I 
OL 
2.1 
R" 
H 
H 
H 
H 
R', R":::: cyc10hexyl 
CH3 CH3 
Table 4.1 Potential inhibitors of type 2.1 
L 
S02CH3 
Ac 
S02CH3 
S02CH3 
S02CH3 
S02CH3 
The a-C substituents of the related succinimide inhibitors 1.41 are proposed to 
interact with the S1 subsite of a-chymotrypsin hence the potent and specific inhibition 
of this enzyme by derivatives of type 1.41 with an aromatic a-C substituent as 
illustrated by the inhibitory activities of 1.41d against human leukocyte elastase and a-
chymotrypsin. It was proposed that by judicious choice of the extent and type of 
substitution present on the glutarimide ring that similar increased activity could be 
observed. 
The retrosynthetic analysis of 2.1 (Scheme 2.17) proceeds in the same manner as the 
second retrosynthetic analysis described for 1.41 (see Scheme 2.2, Section 2.1). 
Disconnection of the bond between the oxygen and that of the reactive moiety (L) gives 
substituted N-hydroxyglutarimides 2.42 and alkyl sulfonic and alky1carboxylic acid 
derivatives. The preferred syntheses of 2-suhstituted N-hydroxysuccimides, the key 
intermediates in the synthesis of derivatives of type 1.41, involved either the anhydride 
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Scheme 2.17 Retrosynthetic analysis of glutarimide inhibitors 2.1 
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or mono ethyl ester. The latter was prepared using the Stobbe condensation of diethyl 
succinate and appropriate aldehyde. Diethyl glutarate cannot be used as a substrate in 
this reaction 157c and hence an efficient route to N-hydroxyglutarimides can only be 
realised through the anhydride. Hence disconnection of 2.42 gives the the glutaric acid 
anhydride 2.43 and hydroxylamine. The anhydride 2.43 is derived from the 
corresponding glutaric acid 2.44. 
The substitution present on the glutarimide ring is directly obtained from that present 
in the glutaric acid starting materials. The prepartion of potent inhibitors therefore 
required a supply of aromatic glutaric acids. The aromatic 2- and 3-phenylglutaric acids 
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are commercially available and hence provided a quick entry point into the synthesis of 
desired inhibitors 2.1 (R, R', R" is aromatic). Of particular interest was the inhibitory 
activity of 2.1c (R == PhCH2, R', R" == H) which possesses the a-benzyl substitutent 
found to impart higher inhibitory activity towards a-chymotrypsin in the succinimide 
series (compare 1.41a and 1.41d above). 
The required synthesis of 2-benzyl-glutaric acid 2.44b was carried out employing 
Michael reaction chemistry181 following literature procedures for the preparation of 2-
alkyl glutaric acids.182 
A 
.. 
2.10 2.45 
~ 
O~ ~O 
OH OH 
2.44b 
Scheme 2.17 A, acrylonitrile, 30% KOH, MeOH, t-BuOH, 4.5h, rt 
B, 68% RBr, Id, reflux 
A Michael reaction between diethyl benzylmalonate 2.10 and acrylonitrile gave the 
malonate eser 2.45 in 50% yield after distillation at reduced pressure. Acid hydrolysis of 
2.47 then followed to give 2-benzylglutaric acid 2.44b in 72% yield. 
As part of research being undertaken into anti-epilepsy agents within the University 
of Canterbury Chemistry Department methodology for the preparation 3,3-disubstituted 
glutaric acids 2.44 was being developed. To extend the scope of the SAR study of the 
glutarimide inhibitor series 4,4-disubstituted inhibitors 2.1 (R == H, R', R" == alkyl) were 
prepared from the corresponding 3,3-disubstituted glutaric acids. 
Of the synthetic methods available for the synthesis of 3,3 disubstituted glutaric acid 
derivatives the Guareschi route (Scheme 2.18) is the most favoured where applicable. 
The formation of the key "Guareschi" imide intermediate 2.48 of Scheme 2.18 is 
believed to occur in two steps at least. The starting ketone represented by structure 2.46 
undergoes a Knoevenagel condensation with ethyl 2-cyanoacetate, which was used in 
our synthesis, catalysed by the liquid ammonia solvent to give the a-~ unsaturated 
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compound 2.47. This undergoes a Michael reaction with 2-cyanoacetamide resulting 
from solvolysis of ethyl cyanoacetate and concomitant cyclisation to give the Guareschi 
imide 4,4-dialkyl-3,5-dicyanoglutarimide 2.48. Simple acid hydrolysis of 2.48 gives the 
desired 3,3-disubstituted glutaric acids. 
'R R" 
'IT A 
o 
2.46 
2.46a R', R" = CH3 
2.48 
2.48a R', R" = CH3 
B 
'R R" 
Nc1C02Et 
2.47 
'R R" 
:1\0 
OH OH 
2.44 
2.44e R = H, R', R" = CH3 
Scheme 2.18 Guareschi route to 3,3-disubstituted glutaric acids 
The Guareschi route has been applied to a number of substrates however the key 
Guareschi imide intermediate has not been observed in a number of examples.185 This 
occurs when the starting materials do not suit the chemistry of the Knoevenagel 
condensation or if suitable give derivatives of type 2.47 which are unsuitable for the 
following Michael reaction and ring closure. Hence the scope of the reaction is limited 
to ketones which are not sterically hindered and less certainly those that have an 
enolizable a-proton)86 Acetone fits this criteria and, therefore, it was proposed to use 
this Guareschi imide methodology in the preparation of 3,3-dimethyl glutaric acid 
2.44e. Cyclohexylglutaric acid 2.44d was also prepared in this manner and the 
corresponding Guareschi imide was a generous gift from Dr. Rob McKeown. 
Subsequently the synthesis of 3,3-dimethyl glutaric acid 2.44e was carried out using 
the Guareschi route. The Guareschi imide 2.48a was prepared in 42% by acidification of 
the ammonium salt that was deposited on storing a solution of ethylcyanoacetate and 
acetone 2.46a in ethanol saturated with ammonia for three days at ca -5 °C. Subsequent 
sulfuric acid hydrolysis of 2.48a gave the desired 3,3-dimethylglutaric acid 2.44e. 
The preparation of the desired substituted N-[(alkylsulfonyl)oxy]glutarimide 
inhibitors 2.2 from glutaric acid precursors was then carried out according to Scheme 
2.19 
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The variously substituted glutaric acids whether obtained from a commercial source 
or synthesised as described above were treated with either acetyl chloride (in the case of 
2.44a) or acetic anhydride (for 2.44b-e) under refluxing conditions to give the 
respective anhydrides in high yields ranging from 84% for the preparation of 2-
phenyl glutaric anhydride 2.43a to 91 % for cy!cohexylglutaric anhydride 2.43d. 
The anhydrides 2.43 were then refluxed with O-benzyloxyamine to give the N-
protected glutarimides 2.49 in typically 80% yield. Hydrogenolysis of these gave the N-
hydroxyglutarimides 2.42 in yields of 70% which were then treated with the appropriate 
alkyl sulfony!Chloride or acid chloride to give the desired inhibitors. As observed with 
the succinimide series of compounds this reaction proceeded in nearly quantatative 
yield. 
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Shorter routes to the desired inhibitors were realised by the reaction of 
hydroxylamine directly with the anhydride 2.43. Both 4,4-dimethyl-N-
hydroxyglutarimide 2.42e and 3-phenyl-N-hydroxyglutarimide were prepared in 50% 
yield in this manner. A short route to 2.42e was also investigated by coupling 0-
benzyloxyamine directly to the acid 2.44e using EDAC however the low yield of this 
reaction (12%) indicated this route was of poor preparative value considering the high 
yields of the reactions of Scheme 2.19. 
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2.6 SIJMMARY 
A brief retrosynthetic analysis of the target inhibitor 1.41 suggested two general 
syntheses. The chemical competency of these was examined and a route involving 3-
substituted N -hydroxysuccinimides as key intermediates was identified to be the most 
desirable to the demise of a route proceeding via 2-substituted succinimides. This route 
involved the reaction of succinimides with silver carboxylate and sulfonate salts as a 
means of preparing inhibitors of type 1.41 but this reaction was unsuccessful. 
The synthesis of 3-substituted N-hydroxysuccinimides 2.8 was carried out by 
reaction of activated 2-substituted succinic acid derivatives and either hydroxylamine or 
a protected form of this O-benzyloxyamine. The synthesis of 3-benzyl-N-
hydroxysuccinimide was a key goal as inhibitors derived from this display increased 
specificity for a-chymotrypsin. Consequently some effort was directed towards 
investigating routes to this key intermediate from activated 2-benzylsuccinates requiring 
a good synthetic supply of 2-benzylsuccinic acid. Three methods for the preparation of 
the representative 2-benzylsuccinc acid were therefore compared. A route employing 
the Stobbe condensation between benzaldehyde and diethylsuccinate gave the highest 
overall yield and was preferred for the ease of its well established reactions. However a 
short (two step) and general synthesis which involved the sodium amide mediated 
benzylation of succinimide as a key reaction may provide the ideal route to 2-
alkylsuccinic acids with further optimisation. 
The failed preparation of 3-benzyl-N-hydroxysuccinimide from the reaction of 2-
benzyl succinic acid activated in situ by treatment with the coupling reagent EDAC with 
O-benzyloxyamine prompted the use of more activated derivatives. Of those derivatives 
successful syntheses of 3-benzyl-N-hydroxysuccinimide were carried oput from the 
anhydride and 2-benzylsuccinic acid mono ethyl ester in six and five steps respectively 
with O-benzyloxyamine. The reaction of hydroxylamine and the anhydride proved to be 
a successful preparation of 3-benzyl-N-hydroxysuccinimide in five steps whereas the 
use of hydroxylamine in reaction with the mono ethyl ester failed.Of the two successful 
five step syntheses a greater overall yield was observed with that route involving the 
mono ethyl ester (30%) than that involving the anhydride (18%) and in conclusion this 
synthesis was found to be the preferred preparation of 3-benzyl-N-hydroxysuccinimide. 
To complete the synthesis of the target inhibitors 1.41 (R = Ph, PhCH2, L = S02R') 
various sulfonyl chlorides were coupled to the 3-substituted N-hydroxysuccinimides 
2.28 and 2.34 using modifications of literature procedures. The nature of the sulfonyl 
chloride used affects the potency of the resulting inhibitors and hence is an important 
design element. Literature SAR results indicated that bulky sulfonyl chlorides with 
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good electron withdrawing properties would furnish the most potent inhibitors in this 
series and subsequently an aromatic series was studied. To add to a conceived strategy 
of enhancing inhibitory activity by incorporating the inhibitors of type 1.41 into a 
complete psuedo peptide sequence a tailored sulfonyl chloride was synthesised 
permitting the preparation of an inhibitor extending in the C-direction. Two examples 
of so-called "dimeric" inhibitors were prepared to study the effects of stoichiometry on 
inhibition. 
N-Acyloxyimides are also known to undergo a Lossen rearrangement when treated 
with nucleophiles hence these were proposed to be potential mechanism-based 
inhibitors of the same ilk as N-sulfonyloxyimides. 88 The acylation of 2.28 and 2.34 
using Hunigs base or triethylamine with DMAP as a catalyst gave crude products. An 
improved procedure employed the use of TMSOTf as a catalyst for acetylations which 
was expanded to include acylations using mixed anhydride methodology. Acyl 
chlorides and anhydrides were chosen so that a number of the the resulting inhibitors 
possessed the same substitution as the related N-sulfonyloxyimides to provide a direct 
comparison in activity. An extended inhibitor of type 1.41 (R = PhCH2, L = C(O)R') 
was prepared by the coupling of N-protected phenylalanine to 2.28 . 
To study the effect of ring size on inhibitory activity six membered glutarimide 
inhbitors were prepared using the synthetic methodology developed above for the 
succinimide series. The favoured route for the succinimides using the Stobbe 
condensation was not applicable to the glutarimides series as this reaction cannot 
tolerate glutarimide substrates and therefore the method employed proceeded through 
the anhydride. 
It was also desirable to examine what effect the type and extent of substitution had 
on inhibitory activity which required a supply of both mono and disubstituted alkyl and 
aromatic glutaric acids. The synthesis of a-benzylglutaric acid was effected through 
Michael reaction chemistry and a number of dialkyl glutaric acids were prepared using 
the Guareschi route. Glutarimide inhibitors were then prepared in good yield from the 
respective acids through a four step synthetic sequence proceeding through the 
anhydride, N-protected glutarimide and N-hydroxyglutarimide. 
CHAPTER 3 
a-CHYMOTRYPSIN 
INHIBITION ASSAYS 
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3.1 MECHANISM FOR INACTIVATION OF ct-
CHYMOTRYPSIN BY N-[(ACYL AND ALKYL AND 
ARYL SULFONYL) OXY]IMIDES 
The mechanism of inactivation of a-chymotrypsin by the substituted N-[(acyl and 
sulfonyl)oxy]imides (1.41 and 2.1) is proposed to be the same as that identified by 
Groutas et a185 for the succinirnide inhibitor 1.41d. This mechanism is depicted in 
Scheme 3.1. 
R 
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L=S02R' 
= C(O)R' 
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Rfl'R R" 
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Accommodation of the inhibitor in the active-site of the enzyme through interactions 
between the R substituent and the primary specificity site S 1 of the enzyme to give the 
enzyme-inhibitor Michaelis complex (3.1), is followed by acylation of the active site 
serine (Ser-195) to yield 3.2. Lossen rearrangement of 3.2 then generates an enzyme 
bound isocyanate 3.3 which competes with deacylation which gives the free isocyanate 
3.5. The enzyme bound isocyanate 3.3 then reacts rapidly with a nucleophile present in 
the active site. In particular, acylation of the imidazole ring of the active site amino acid 
His-57 (Pathway I) results in formation of 3.4, the likely final inactive enzyme species. 
Hydrolysis of the Ser-195 ester linkage of 3.3 (Pathway II) results in the release of the 
reactive free isocyanate 3.5 from the enzyme in a "turnover" event. Hydrolysis of the 
isocyanate 3.3 (pathway III) gives the acyl enzyme 3.6. If stable, 3.6 may inactivate the 
enzyme during its lifetime which depends on the rate of hydrolysis to the amine 3.7. It 
is believed that the acyl enzyme 3.6 is short lived and hence pathway III will be acting 
predominantly as a "turnover" pathway. The urea linkage of the inactive enzyme-
inhibitor adduct 3.4 is also susceptible to hydrolysis, by analogy with related imidazole 
N-carboxarnides,53 leading to fonnation of 3.5. 
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Scheme 3.1 Proposed mechanism of inhibition of a-chymotrypsin by 1.41 and 2.1 
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The reactive enzyme bound isocyanate 3.3 reacts in three ways (Pathways I-In) all 
of which ultimately lead to the release of free isocyanate 3.5 from the enzyme. This 
undergoes rapid hydrolysis with concomitant decarboxylation to form the highlighted 
amine 3.7. Aliphatic isocyanates, such as 3.5, have been shown to be act as inactivators 
of serine proteases, including a-chymotrypsin,49 and hence it is thought that the 
isocyanate 3.5 or the amine 3.7 may playa part in the inactivation process in concert 
with the enzyme bound isocyanate 3.3. 
Indirect evidence supporting the proposed mechanism (Scheme 3.1) has been 
obtained.84,87e Reaction of equivalent amounts of the inhibitor lAId and sodium 
methoxide in methanol resulted in formation of a mixture of two isomeric Lossen 
rearrangement products 3.8 and 3.9 (Scheme 3.2). 
PhL\ Ph 0 Phh A r~~CH3 + H3COyNH COZCH3 o N 0 
1 o OCH OSOzCH3 3 0 
1.41d 3.8 3.9 
Scheme 3.2 A, NaOCH3, CH30H, Ih, rt. 
The isocyanate 3.10 has also been observed to react with imidazole to give the 
imidazole N-carboxamide 3.11 in quantitative yield. 
eCOzEt 
A eCO~t 
.. 
NJlN:it N"C H 'LJ 
"0 
3.10 3.11 
Scheme 3.3 A, imidazole, Ih, room temperature 
The urea linkage of imidazole-N-carboximides such as 3.4 is labile to nucleophiles, 
and hence treatment of inactivated enzyme with appropriate nucleophilic reagents 
should result in reactivation of the enzyme. Reactivation of inactivated enzyme has 
been observed in experiments undertaken with hydroxylamine and dithiothreitol, results 
which support formation of 3.4. 
Isocyanates 3.3 and 3.5, are both reactive towards nucleophiles. If an external 
nucleophile is present during the inactivation process it will scavenge both 3.3 and 3.5, 
and if these are involved in the inactivation process, the enzyme will be protected. 
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Experimentally a lower rate of inactivation will be observed for an inhibition 
experiment carried out in the presence of an external nucleophile than the control 
experiment carried out in its absence. This result has been observed in these types of 
experiments performed by Groutas et al,84 and supports the existence of isocyanates 3.3 
and 3.5 in the proposed mechanism (Scheme 3.1). 
Direct evidence85 in support of the proposed mechanism of inactivation has been 
obtained from a high resolution 13C NMR experiment in D20 (7.5% DMSO-d6) using 
13C labelled (C-5) inhibitor 3.12. Incubation of an equivalent amount of 3.12 with a-
chymotrypsin led to the appearance of resonances at 176 and 126ppm in the 13C NMR 
spectrum. These resonances are consistent with the formation of the imidazole-N-
carboximide 3.4 due to pathway I and the free isocyanate 3.5 presumably resulting 
from pathway II of Scheme 3.1. 
3.12 
The elucidation of the mechanism of inactivation of Scheme 3.1 provides evidence 
that inhibition of a-chymotrypsin by 1.41d involves the catalysis by the enzyme. This 
is one criterium of a set of criteria that have been developed to establish the occurrence 
of mechanism-based Inhibition. Important criteria include: 
Time-dependent loss of activity: for mechanism-based inactivation enzyme activity 
should decrease over time. Ideally, psuedo first-order kinetics is observed. 
Saturation: the rate of the inactivation is dependent on the extent of formation of the 
Michaelis enzyme-inhibitor complex. A point will be reached when all the enzyme is 
saturated with inhibitor and the addition of further amounts of inhibitor will not affect 
the rate of inactivation. Therefore there will exist a maximum rate of inactivation for a 
mechanism-based inhibitor. 
Irreversibility: mechanism-based inactivation is irreversible in nature; in general the 
inactive enzyme-inhibitor adduct contains a functionally covalent linkage and, unlike a 
reversible inhibitor, no enzyme activity will be recovered on gel filtration or dialysis. 
Inactivation Occurs Prior to Release of the Activated Species: one of the features of 
mechanism-based inhibition is that it is specific. This specificity of action will be lost if 
the active species escapes and then returns to inactivate the enzyme as is the case for 
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affinity labels or a so-called "paracatalytic" inhibitors. Mechanism-based inactivation 
will show no "lag" phase and will not be affected by the presence of nuc1eophiles. 
Partition Ratio: this concept is unique to mechanism-based inhbition. This term 
introduced by Walsh, 54 describes the ratio of the number of latent inhibitor molecules 
converted and released as product relative to each turnover leading to enzyme 
inactivation. The partition ratio, therefore is a measure of the efficiency of the 
inhibition. 
Frequently in practice, as in this thesis, only a few of the criteria developed for 
mechanism-based inactivation are investigated when a potential mechanism-based 
inactivator is studied. However, to unambiguously charaterize an inactivator as being 
mechanism-based the criteria above should be satisfied. The first two criteria define any 
covalent or tightly bound, slow binding, non-covalent competitive inhibitor which 
would be analysed in a different manner than a mechanism-based inhibitor. The last 
three criteria, in combination, are definitive for a mechanism-based inhibitor. It is the 
object of this chapter to discuss the assay of N-[(acyl and sulfonyl)oxy]imides 1.41 and 
2.1 using kinetic models developed for mechanism-based inactivation. The question 
then arises are we justified in using these models? 
A preliminary answer to this question and a preview of the activity of compounds 
1.41 and 2.1 can be provided by the results Groutas et aZ84,87a obtained in carrying out 
experiments prescribed to establish mechanism-based inhibition for 1.41d. This 
compound has been found to inhibit a-chymotrypsin in a time dependent manner with 
the observation of pseudo first-order kinetics over 15 minutes. Experiments carried out 
at increasing inhibitor concentration point to the a maximum rate of inactivation. The 
urea linkage of the inactive enzyme (see Scheme 3.1, structure 3.4) is susceptible to 
hydrolysis (t1l2 = Ih) and therefore inhibitors of type 1.41 and 2.1 will only be acting as 
irreversible inhibitors over a short time. 
Although the addition of the nuc1eophile dithiothreitol results in a lower rate of 
inhibition it is believed that inactivation does occur before the reactive species escapes 
the active site as there is no "lag" phase for inhibition. This result may be explained by 
dithiothreitol entering the active site and reacting with the enzyme bound isocyanate 
(Scheme 3.1, structure 3.3). 
The partition ratio for 1.41d will depend on the reactivity of the enzyme bound 
isocyanate, its rate of hydrolysis and hence diffusion from the active site, and the 
proximity of the imidazole ring for carbamate bond formation. No partition ratio 
analysis has been undertaken for 1.41d, however 13e NMR and reactivation studies 
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carried out by Groutas et aZ84,85 suggest that the rate of hydrolysis of the enzyme bound 
isocyanate 3.3 and inactive enzyme 3.4 are significant. It is therefore proposed that the 
partition ratios for inhibitors of type 1.41 and 2.1 will be far from the ideal value of 
zero. 
The predicted high partition ratios for 1.41 and 2.1 will have practical implications 
for the inhibition assays as depletion of the inhibitor during assay will be significant 
and problematic. It appears therefore that the N-[(acyl and sulfonyl)oxy]imide inhibitors 
1.41 and 2.1 will only be acting as true mechanism-based inactivators at high 
concentrations and over a short period of time after which deviation away from psuedo 
first-order kinetics is expected. There is also evidence to suggest that a species other 
than the initial compound l.4ld, most probably the amine 3.7, contribute to the 
inactivation, although not initially. 
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5.2 INACTIVATION KINETICS 
The evaluation of the inhibitory activity of a compound is routinely carried out using 
two methods. The first procedure commonly referred to as the "incubation method" or 
"pre-incubation method"71,72,79,187-9 as it name suggests involves incubating an assay 
mixture containing the enzyme and an excess of inhibitor. Periodically, aliquots are 
removed from this assay mixture and reacted with a "monitoring" substrate. The rate of 
hydrolysis of the substrate is a measure of the enzyme activity of this sample. A 
chromogenic substrate is used so that its rate of hydrolysis can be followed 
spectrophotometrically by noting the proportional rate of increase in absorbance of its 
hydrolysis product. The assay mixture contains only enzyme and inhibitor and hence 
kinetic analysis involves consideration of only those two species. 
The incubation method can be used only to assay relatively slow inhibitors because 
sampling techniques are employed. Faster or more potent inhibitors cannot be 
adequately examined using this method hence a second assay procedure capable of 
measuring rapid inactivation is required. The procedure commonly employed is the 
progress curve method.190-192 To an assay mixture containing "monitoring" substrate 
and inhibitor an aliquot of enzyme is added, and the progress of the reaction followed 
by the rate of hydrolysis of the substrate. 
Practically, the incubation method of assay is more demanding. Several inhibition 
and control experiments have to be undertaken to afford the rate measurements that on 
simple analysis give the inhibitory activity of the compound being assayed. For the 
incubation method the bimolecular constant kobs/[I] is used eXclusively as the index for 
inhibitory activity. As discussed in the following section, for slow inhibitors kobJ[I] 
serves as an approximation for the ratio kinact/Kr which is the ideal constant for 
quantifying inhibition. For potent inhibitors this ratio is high, for weaker inhibitors it is 
lower. 
For those fast inhibitors able to be analysed using the incubation method kobsl[I] 
approximates kinactlKr less well but kobs/Kr is still used as an index of potency, faster 
inhibitors again displaying a higher value. A rigorous value for kinact/Kr can be 
obtained using the incubation method but requires that experiments be carried out at 
several different inhibitor concentrations (five are recommended)25 which adds to the 
already high experimental demand for this method. 
The progress curve method requires only one inhibition experiment for evaluation of 
kobs/[I] but the data analysis is more complicated and time consuming. The expression 
for kobs/[I] for the progress curve method is different from that for the incubation 
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method having a different dependence on the inhibitor concentration and including 
substrate terms and hence the two are not compared. The ratio kinaet/Kr is exclusively 
reported and can be determined rigorously using the progress curve method. Again 
experiments are run at different inhibitor concentrations but the fact that the progress 
curve method is less labour intensive facilitates these operations. Values for kinaet/Kr 
can be compared between the two methods and a good agreement is normally 
ob served. 62e 
The assay mixture for the incubation method contains enzyme and inhibitor whereas 
for the progress method the assay mixture contains enzyme, inhibitor, and substrate and 
hence a more complicated kinetic analysis will be required. The kinetic models used in 
the analysis of inhibitors using these two methods is discussed below. 
INCUBATION METHOD KINETICS 
The corresponding kinetic scheme for the interaction between enzyme and inhibitor 
for the proposed mechanism of inactivation of a-chymotrypsin by 1.41 and 2.1 is 
shown below (Scheme 3.4). 
KI EJ ka E-I 
kz E-I' E-I" E+I .. • 
I kd I k3 I k, 
E+P E+P E+P 
Scheme 3.4. Kinetic scheme for mechanism-based inhibitors of type 1.41 and 2.1 
In this scheme E is the free enzyme; I is the N-acyl or sulfonyloxy imide inhibitor 
1.41 or 2.4; E.I the Michaelis complex for the enzyme and inhibitor (structure 3.1 of 
Scheme 3.1); E-I is the acyl enzyme (3.2); and E-I' is the reactive isocyanate (3.3) 
tethered at the active site; E-I" is the inactivated enzyme with the inhibitor covalently 
attached (3.4); and P represents the free isocyanate (3.5) and the amine (3.7) which are 
the products resulting from hydrolysis of the inhibitor. 
The inhibitor initially interacts with the enzyme in the same way as a substrate to 
give an enzyme-inhibitor Michaelis complex E.L The binding of enzyme and inhibitor 
is described by Kr the dissociation constant for the Michaelis complex. Acyl enzyme 
formation (ka) proceeds as with a normal substrate, however, it is accompanied by the 
release of the latent reactivity i.e. the Lossen rearrangement (k2) to the enzyme bound 
isocyanate. Deacylation of the acyl enzyme (kd) may also occur via a so-called 
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"turnover" pathway which does not result in enzyme inactivation. Acylation of the 
imidazole ring of His-57 by the enzyme bound isocyanate (k4) leads to inactivated 
enzyme (E-1"). This competes with other "turnover" hydrolysis pathway (k3). The rate 
constant for hydrolysis of the inactivated enzyme species (ks) determines the 
"irreversibility" of the inactivator. 
lung and Metcalfe187b have developed a kinetic model for mechanism-based 
inhibitors extending the work undertaken by Kitz and Wilson187a for the kinetic 
analysis of active-site directed irreversible inhibitors. Groutas et a184 ,8S,87 have 
analysed inhibitors of type 1.41 (L = S02R') such as 1.41d, using the model of Jung 
and Metcalfe and hence this model was adopted for the initial inhibition studies of this 
thesis. 
Since the progress of the overall inhibition reaction is monitored by the decrease in 
total active enzyme (i. e. accumulation of E-I"), E.I, E~ I, and E~ l' are not observed 
independently and hence Scheme 5.2 can be simplified to give the kinetic scheme 
shown below (Scheme 3.5). 
The assumption made in this approximation is that the inhibition reaction is carried 
out with an excess of inhibitor so that the concentration of the Michaelis complex is 
constant throughout the assay. If the inhibition experiment is designed so that these 
ideal conditions are maintained then psuedo first-order kinetics will be observed. 
E+1 E*1 .. E-1" 
Scheme 3.5 Simplified incubation method kinetic scheme for mechanism-based 
inhbitors 1.41 and 2.1 
In this scheme E*I represents the kinetic composite of E.I, E~I, and E-I' and kinact is 
the rate constant for the inactivation process. The rate constant kinact is a mixture of the 
microscopic rate constants k2, k3, k4 and kS of Scheme 3.2. Waley 193 has applied a 
steady-state hypothesis to the kinetic scheme for a general mechanism-based inactivator 
which includes all the terms considered in Scheme 3.4 excepting ks as this is zero for 
inactivation. The expression obtained for kinact is shown below in equation (3.1). 
(3.1) 
From equation (3.1) it is observed that the magnitude of kinact is proportional to k2, 
the rate constant for the Lossen rearrangement to the inactivating species; and k4, the 
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rate constant for the reaction between the inactivating species and His-57 to form 
inactive enzyme. The magnitude of kin act is inversely proportional to k3, the rate 
constant for the turnover pathways which result in no net inactivation. 
Typically k2 is found to be the rate determining step in the inhibition process, in this 
case equation (3.1) reduces to: 
(3.2) 
From equation (3.2) the magnitude of kin act will be proportional directly to k3 and k4 
(but in a more complicated manner) but inversely proportional to k3. 
The ratio kinacJKr provides a measure of inhibitory activity. A potent inhibitor will 
have a high kinactlKr value whereas a weaker inhibitor will have a lower value. Hence a 
potent inhibitor will have a low Kr, demonstrating that it has high binding affinity for a-
chymotrypsin and a high kin act demonstrating that the Lossen rearrangement and 
reaction of the resulting isocyanate with His-57 is rapid, but deacylation and hydrolysis 
of the isocyanate and inactive enzyme are slow. 
The kinetic scheme above (Scheme 3.5) can be analysed by the method of Kitz and 
Wilson.l87 Provided the enzyme-inhibitor solution is extensively diluted before assay, 
and that the inhibitor concentration is at such an excess over enzyme that it remains 
constant dUling the course of the assay it can be shown that: 
[E] 
In[E
o
] 
where 
kobs 
_ kinact 
- Kr 
1 + [I] 
(3.3) 
(3.4) 
Experimentally, the quantity [E] is measured by the rate of hydrolysis of the 
monitoring substrate in the presence of inhibitor, Vt. The quantity [Eo] is measured by 
the rate of hydrolysis of monitoring substrate in the absence of inhibitor, vo, such that 
equation (3.3) can also be expressed as: 
1 Vt n-
Vo 
(3.5) 
Inhibition 
Therefore, a plot of In Vt, which serves as a measure of enzyme activity, versus time 
Vo 
should give a straight line with a slope of -kobs. 
Looking at equation (3.4): 
kobs (3.6) 
If [I] « Kr, for a poor inhibitor, then: 
kobs ~ kinact. [I] Kr 
kobs 
"'" 
kinact 
.. [I] KI~~ (3.7) 
Thus, k[I]s can be an approximation for the second order rate constant (k~~ct) 
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The inhibitory constant kinactIKr can be obtained in a more rigorous manner using 
the method of Khz and Wilson.1 87a The experimental quantity kobs is obtained for a 
number of inhibition experiments where the excess of inhibitor over enzyme is varied. 
The half-lives for inhibition, (t1l2), for these experiments are then simply calculated 
using equation (3.8) which is derived from equation (3.5): 
ln2 
t1l2=-kobs (3.8) 
If the t1l2 values for inhibition are plotted against the reciprocal of the inhibitor 
concentrations, according to equation (3.9), obtained from substitution of equation (3.8) 
into equation (3.6) , two possibilities can exist (Figure 3.1). 
t1/2 = ~2 + 1~2KI kmact kmact (3.9) 
Of the plots displayed in Figure 3.1 Graph A depicts the case when enzyme 
saturation is observed while Graph B depicts the situation when saturating conditions 
do not exist. The inhibitory constant kinactlKr can be only obtained from the gradient 
and y-intercept of Graph A as shown, demonstrating the importance of maintaining 
saturating inhibitor concentrations during the course of the enzyme assay. 
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]n2lkinact 
1/[1] 
Figure 3.1 Kitz and Wilson plot for an inhibitor exhibiting saturation (A) or (B) not 
exhibiting saturation 
To determine kinactlKr using Graph A requires first the calculation of t1/2 from kobs 
as described above and then of the gradient and y-intercepts. A modified Kitz and 
Wilson plot of [I]/kobs versus [I] (Figure 3.2) according to equation (3.10) , derived 
from equation (3.6), also gives a straight line with positive slope and postive y-
intercept. A value for kinactlKr can be obtained directly from the y-intercept of this 
graph and hence more simply than a determination using Graph A of Figure 3.1 and 
without the required t1/2 calculations. 
l!L = ~ + -.L!L (3.10) 
kobs kinact kinact 
[I]lkobs _1_ 
kinact 
Krlkinact 
[1] 
Figure 3.2 Plot of [I]lkobs versus [1] to determine kinactlKr 
PROGRESS CURVE KINETICS 
The kinetic scheme for the interaction of enzyme, inhibitor and substrate for the 
proposed mechanism of inactivation of a-chymotrypsin by 1.41 and 2.1 is shown 
below. 
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Scheme 3.6 Progress curve method kinetic scheme for mechanism-based inhibitors of 
type 1.41 and 2.1 
This kinetic scheme can be analysed according to the method of Tsou. 190 Provided 
that the rate of the enzyme-substrate reaction is faster than the enzyme-inhibitor 
reaction and the inhibitor and substrate concentrations remain constant during the 
course of the assay it can be shown that there will be an exponential release of product 
with time according to equation (3.11). 
At t = 00, from equation (3.11): 
V 
kobs 
(3.11) 
(3.12) 
where kobs is the rate constant for the observed inhibition and V the rate of the enzyme-
substrate reaction in the absence of inhibitor which are given by: 
k kinact + [10] obs = S 
[10] + KI[1 + k~] (3.13) 
v 
At ..... "n"·.n Inhibition 84 
(3.14) 
To determine the kinetic constants for irreversible inhibition, kobs/[I] and kinact!KI, 
using the progress curve kinetic method, a suitable irreversible curve of type A (Figure 
3.3) which is described by equation (3.11) must be obtained. Therefore an important 
experimental task when using the progress curve method is the design of inhibition 
conditions so that this irrevesible curve is obtained. This involves changing inhibitor 
and substrate concentrations, however, the change must be such that the inhibitor and 
substrate are present at saturating levels. Once a suitable curve is obtained analysis can 
be carried out as follows. 
v/ekobs 
Absorbance 
Figure 3.3 Irreversible Curve A 
, 
, 
" v 
-ji·-- ...... --
" , . , . 
• I 
time 
A 
From equations (3.11) and (3.12) it can be simply shown that: 
In([poo] - [PrJ) = In[Poo] - kobs.t (3.15) 
The quantities [Pt] and [Poo] can be interchanged with the corresponding 
absorbances, At and Aend, which can be directly read off the absorbance versus time 
curves obtained experimentally (see Figure 3.3). Therefore equation (3.15) can also be 
expressed as: 
In(Aend - At) = In(Aend Ie) - kobs.t (3.16) 
Hence kobs can be obtained from the slope of the initial portion of the logarithmic 
plot In(Aend - At) versus time using linear regression analysis. Alternatively kobs can be 
determined by fitting experimental absorbance versus time data to equation (5.9) using 
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non-linear regression analysis with initial parameter values obtained from the 
extrapolations shown in Figure 3.3 as suggested by Walsh and Morrison.191 
(3.17) 
Determination of the inhibition constant kinact/KI is carried out by evaluating [I]/kobs 
at different inhibitor concentrations at saturating conditions. A Tsou plot of [J]/kobs 
versus [I] according to equation (3.17) should give a straight line for a mechanism-
based inactivator with positive slope and y-intercept as shown in :Figure 3.4 which can 
be determined by linear regression analysis. Since KM 194 and [So] are known kinact/KI 
can be simply calculated. 
[So] 
[I] KI[1 + KM] [I] 
--= +--
kobs kinact kinact 
[I]/kobs 
KI[1 + [So]/KMJ 
kinact 
(3.18) 
Figure 3.4 Tsou plot used to determine kinacVKI. 
_1_ 
kinact 
[I] 
Earlier the differences between the incubation and progress curve methods were 
discussed. The question arose as to whether results obtained for compounds which are 
poor inhibitors, assayed using the incubation method can be compared with those 
obtained for compounds, which are potent inhibitors, assayed using progress curve 
techniques. The following section compares the kinetic models for the two methods to 
provide an answer to this question. 
The quantity kobs/[I] is used routinely as an index of inhibitory activity, with more 
potent inhibitors displaying a higher value than those compounds which are less potent. 
The equations for kobs/[I] derived for the incubation method (3.6) and (3.7) and 
progress curve method (3.14) are shown respectively below. 
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(3.6) 
(3.7) 
(3.14) 
It can be observed that both the equations are not independent of the inhibitor 
concentration and cannot therefore serve as an index of inhibitory activity unless 
inhibitors are compared at the same inhibitor concentration in which case kobsl[I] 
values can only be compared if obtained using the same assay technique; no valid 
comparison can be made between the two methods. As discussed above, if a poor 
inhibitor is being assayed using the incubation method kobs/[1] serves as an 
approximation for kinact/Kr, however this is not the case for compounds assayed using 
progress curve kinetics. 
The equations for the experimental quantity [IJlkobs for the incubation (3.10) and 
progress curve method (3.18) are shown respectively below. 
[I] KI [I] 
--=--+--
kobs kin act kinact (3.10) 
K [·1 [So]] [1J I + KM [1] 
--= +--kobs kinact kinact (3.18) 
Observation of these equations shows that they are of the same form and 
demonstrate the same dependence with the inhibitor concentration [I]. Hence it is by 
considering the term [I]/kobs that the two methods converge; plots according to these 
equations will show the same trends (Figure 3.5) and as discussed can be manipulated 
to determine a value for kinactiKI which is independent of which method is used. 
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Figure 3.5 Analytical graphs for incubation method (A) and progress curve method (B) 
3.3 EXPERIMENTAL PROCEDURES 
GENERAL 
Kinetic assays were performed using a Hewlett-Packard 8451A single beam diode 
array spectrophotometer and 1cm path length quartz cuvettes incubated in a customised 
heating block fitted to the spectrophotometer. a-Chymotrypsin (bovine pancreatic; 
three times crystallised and free of autolysis products and low molecular contaminants) 
and N-Succ-(Alah-Pro-Phe-p-nitroanilide were obtained from Sigma Chemical 
company. N-Benzoyl-L-tyrosine ethyl ester (BTEE)195 was purchased from Aldrich. 
All kinetic studies were performed at 25°C. 
The following solutions were prepared fresh for assay: 
O.lM KH2P041K2HP04 potassium phosphate buffer, pH 7.2. Prepared from a O.lM 
solution of KH2P04 in distilled H20 and adjusting the pH of this solution with 5M 
NaOH as monitored by a meter previously calibrated with sodium phthalate buffer, pH 
4.01. 
a-Chymotrypsin: Stock solution of 20J.lM (4.3mg in lOmL O.lM phosphate buffer). 
Bovine pancreatic a-chymotrypsin has Mr = 21 600 Da.196 The stock solution was 
diluted 5-fold in phosphate buffer before use, to give a concentration of 4J.lM. 
N-Succ-(Alah-Pro-Phe-p-nitroanilide: Stock solution 120J.lM in phosphate buffer. This 
required slight warming for dissolution. 
BTEE: Stock solution 120~ in 1:1:2 MeOHlH20/phosphate buffer. 
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Inhibitor solutions: Stock solutions of 5mM or lOmM in CH3CN were prepared and 
were diluted when required by the assay. 
INCUBATION ASSAY PROCEDURE 
Typically, a solution of a-chymotrypsin in O.lM (potassium) phosphate buffer 
(lmL, 41lM, final concentration 3.922IlM) was incubated at 250C with various 
concentrations of inhibitor (three-, five-, ten- or 25-fold excess over enzyme) added as a 
volume [xllL of a 5mM or more dilute stock MeCN inhibitor solution plus a volume 
(20-x)IlL of acetonitrile (MeCN)]. Aliquots (25!lL) were withdrawn at typically 1,3,5, 
7, 9, 11, 15, 20 and 30min intervals (though assays were carried out at longer time 
intervals) and added to quartz cuvettes containing a solution of either BTEE in 1:1:2 
MeOH/H20/buffer (lmL, 120/lM) for compounds l.4ld-q and 2.lb and 2.d-f; or N-
Succ-(Alah-Pro-Phe-p-nitroanilide in buffer (ImL, 1201lM) for compounds l.4le and 
hand 2.1f and 2.le held in a heating block thermostated at 25°C. 
Reaction progress was then followed immediately by recording the increase of 
absorbance at 256nm (BTEE) or 410nm (N-Succ-(Alah-Pro-Phe-p-nitroanilide) for 80s 
relative to a "blank" cuvette containing BTEE (lmL, 120llM in 1:1:2 
MeOH/H20/buffer, final concentration 117/lM) or N-Succ-(Alah-Pro-Phe-p-
nitroanilide (lmL, 120llM in buffer) and buffer (25IlL). 
The absorbance versus time data obtained were linear plots with slope equal to the 
rate of reaction, (in the presence of inhibitor), Vt. This was calculated by linear 
regressional analysis of data over 20-70s. The rate of reaction (in the absence of 
inhibitor) Vo was determined in the same manner but enzyme was incubated with 20llL 
MeCN. Vo was observed to remain constant over the 30min period of incubation and 
hence an average value was used in subsequent calulations. The ratio vo/vt is a measure 
of residual enzyme activity.I 87a 
PROGRESS CURVE PROCEDURE 
Typically into a ImL quartz cuvette 9581lL of the stock solution of BTEE (final 
concentration 117J.1M) and a solution of inhibitor in acetonitrile were combined. The 
inhibitor was added as a volume x mL of a 15mM or more dilute stock inhibitor 
solution in acetonitrile plus a volume (25-x)IlL of acetonitrile. The final concentrations 
of inhibitor ranged from 0.189J.1M (three-fold excess over enzyme) to 18.25J.1M (250-
fold excess over enzyme). This solution was incubated for five minutes at 25 °C after 
which 17/lL of the buffered enzyme stock solution (final concentration 0.073J.1M) was 
added and the reaction progress was then followed immediately by recording the change 
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in absorbance at A, ::: 256nm over a time interval not greater than 30min. The change in 
absorbance was measured relative to a "blank" cuvette containing 958~L of BTEE 
stock solution, 25~ acetonitrile and 17~L phosphate buffer. 
A control experiment in the absence of inhibitor was also routinely carried out in the 
same manner excepting 958~L of the stock BTEE and 25~L of acetonitrile only were 
incubated before addition of the enzyme. The reaction was monitored as above. 
The time delay involved from addition (at t::: 0) of the 17~L aliquot of the buffered 
enzyme stock solution to the incubated inhibitor-substrate solution in an open cuvette, 
removal of the cuvette from the water bath, placement of the cuvette's plastic cap, 
agitation of the cuvette to mix the assay solution and placement of the cuvette into the 
incubated cell of the spectrophotometer and finally employment of the latter took 
approximately 15s in our experience. This mixing time was noted for each inhibition 
experiment and subsequently was entered into the analysis of absorbance data. 
Three types of absorbance versus time curve were generally obtained and are shown 
in Figure 3.6. Graph A depicts a progress curve typical of irreversible inhibition and 
can be analysed using the Tsou logarithmic plot of In(Aend-At) versus time, or by non-
linear regression analysis to obtain a value for the observed inhibiton rate constant kobs. 
, 
I 
, 
r.1"r,,, .... <",n Inhibition 
J 
J 
" V - i' - _ ...... 
,', 
" I' I • 
I • 
J 
I 
• 
1lkobs 
time 
A 
time 
Figure 3.6 Idealised experimental progress curves 
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Graph B depicts a progress curve observed typically for reversible inhibition but was 
observed for the N-acyl and sulfonyloxy imide inhibitors 1.41 and 2.1 studied. This 
result suggests that the experiment was run at a low inhibitor concentration and this was 
depleted during the course of the inhibition experiment. This was considered to be a 
likely event for 1.41 and 2.1 because their partition ratios are predicted to be high. 
When this result was obtained the inhibition experiment was repeated at a higher 
inhibitor concentrations to obtain saturating conditions such that an irreversible curve of 
type A was observed. 
Graph C depicts a case where a high excess of inhibitor was used having the effect 
that the enzyme was totally inactivated within the mixing period. In reality a straight 
line was not obtained but rather a noisy absorbance trace with a positive slope 
indicating that with time the inhibitor was being depleted and enzyme activity returning. 
When this result was obtained the inhibition experiment was repeated at a lower 
inhibitor concentration in an effort to obtain a curve of type A. 
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The major task therefore when using the progress curve assay method is finding 
suitable inhibitor concentrations that give curves of type A suitable for analysis of kobs. 
Several inhibition experiments were carried out to determine kobs at different inhibitor 
concentrations and the resulting data analysed using a Tsou plot of [I]/kobs versus m 
from which kinactiKI can be obtained. 
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5.4 ASSAY RESULTS 
Each inhibitor of type 1.41 and 2.1 shown in Tables 3.1 and 3.2 respectively was 
assayed using the incubation method detailed above to quickly determine the activity-
time profile. Subsequent experiments depended on the potency and type of inhibition 
observed in these preliminary experiments. In general five results were obtained from 
the incubation assay. 
a) The compounds were inactive. 
b) The inhibitors inactivated a-chymotrypsin in a time-dependent manner at 
such a rate that a number of data points could be obtained for analysis. 
The inhibition constants kobs and kobs/[I] were then determined as 
described above. 
c) A rapid loss in enzymic activity was observed followed by a rapid regain 
of this activity. It was proposed that these compounds were acting as 
poor alternate substrate inhibitors. No further analysis was undertaken. 
d) The rate of inactivation was too fast to be determined using the 
incubation assay. These potent inhibitors were assayed using 
progress curve kinetic methods. 
e) The compounds were of such potency that they could notbe measured 
accurately using the progress curve method at an inhibitor concentration 
of ten-fold excess over enzyme. 
Chapter 3 a-Chymotrypsin Inhibition Assay 
R 
o):;Ao 
Compound R 
number 
1.4ld PhCH2 
e Ph 
f PhCH2 
g PhCH2 
h PhCH2 
i Ph 
j PhCH2 
k PhCH2 
1 PhCH2 
m PhCH2 
n PhCH2 
I 
OL 
1.41 
L 
S02CH3 
S02CH3 
S02 
~Ph 
S02-{ ) 
S02-Q-CH3 
S02-Q-CH3 
S02-\ ~ > 
N02 
S02-\ ~ 
CH3 A S02 C02Et 
o Ph S020-\=l 
S02-\ ~ 0 
J:(Ph 
--0--0- ¥ 0 
S02 ~ /; ~ /; S020 
Table 3.1 N-[(sulfonyl)oxy]imide inhibitors of type 1.41 
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Compound R 
number 
0 PhCH2 
P Ph 
q PhCH2 
r PhCH2 
L 
Ac 
Ac 
c~Ph 
II 
0 
0 
I 
OL 
1.41 
Ph':, 
CANAO ........... Ph 
II H 0 
Table 3.2 N-[(acyl)oxy]imide inhibitors of type 1.41 
Compound R 
number 
2.1a Ph 
2.1b Ph 
2.1c PhCH2 
2.1d H 
2.1e H 
2.lf H 
R' 
H 
H 
H 
Ph 
RY" 
~~y,l 
o N 0 
I 
OL 
2.1 
R" 
H 
H 
H 
H 
R', R" = cyc10hexyl 
CH3 CH3 
L 
S02CH3 
Ac 
S02CH3 
S02CH3 
S02CH3 
S02CH3 
Table 3.3 N-[(acyl and alkylsulfonyl)oxy]glutarimide inhibitors of type 2.1 
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INACTIVE COMPOUNDS 
When no appreciable net loss of enzyme activity was monitored over the time course 
of the experiment the compounds being assayed were considered to be inactive. In these 
cases the compound concentration was increased up to 50-fold excess over enzyme in 
an attempt to increase the rate of inactivation so that it could be measured, however, 
stm no inhibitory activity was observed. Figure 3.7 depicts the results obtained on 
assay of 1.410 which is representative of the N-[(acyl)oxy]succinimides 1.410-r which 
were found to be inactive. 
90 
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Figure 3.7 Assay of inhibitory activity of compound 1.41 against a-chymotrypsin. a-
Chymotrypsin (4!lM) was incubated with (A, 4JlM; B, lOOJlM) and enzyme activity 
assayed using either N-Succ-(Alah-Pro-Phe-p-nitroanilide (A, 117JlM) or BTEE (B, 
117JlM). 
The oscillating nature of the graph suggests that there is a period of inhibition 
followed by a temporary regain in activity. This trend could be explained in the terms 
that several inactivating species are present in the assay mixture each of which only 
inhibit the enzyme for a transient period before being metabolised by the enzyme. 
These results are more likely to be explained, however, by the error associated with the 
sampling measurements used in the incubation method. Although the individual rate 
measurements are precise (± 1-2% error observed) they are difficult to reproduce 
accurately; hence erroneous results can give the impression of enzyme inhibition or 
activation. Therefore experiments need to be run in duplicate or triplicate for true 
activity versus time profiles to become evident. 
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TIME DEPENDENT INHIBITORS 
Once it was shown by the appropriate logarithmic plot that inhibition was psuedo-
first order, work was undertaken to optimise the inhibitor concentration so that an 
accurate value of kobs was obtained. In practice this required finding the highest 
inhibitor concentration that gave linearity over as many data points over the time course 
of the assay. The analysis of the inhibition of a-chymotrypsin by compound 2.lf whose 
activity versus time profile (Figure 3.8) serves as a representative example. 
120~----------------------------------------~ 
100 .) 
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40 - 13 
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o 20 40 60 
time (min) 
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Figure 3.8 Time-dependent inactivation of a-chymotrypsin by 2.lf. a-Chymotrypsin 
(4,-"M) was incubated with 2.lf (100J-LM) and enzyme activity assayed using N-Succ-
(Alah-Pro-Phe-p-nitroanilide (l17J-LM). 
Figures 3.9 and 3.10 display logarithmic plots obtained from the activity versus time 
data of Figure 3.8 firstly over the full time course of the assay (100 minutes) and then 
over the initial nine minutes. 
Observation of the logarithmic plot displayed in Figure 3.9 indicates there is 
deviation away from the psuedo first-order kinetics with time. The logarithmic plot 
displays three phases. Initially psuedo-first order kinetics is observed. There is no "lag 
phase" indicating immediate inhibition of a -chymotrypsin is due to the N-
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mesylglutarimide rather than a metabolite. This initial inhibition phase is followed by 
an upward deviation away from psuedo-first-order kinetics i.e. the rate of inactivation 
decreases with time. This may be accounted for by depletion of inhibitor due to 
turnover. The final phase depicts a downward deviation indicating a second period of 
inactivation of the enzyme at a slower rate than that observed initially. These 
observations are consistent with possibly a hydrolysis product of the N-
mesylglutarimide being a potential inhibitor of a-chymotrypsin. Over the time course 
of the assay this species has increased beyond a threshold concentration such that has 
returned to inactivate the cnzyme. 
Given that there is deviation from psuedo-first order kinetics as the time course of 
the assay increases linear regression analysis of data to determine kobs was carried out 
only over the initial portion of the logarithmic plot of Figure 3.9 as shown in Figure 
3.10. The initial data points are more dependable as indicated by comparison of the 
correlation coefficients of the regressions carried out for the plots of :Figures 3.9 (r2 = 
0.827) and 3.10 (r2 = 0.965). Analysis of the data in Figure 3.10 gives a value of 39 M-
Is-1 for kobs/[I] for derivative 2.lfwhen N-Succ-(Alah-Pro-Phe-p-nitroanilide was used 
as the incubation assay substrate. 
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Figure 3.9 Logarithmic plot of enzyme activity versus time over 100 minutes for the 
data displayed in Figure 3.8. 
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Figure 3.10 Logarithmic plot of enzyme activity versus time over nine minutes for 
inhibition data displayed in Figure 3.8. 
The inhibition of a-chymotrypsin by 2.1f was then studied at different inhibitor 
concentrations at 15-, 20-, 25-, 30-fold excess over enzyme with the ultimate aim of 
determining a rigorous value for kinact/Kr for this inhibitor. The trend of the kobs values 
with inhibitor concentration is shown below (see Figure 3.11). 
3~------------------------------~ 
2.1f 
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I I I 
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[I] (f.LM) 
Figure 3.11 Plot of kobs versus [10] for compound 2.1f 
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As observed from Figure 3.11 the value for kobs is increasing with inhibitor 
concentration but the graph is characterized by an asymptote indicating there is a 
maximum value for kobs. This results confirms that saturating kinetics are being 
observed for the inhibition of a-chymotrypsin by compound 2.U which is one of the 
features that identifies true mechanism-based inactivation (see Section 3.1 for a 
discussion). 
The analysis of this data using the Kitz and Wilson plot described previously 
(Section 3.2) for determination of kinacJKI is shown below (Figure 3.12). 
t1l2 (s) 400 - 2.1f 
EI 
300 - EI 
EI 
200 J I J I 
0.008 0.010 0.012 0.014 0.016 0.018 
1/[1] (IlM-1) 
Figure 3.12 Kitz and Wilson plot for inhibition of a-chymotrypsin by 2.U 
The above plot is of the type obtained when non-saturating conditions are prevalent. 
Linear regression analysis of this plot gives the y-intercept as negative and hence a 
value for kinact/Kr cannot be obtained. This result may be explained in the tenus that the 
kinact for the compound is high, however, analysis by the incubation method has shown 
this compound to be a poor inhibitor which would normally possess a relatively low 
kinact value. The error for each individual calculation of t1/2 at each of the four inhibitor 
concentrations is high 15%) and will contribute to the non-saturating shape of the 
graph. However the above graph is distinguished by a sharp rise in t1/2 at a lower 
inhibitor concentration and therefore it could be considered that analysis at this 
inhibitor concentration ([10 ] = 59mM, I5-fold excess over enzyme) has been 
undertaken in non-saturating conditions. 
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A Kitz and Wilson plot of the first three data points of Figure 3.12 which were 
deemed to be obtained from inhibition experments carried out at saturating inhibitor 
concentrations is shown below (Figure 3.13). 
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Figure 3.13 Khz and Wilson plot for inhibition of a-chymotrypsin by 2.lf at saturating 
conditions 
The above plot is of the type obtained at saturating conditions permitting analysis of 
kinactIKr which was determined to be 37 M- 1s-1 (kinact = 0.006 s-1, Kr = 156 JiM). A 
plot of [I]/kobs versus [I] also gave a value of 37 M-1s-1. 
This highlights the caution required when using kobs/[I] values as approximations for 
kinactlKr. For a poor inhibitor, the kobs/[I] values calculated from inhibition experiments 
where the inhibitor concentration is less than the Kr serve as an approximation for 
kinact!I(r. The data points of Figure 3.13 were obtained from inhibition experiments 
carried out at inhibitor concentrations 20-fold (78JiM), 25-fold (98~), and 30-fold 
(l17JiM) excess over enzyme. The kobsl[I] values calculated from these experiments 
were 24 M-1s-l, 24 M-1s-1 and 21 M-1s-l respectively. These inhibitor concentrations 
are lower than the Kr calculated for 2.lf (156~LM) but the kobs/[I] values poorly 
approximate kinacVKr. 
In a series of other experiments a determination of kinactlKr was undertaken using 
the progress curve method. A plot of [I]/kobs versus [I] gave a plot typical of non-
saturating conditions hence kinact/Kr was unable to be calculated. However a value for 
kinact (0.003s- 1) was obtained from the slope of this graph and is of the same magnitUde 
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of that value obtained from the incubation method above (kinact = 0.006s-1). On this 
basis there appears to be a good agreement between the two methods for compound 
2.lf. 
ALTERNATE SUBSTRATE INHIDITORS 
Alternate substrate inhibitors 71,80,97(a),197 function as substrates of the target 
enzyme; however instead of chemically reacting with the enzyme, the alternate 
substrate becomes bound so tightly to the active site that further access by natural 
substrate molecules is prevented. 
Compounds 1.41 and 2.1 may act as alternate substrate inhibitors if on formation of 
the acyl enzyme the Lossen rearrangement is unable to occur. In this case the enzyme 
would remain inhibited for the lifetime of the acyl enzyme species. The goal therefore 
in the design of alternate substrate inhibitors is to prolong the life span of the acyl 
enzyme by hindering the deacylation process using strategies based on either electronic 
or steric reasoning. 189 If the deacylation process is rapid then the inhibitors will merely 
be acting as substrates of the enzyme. 
Compounds 1.41e and 1.41h displayed activity time profiles consistent with 
alternate substrate inhibitors that only transiently inhibit the enzyme. As the results 
obtained on assay of compound 1.41e (Figure 3.14) show there is initial rapid 
inhibition of the enzyme the rate of inhibition increasing for increased inhibitor 
concentration (compare graphs A and B). The enzyme then remains inhibited for a 
period of time dependent on the initial concentration of inhibitor ([laD used in the 
experiment. When [10 ] was ten-fold excess over enzyme this period was ca 7minutes 
but increased to ten minutes when [Io] was increased to 25-fold excess over enzyme. 
During this period the inactive enzyme is actively being hydrolysed but there still 
remains enough inhibitor to elicit inactivation until a point where this is depleted and 
enzyme activity is regained. 
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Figure 3.14 Assay of inhibitory activity of compound 1.41e against a-chymotrypsin. 
a-Chymotrypsin (4JlM) was incubated with 1.41e CA, 40JlM; B, 100JlM) in O.lM 
phosphate buffer, pH = 7.2, and 2.5% CH3CN. Aliquots (25JlL) were removed 
periodically and assayed for activity for enzymic activity using N-Succ-(Alah-Pro-Phe-
p-nitroanilide (A, B 117JlM) according to the incubation assay procedure discussed 
previously. 
POTENT INHIBITORS 
The rate of inhibition of a-chymotrypsin by compounds 1.41d, 1.4lf, 1.41g, 1.41h, 
1.41j, l.4lli, 1.41m, 1.41n, 2.1a, 2.1c, 2.1d, 2.1e was too fast to be determined using 
the incubation assay indicating that these were potent inhibitors. To obtain a 
measurable rate the inhibitor concentration was reduced but even at the lower inhibitor 
concentrations employed some inhibitors still inactivated a-chymotrypsin at a rate too 
rapid to be measured by the incubation assay. With other inhibitors an increased 
number of assay points was able to be obtained however substantial deviation from 
psuedo first order kinetics was observed. 
In another attempt to determine a value for the inhibitory activity of these potent 
inhibitors using the incubation method the sampling periods were changed for analysis. 
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In a typical incubation experiment aliquots of the enzyme-inhibitor assay mixture were 
withdrawn at 1,3, 5,7,9 etc. minute intervals. To obtain a greater number of data 
points for the initial period of inhibition aliquots were withdrawn at smaller time 
intervals requiring that the duration of the data set collection for the calculation of Vt, be 
decreased from 80s to 50s. The inhibitory activity of 1.41d was assayed in this manner 
(Figure 3.15) and the subsequent logarithmic plot is shown below (Figure 3.16). 
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Figure 3.15 Assay of inhibitory activity of compound 1.41d against a-chymotrypsin. 
Incubation of a-chymotrypsin (4rnM) with 1.41d (21mM, 5-fold excess over enzyme) 
in O.IM phosphate buffer, pH = 7.2, with 2.5% CH3CN. Aliquots were withdrawn at t = 
0.5, 1.75, 3min intervals before the enzyme was totally inactivated. 
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Figure 3.16 Logarithmic plot of enzyme activity versus time over 200 seconds for the 
data displayed in Figure 3.15. 
A logarithmic plot with negative slope is obtained but as alluded above there is 
substantial deviation away from psuedo first-order kinetics (r2 = 0.886). Therefore 
kobs/[I] (502 M-1s-l) will serve as a poor approximation ofkinacJKr, but none the less is 
a useful figure as it serves as a lower limit for kinactIKI. Comparison with the value 
obtained for the glutarimide inhibitor 2.lf (kinacJKI = 37 M-1s-I, see previous section) 
indicates that 1.41d is at least 13-fold more potent than 2.1f. Both 1.41d and 2.lf 
contain a mesylate leaving group hence the difference in inhibitory activity is related to 
the different ring size and substitution possessed by these compounds. 
The activity versus time profile of the inhibition of a-chymotrypsin by compound 
2.1d (Figure 3.17) serves to illustrate the activity displayed by compounds that were 
found to be potent inhibitors over an extended period of time. 
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Figure 3.17 Assay of inhibitory activity of compound 2.1d against a-chymotrypsin. 
Incubation of a-chymotrypsin (4~) with 2.1d CA, 1O~, 3-fold excess over enzyme; 
B, C, 20flM, 5-fold excess over enzyme) in 0.1M phosphate buffer, pH = 7.2 with 2.5% 
CH3CN. Aliquots (25flL) were withdrawn periodically and assayed for enzymic 
activity using BTEE employing the incubation method. 
Incubation assay of compound 2.1d carried out at an inhibitor concentration five-
fold excess over enzyme (data sets B and C of Figure 3.17) resulted in a rapid loss of 
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enzyme activity followed by a partial regain in enzyme activity (ca t = 20-30min) then 
a second rapid and ireversible loss of activity. A subsequent experiment was carried out 
at a lower inhibitor concentration (three-fold excess over enzyme) (Figure 3.17, Data 
Set A) in an attempt to lower the rate of inactivation and hence obtain data suitable for 
analysis. Less rapid inactivation was observed «1 % activity remaining after seven 
minutes) followed by a smaller recovery of enzymic activity compared to experiments 
B and C. After this partial regain in enzymic activity a second irreversible loss was also 
observed. 
These results are similar to those obtained for the assay of compound 2.lf (see 
Figures 3.8-3.10) and support an inhibition scenario where initial inactivation of a-
chymotrypsin is due to the unreactive imides 1.41 and 2.1 acting as "tme" mechanism-
based inactivators. Hydrolysis of the inactive enzyme and inhibitor results in a 
temporary regain in enzyme activity followed by a second but less rapid phase of 
inactivation thought to be due to a hydrolysis product of the imides. These rates of 
hydrolysis appear to be greater for more potent inhibitors. For example, there is a 
smaller recovery of enzyme activity for the inhibition of a-chymotrypsin by 2.1d at 
three-fold excess over enzyme than at five-fold excess (compare experiment A with B 
and C of Figure 3.17). To whit there was only a slight recovery of enzyme activity 
observed on assay of compound 2.lf (see Figures 3.8 and 3.9). 
Assay of 1.41d using the incubation method gave results indicating that the rate of 
inactivation of a-chymoptrypsin by this compound was too rapid to measured by this 
technique. The inhibitory activity was then evaluated using progress curve kinetics. 
Groutas et a184 have previously assayed 1.41d using this technique obtaining a value for 
kobs/[IJ of 9000 M-1s-l. This experiment was repeated and the results are shown below. 
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Figure 3.18 Progress curve assay of inhibitory activity of a-chymotrypsin of compound 
1.41d against a-chymotrypsin. a-Chymotrypsin (0.073f1M) was added to an incubated 
solution of 1.41d (0. 189j.LM; 3-fold excess over enzyme) and BTEE (117j.LM). Reaction 
progress was monitored by change in absorbance at 'A = 256nm. 
Analysis of this curve according to the graphical method of Tsou is shown below 
(Figure 3.19). 
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Figure 3.19 Initial portion of Tsou plot obtained for absorbance curve (see Figure 3.18) 
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There is a good correlation between the data and the kinetic model (r2 = 0.962) and a 
value for kobsl[I] of 64 497 M-1s-l ± 10% was obtained. The ± 10% error in this 
measurement, which is typical of progress curve measurements, was determined by 
addition of the error evaluated by the regression process in the calculation of kobs (± 
5%) and that in the experimental measurement of the inhibitor concentration, which 
incorporated weighing of the inhibitor to prepare the stock solution and subsequent 
dilution of this as required by each inhibition experiment. 
It appears therefore that the progress curve measurements are more accurate than 
those obtained with the incubation method where errors of up to ± 15% were calculated 
for determination of kobs which reflects the greater number of experimental 
measurements that need to made to determine kobs when using the incubation method. 
However results were obtained for identical progress curve inhibition experiments that 
were far beyond within 10% of each other even though the same buffer, enzyme, 
inhibitor and substrate solutions had been used. It is considered that the extent of 
mixing and the time taken to achieve this are of critical importance in obtaining 
accurate measurements. Even though a mixing time of not more than 20 seconds was 
strictly adhered to the extent of mixing is a hard variable to control. To minimise the 
error in measurements experiments were repeated so that two values for kobs within 
10% of each other were obtained. 
The fact that the logarithmic plots conceal alot of error in progress curve 
measurements contributes to the difference in the value we obtained for the inhibition of 
a-chymotrypsin by 1.41d (kobsf[I] :::: 64 497M-1s-l) to that obtained by Grouta..'l et al84 
(kobs/[I] :::: 9 000 M-1s-l). 
These values differ by an order in magnitude and illustrate the care that needs to be 
taken when comparing inhibition results between laboratories. 
Of the experimental details offered by Groutas et al84 in publishing their kobsf[I] 
value the only difference between the experimental conditions we employed is the use 
of DMSO as opposed to CH3CN however the volume of these solvents used in the 
assay is small and is considered to have a negligible effect compared to other assay 
variables. These include inhibitor purity and the freshness of the solutions used in the 
assay; the loss of enzyme activity of a stock solution of enzyme in phosphate buffer was 
noted and stock solutions of BTEE should be prepared daily.195b The above 
experiments have also been run at low inhibitor concentration of 3-fold excess over 
enzyme and hence there will be deviation away from the kinetic model used; this will 
also contribute to the discrepancy between the two results. 
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As stressed earlier it is important that inhibition experiments are carried out at 
saturating inhibitor and substrate concentrations for the steady-state assumption of the 
kinetic model to remain valid. It is quoted that less than ten percent of the substrate 
should undergo hydrolysis during the assay so that the steady-state for enzyme-substrate 
reaction of an inhibition experiment does not differ from that of the control 
experiment.198 The extent of hydrolysis can be calculated directly from the absorbance 
versus time curve using the Beer-Lambert Law. Calculation for the above curve (Figure 
3.18) indicates that 70% of BTEE has undergone hydrolysis. 
An experiment run at this low inhibitor concentration could be considered to be 
overstretching the steady-state assumption of the kinetic model even though other 
researchers have reported assay conditions with similar low inhibitor excesses. It has 
been shown that an inhibitor with a low partition ratio can be analysed at low inhibitor 
excess with little deviation away from psuedo first-order kinetics.25 There is evidence 
to suggest, however, that significant "turnover" pathways for N-acyl and sulfonyloxy 
imide inhibitors 1.41 and 2.1 exist and hence their partition ratios will be high. 
For accurate measurement of kobs/[I] using the progress curve method high 
concentrations of inhbitor will have to be used to achieve the all important saturating 
conditions. This was observed in the inhibition of a-chymotrypsin by compound 2.1f 
where a Kitz and Wilson plot to test for saturating conditions gave a result indicative of 
non-saturating conditions when low inhibitor concentrations were employed (see 
Figure 3.12). 
The results of the inhibition of a-chymotrypsin by 1.41d at higher concentrations is 
shown below (Figure 3.20). 
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Figure 3.20 Progress curves for inhibition of a-chymotrypsin by 1.41d. a-
Chymotrypsin (0.073).lM) was added to an incubated solution of 1.41d (A, 0.189!lM, 3-
fold excess over enzyme; B, 0.365mM, 5-fold excess; C, 0.949).lM, 13-fold excess) and 
BTEE (l17).lM). Reaction progress was monitored by change in absorbance at A = 
256nm. 
From :Figure 3.20 it can be observed that curves Band C fall over more sharply than 
does curve A. Hence the rate of inhibition of a-chymotrypsin is more rapid at higher 
concentrations. Analysis of curve B gives kobsl[l] = 17 790 M-1s-l (r2 = 0.989) and 
kobs/[l] = 3 562 M-1s-l for curve C (r2 = 0.993) and as alluded the correlation between 
data and model is better for higher inhibitor concentrations. Suprisingly the Aend values 
are higher for these curves than that of curve A suggesting the extent of substrate 
hydrolysis is greater. Curve C has the appearance of a curve associated normally with 
reversible inhibition. These results suggest that the inhibitor is being depleted 
significantly during the course of the experiment making the maintainence of saturating 
conditions difficult for this inhibitor. This is confirmed by the Tsou plot of [IJlkobs 
versus [IJ for 1.41d (Figure 3.21). 
Chapter 3 a-Chymotrypsin Inhibition Assay 
1000 
800 
600 
[I]/kobs (/lMs) 
400 
200 
0 
0 1 
Ph~ 
O~N~O 
I 
OS02CH3 
1.41d 
[I] (/lM) 
Figure 3.21 Tsou plot of [I]/kobs versus [1] for 1.41d 
110 
2 
The above plot is of the type obtained when non-saturating conditions are prevalent 
characterized by a poor correlation (r2 = 0.886). The y-intercept is negative and hence a 
value for kinactlKr can not be obtained however a value for kinact (0.00 13s-1) was 
obtained from the slope which provides valuable information regarding the inhibition 
process. 
The graph above however is distinguished by a sharp rise in [I]/kobs at higher 
inhibitor concentrations and therefore it could be considered that these have been 
obtained at the necessary saturating conditions required for analysis. A plot of these two 
data points cut the positive y-axis and subsequently an approximate value of kinactlKr 
was found to be 4 653 M-1s-l. Comparison with the kinactlKr value obtained for the 
glutarimide inhibitor 2.1f (kinact/Kr = 37 M-1s-l) indicates that 1.41d is IOO-fold more 
potent. Comparison of the kinact and Kr values obtained for these inhibitors provides the 
valuable insight that 1.41d owes its increa'ied potency to greater binding affinity for a-
chymotrypsin. 
To allow an accurate kinactlKr analysis a number of experiments have to be carried 
out at high inhibitor concentration however this was found to be excruciatingly 
frustrating to achieve as illustrated by the progress curve analysis of compound 1.41g. 
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Figure 3.22 Progress curves for inhibition of a-chymotrypsin by 1.41g. a-
Chymotrypsin (O.073J.LM) was added to an incubated solution of 1.41g (A, O.189!lM, 
[1o]/[Eo] = 3; B, 0.365mM, [Io]/[Eo] = 5; C, O.55mM, [1o]/[EoJ = 8) and BTEE 
(l17J.LM). Reaction progress was monitored by change in absorbance at A = 256nm. 
Figure 3.22 displays the progress curves obtained for inhibition of a-chymotrypsin 
by 1.41g obtained at three different inhibitor concentrations. As the inhibitor 
concentration increases the curves fall over more steeply as seen in the trend from curve 
A to curve C. The initial rates of reaction are also observed to decrease reflecting 
increased rate of inhibition and the Aend value is lower hence less substrate has been 
hydrolysed. Therefore saturating conditions are more likely to be prevalent in the 
inhibition experiment C than A or B. 
This is confirmed by the Tsou plot of [1]/kobs versus [I] for 1.41g which has a 
negative y-intercept. As observed in the Tsou plot for 1.41d (Figure 3.21) there is a 
sharp rise from a data point considered to be obtained in non-saturating conditions to 
data points obtained at saturating conditions. A plot of [1]lkobs versus [I] for these two 
points (not shown) also cuts the negative y-axis. 
To determine kinactlKI for compound 1.41g it was therefore necessary that 
experiments be carried out at higher inhibitor concentrations. However, in an 
experiment carried out at an inhibitor concentration ten-fold excess over enzyme the 
enzyme was found to be totally inactivated within the mixing period as characterized by 
a flat absorbance versus time graph (see graph C of Figure 3.6). It was not possible, 
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therefore, to obtain a value of kinact/Kr for this compound as the rate of inhibition at 
saturating inhibitor concentrations was too rapid to be measured. 
These results indicate that the progress curve method is inadequate for measuring the 
inhibition of a-chymotrypsin by 1.41£. The potent activity displayed by 1.41£ is such 
that only the activity at low inhibitor concentrations can be measured however these 
measurements will be inaccurate and deviate away from the pseudo first-order kinetics 
of the modeL An accurate measurement of the rate of inhibition of a-chymotrypsin by 
compound 1.41g in order to determine kinactlKr would require the use of stopped-flow 
methods. 
The results described above still, however, provide a qualitative description of 
structure and activity relation when compared to those obtained for other inhibitors at 
the same concentration. For example, the inhibition experiment carried out for 1.41d at 
an inhibitor concentration ten-fold excess over enzyme resulted in a normal progress 
curve (see progress curve C of Figure 3.20) whereas, as above, 1.41g totally inactivated 
a-chymotrypsin at this concentration. Therefore the inhibition of a-chymotrypsin by 
1.41g is more rapid than that of 1.41d. 
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Figure 3.23 Tsou plot of [l]/kobs versus [I] for 1.41g 
For an accurate measurement of kinact/Kr we require kobs values at saturating 
inhibitor concentrations. Accuracy will be improved if a greater number of inhibition 
concentrations are used. A larger data set has been obtained for the glutarimide inhibitor 
2.1g, with [I]/kobs values being obtained from inhibitor concentrations ranging from 
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0.189JlM (three-fold excess over enzyme) to 18.2SJlM (2S0-fold excess over enzyme). 
The Kitz and Wilson plot for 2.1e is shown below (Figure3.17). 
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Figure 3.24 Tsou plot of [I]/kobs versus [1] for 2.1e 
Again a straight line with negative slope is obtained from which a value for kinact 
(0.009s- 1) can be obtained however the y-intercept is not positive, which does not 
permit analysis of kinactlKJ. 
The results discussed for the succinimide inhibitors 1.41d and 1.41f and the 
glutarirnide inhibitor 2.1g were representative for the other potent inhibitors of type 
1.41 and 2.1. Due to the inability to calculate kinactIKI which was to be used as the 
measure of inhibitory activity providing the basis for structure activity comparison other 
means have to be used. 
As discussed earlier kobsl[I] is conventionally used when comparing the potencies of 
inhibitors. A high kobsl[I] value for a compound indicates that it is a more potent 
inhibitor than a compound with a lower kobi[I] value. The constant kobsl[I] is used 
routinely to compare compounds assayed using the incubation method however this 
term is not independent of inhibitor concentration for potent inhibitors a'lsayed using 
the progress curve method; hence for a valid comparison to be made experiments for 
each inhibitor will have to be run at the same inhibitor concentration (an inhibitor 
concentration of ten-fold exces over enzyme was chosen for this study). 
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In noting the trends in kobs/[I] values for compounds assayed using the progress 
curve method we found that, suprisingly, those compounds which were determined to 
be more potent inhibitors by the incubation method possessed lower kobs/[I] values than 
those determined to be weaker. For example, compound 1.41d could not be analysed 
accurately using the incubation method because it inactivated a-chymotrypsin rapidly 
within four minutes at an inhibitor concentration five-fold excess over enzyme. By 
decreasing the time intervals used in the sampling a lower limit for kobs/[I] was able to 
be calculated (kobs/[I] z kinact/Kr = 502 M-1s-l) indicating that 1.41d was at least 13-
fold more potent than the glutarimide 2.1f (kinacJKr = 37 M-1s-l). Compound 2.1f only 
inactivated a-chymotrypsin within 100minutes at an inhibitor concentration 25-fold 
excess over enzyme. On progress curve analysis the converse trend in the kobs/[I] values 
was observed; 1.41d (3 562 M-1s-l) versus 2.1f (7888 M-1s-l). 
This trend is also observed in comparing the inhibitory activities of compounds 
1.41d and 2.1e. Compound 2.1e, like 1.41d, could not be assayed accurately using the 
incubation method because it rapidly inactivated a-chymotrypsin. Assay at a low 
inhibitor concentration 3-fold excess over enzyme served to provide a lower limit for 
kinacJKr for the inhibition of a-chymotrypsin by 2.1e (kob/[I] z kinactlKr 403 M -1 s-l) 
hence 1.41d (kobs/[I] z kinactlKr =502 M-1s-l) is more potent. 
Progress curve assay of these compounds confirmed this result. At a concentration of 
twenty-fold excess over enzyme compound 1.41d totally inactivated a-chymotrypsin 
within the mixing time. In comparison, at a concentration of 2.1e 250-fold excess over 
enzyme a-chymotrypsin remained active. Based on these results 1.41d is more potent 
than 2.1e but this compound has a lower kobs/[I] value 1.41d (kobs/[I] == 3 562 M-1 s-1) 
versus 2.1e (kobs/[I] == 14321 M-1s-l). 
A preliminary explanation for the reversal in trends for kobJ[I] may lie in 
consideration of the inhibitor concentration dependence for kobs/[I]. For the 
mechanism-based inhibitors of type 1.41 and 2.1 studied [I]/kobs is observed to increase 
with inhibitor concentration. For kobs/[I] the converse will be observed i.e. kobs/[I] 
decreases at increased inhibitor concentration. A tentative hypothesis predicts a lower 
kobs/[I] value for a more potent inhibitor if for inhibition experiments run at the same 
inhibitor concentration the more potent inhibitor is acting as the weak inhibitor but at a 
higher concentration. 
In the absence of a theoretical basis for an explanation as to why more potent 
inhibitors possess lower kobs/[I] values when assayed using progress curve kinetics this 
method for comparison has its basis in the empirical observations described for the 
representative inhibitors above. 
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In the following structure-activity discussion the activities of inhibitors have 
beencompared on the basis of kobs/[I] values obtained from inhibition experiments run 
at a ten-fold excess of inhibitor over enzyme where there exists no more rigorous 
information regarding the inhibition process. Hence compounds possessing a low 
kobs/[I] when assayed employing the progress curve are considered to be more potent 
inhibitors than compounds with high values. 
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3.5 STRUCTURE-ACTIVITY DISCUSSION 
Compound R 
number 
1.41d PhCH2 
: e Ph 
f PhCH2 
g PhCH2 
h PhCH2 
i Ph 
j PhCH2 
k PhCH2 
L 
S02CH3 
S02CH3 
R 
o):;Ao 
I 
OL 
1.41 
S02 
~Ph 
S02-{ > 
S02-Q-CH3 
S02-Q-CH3 
SOz-{ < ) 
N02 
SOz-{ ) 
kinact 
(s-l) 
0.0013 
A 
A 
A 
A 
A 
0.0004D 
O.003D 
TABLE 3.3 Inhibition of a-chymotrypsin by inhibitors of type 1.41 
kobs/[I] 
(M-Is-I) 
3562B 
Alternate 
Substrate 
6471B 
C 
C 
Alternate 
Substrate 
826B 
6427B 
A Unable to be calculated because alternate substrate inhibitor or inactivated a-
chymotrypsin too rapidly at [lorEo] > 10 for kobs/[I] values to be determined. 
B Value obtained from progress curve analysis [lorEo] = 10; [Eo] = 0.073f..lM; [S] 
= 117f..lM. The lower the value the more potent the inhibitor. 
C Inhibition too rapid to be measured by progress curve method at [lorEo] = 10; 
[Eo] 0.073IlM; [S] = 1171lM. 
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D Value obtained from slope of Tsou plot of [I]/kobs versus [I] by linear regression 
analysis 
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In comparison to the "reference" inhibitor 1.41d it can be seen that the incorporation 
of an aromatic substitutent can result in an increase in inhibitory activity. On the basis 
that both 1.4ld and 1.41f totally inactivated a-chymotrypsin at an inhibitor excess 20-
fold over enzyme these compounds are essentially equipotent however a dramatic 
increase in activity was observed with compounds 1.4lg and 1.4Ih. Both inhibited a-
chymotrypsin at a rate too fast to be measured at an inhibitor concentration ten-fold 
excess over enzyme suggesting that these have successfully harnessed the binding 
energy available in interacting with the Sn I subsites of a-chymotrypsin. Compound 
1.4lj was very potent with a kobs/[I] value of 826 M-1s-I (a low value indicates potent 
inhibition) but less so than 1.4lg and h. This perhaps suggests that its larger bulk 
dissuades favourable binding which corroborates with the result obtained with 1.41f, 
also a bulkier inhibitor, which showed no enhancement in inhibitory activity relative to 
1.41d. 
Compound 1.41k was designed with the aim of enhancing the activity of 1.4lg as the 
increased electron withdrawing properties of the nitro group would be thought to 
increase inhibitory activity in two ways. The rate of the Lossen rearrangement has been 
determined to be related directly to the strength of the acid that is released during 
formation of the isocyanate. 86 It is considered that m-nitrobenzene sulfonic acid which 
is released during the inhibition of a-chymotrypsin by 1.4lk is a stronger acid than 
benzene sulfonic acid released during the inhibition cycle of 1.4lg due to the inductive 
effect of the nitro group. A more rapid Lossen rearrangement leads to an increase in 
kinact resulting in more potent inhibition. The increased electron withdrawing ability of 
the nitro group is also thought to have a secondary influence on the potency of 
inhibitors by increasing the electrophilicity of the scissile carbonyl of the succinimide 
ring. This would activate formation of the acyl-enzyme again increasing kinact. 
Despite the prediction of increased inhibitory activity the converse was observed, 
with 1.41k found to be less potent than 1.41g but comparable inactivity to 1.41f. It must 
be noted that the increased electron withdrawing effect of the nitro group in 1.4lk may 
also increase the rate of deacylation so that it competes with the Lossen rearrangement 
such that kinact may remain constant for 1.4lk and 1.41g. A definitive comparison of 
the kinact values for 1.4lg and 1.41k was not possible however as the inhibition of a-
chymotrypsin by 1.41g was too rapid to measure. However a comparison of the kinact 
values of compounds 1.4lj (kinact = 0.0004 s-I), which is thought to have similar 
electronic properties to 1.4lg, and 1.4lk (kinact = 0.003 s-1) does indicate there is a 
favourable ten-fold increase in kinact. Despite this ten-fold increase compound 1.41g is 
more potent, hence it is quite likely that compound 1.4lk lacks the topology to interact 
with a-chymotrypsin to the same extent as does 1.4lg hence the lower inhibitory 
activity. 
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Compound 1.4li in comparison to compound 1.41k has an electron donating methyl 
group on the phenyl ring. This compound was found to have comparable activity to 
1.41g hence the methyl group has no effect on inhibitory activity i.e. the electron 
donating and steric effects of this group are minimal. 
Compounds 1.41e and l.4li, both of which have a phenyl substituent (R) rather than 
the benzyl substituent of the compounds discussed above, were found only to be 
transient alternate substrate inhibitors of a-chymotrypsin. This result may be explained 
in the terms that the Lossen rearrangement to form the inactivating isocyanate has not 
occurred or if it has, the binding of these compounds to a-chymotrypsin has been such 
that the resulting isocyanate does not have the correct geometry or proximity to react 
with His-57. The Lossen rearrangement has been found to not only depend upon the 
strength of the departing acid as discussed above but also on the electron releasing 
power of the substitution present in the resultant isocyanate.86 On this basis it may be 
considered that the benzyl substituent is more favourable in promoting the Lossen 
rearrangement and binds more effectively with the S 1 pocket of a-chymotrypsin. The 
results obtained with compounds 1.41e and l.4li indicate that a benzyl substituent is 
required if a compound is to exhibit mechanism-based irreversible inhibition. 
The increased activity of the aromatic compounds 1.41g and 1.41h relative to the 
simple derivative 1.41d is almost certainly due to a favourable hydrophobic interaction 
between the phenyl ring contained within the fomer with either Phe-81 or Phe-192 
which are located in the Sn' sub sites of a-chymotrypsin.199 To harness this available 
binding energy and in an attempt to further increase enzyme-inhibitor recognition 
compound 1.411 (Table 3.4) was prepared which incorporated the design of the L group 
as an amino acid mimic. Initial design plans focused on the synthesis of the sulfonyl 
chloride 3.15, a phenylalanine mimic, that on coupling to 2.25 would give compound 
3.13 that possesses an aromatic substituent incorporated into an amino acid like 
substituent. An attempted synthesis of 3.13 using the Strecker reaction with the 
phenylalanine derivative 3.14 however was unsuccessful presumably due to the steric 
crowding of the a-centre of 3.14 a conclusion which is supported by documented low 
yields of the Strecker reaction when using secondary alkyl halides. 173 
As shown below in Table 3.4 1.41k, which lacks the desired aromatic substitution, 
was found only to be a moderate inhibitor of a-chymotrypsin. 
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Ph 
B,fC02Et 
3.14 
~A 
P~ Phn Ph + 
CI02/C02Et 
Ph 
o N 0 
o 6s02 ='-CC02Et I OR 
2.25 3.15 3.13 
Scheme 3.7 A, 1) K2S03, EtOHIH20, reflux 2) PCls, POCh, 70 °C 
Compound R L kin act kobs/[l] 
number (s-I) (M-Is-I) 
1.411 PhCH2 CR3 A B SOZA~02Et 
m PhCH2 o Ph O.OOlC 1609D S020-N~ S02~ ~ 0 
n PhCH2 ;:(Pn 0.0l2c 12589D 
-o--ci- Ii 0 
SOz ~;/ ~;/ SOzO 
Table 3.4 Inhibition of a-chymotrypsin by derivatives of type 1.41 
A Unable to be calculated 
B Value (kobs/[I] = 278 M-Is·l) obtained from incubation analysis using N-Succ-
(Alah-Pro-Phe-p-nitroanilide [IolEo] = 10; [Eo] = 0.073JlM; [S] = 117JlM. Note 
that this value cannot be compared to those obtained for 1.41m and n. 
C Determined from slope of a plot of [I]/kobs versus [1] 
D Value obtained from progress curve analysis [lolEo] = 10; [Eo] = 0.073JlM; [S] 
= 117JlM. The lower the value the more potent the inhibitor. 
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The "dimeric" compounds 1.4lm and 1.4ln were designed to release a species 
capable of inhibiting a-chymotrypsin providing a second cycle of inhibition. It was 
thought that compound 1.4lm might be more potent than the related monomeric 
compound 1.41f. Although these compounds showed reasonable activity, the opposite 
trend was observed suggesting that the second inactivating species is ineffectual, 
probably because it escapes from the enzyme active site. 
If a second species derived from the initial compounds 1.41m and n was involved in 
the inhibition process these compounds would display complicated multiphasic kinetic 
behaviour relative to the monomeric compounds, however, in the preliminary studies 
undertaken this was not observed. Further development of these types of inhibitors may 
include incorporation of structural features, i.e. macrocycles, to prevent the release of 
the second inactivating species from the active site. 
Of interest is the difference in the kinact values for the "dimeric" inhibitors 1.4lm 
and l.4ln. There is a ten-fold increase in kinact between the meta substituted compound 
1.4lm and the para substituted compound l.4ln however the former is the more potent 
inhibitor (as indicated by the lower kobs/[I] value; a lower value indicates more potent 
inhibition. This result suggests that l.4ln binds less favourably to a-chymotrypsin than 
1.4lm, perhaps due to its increased steric demands, resulting in poorer inhibition. This 
is consistent with the trend observed with the monomeric compounds where compounds 
1.41f and 1.4lj were found to be less potent than 1.41g and h. In the same manner the 
"extended" dimeric compound l.4ln was found to be two-fold less potent than 1,411 on 
comparison of kobsf[I] values. 
Compound R L Result 
number 
1.410 PhCH2 Ac Inactive 
p Ph Ac Inactive 
q PhCH2 c~Ph Inactive 
II 
0 
r PhCH2 Ph, ~ 0 Inactive 
C'lN.JlO ........... Ph 
I 11 H 0 
Table 3.5 Inhibition results for N-[(acyl)oxy]succinimides 
All the N-[(acyl)oxy]succinimides 1.410-r displayed in Table 3.5 were found to be 
inactive suggesting that an acyl leaving group is unfavourable for inhibition. To 
improve the activity of 1.410 compound 1.4lq was prepared which has a better leaving 
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group as evident by comparison of the pKa values of the respective acids (pKa acetic 
acid 4.74, pKa trans-cinnamic acid 4.44), however this compound too was inactive. An 
attempt was also made to impart activity to this series by increasing enzyme-inhibitor 
recognition and to this end compound 1.41r which contains N-Cbz (L)-phenylalanine as 
a leaving group was prepared however this too was found to be inactive. 
The inactivity of the N-[( acyl)oxy ]succinimides of type 1.410-r appears to be due to 
the lack of a suitable leaving group but may also be rationalised in terms of their ability 
to mimic a natural peptide substrate. The crystal structures of compounds 1.410-q were 
determined during the course of this thesis and comparison to a crystal struture of an 
active inhibitor may prove valuable in determining if N-[(acyl)oxy]succinimides 
possess the favourable binding properties that are required for inhibition. This proposed 
analysis is only approximate as the crystal structures which are obtained in the solid 
state give no indication of the conformations acquired by compounds in the active site. 
The crystal structure of 1.41f, whose inhibitory activity against both a-chymotrypsin 
and human leukocyte elastase is discussed above, has been solved,87g and is pictured in 
Figure 3.18 in contrast to a topological picture obtained for 1.41q from data (see 
Appendix) provided by the refinement for this compound. A comparison of 1.41f with 
1.41q is thought to be representative of the other N-[(acyl)oxy]succinimides 1.410, p, 
and r as 1.41q and 1.4f both contain a trans-styryl group hence the differences in 
conformations will be illustrated more clearly. 
The first point to note on comparison of the inactive N-[(acyl)oxy]succinimide 1.41q 
and the active N-[(sulfonyl)oxy]succinimide 1.41f (Figure3.18) is that 1.41q lacks the 
typical horseshoe or H shape of 1.41f which is commonly observed in the crystal 
structures of dipeptides containing (L)-phenylalanine. This characteristic conformation 
results from the two amino acid side chains extending from the backbone of the 
dipeptide and running approximately paralleJ.200-203 This geometry displayed by the 
natural substrates of serine proteases is reflected in the complementary shape of the 
active sites of these enzymes. 199,204 
It therefore appears that the sulfonyl(oxy) segment of potent inhbitors not only 
imparts favourable electronic properties for inhibition but has a role in setting the 
geometry of the inhibitor such that it mimics a natural substrate. The carbonyl group 
lacks this geometry and imposes a linear and flat conformation to the N-
[(acyl)oxy]imides which is unfavourable for binding to serine proteases. 
rnT',In<",n Inhibition 
o Ph-...r'YO-~~ 
o K Ph o 
1.41q 
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Figure 3.18 Comparison of crystal structure for 1.4lf (above) against that for 1.41q 
(below) 
The results obtained on assay of the six-membered glutarimide compounds 2.1a-f 
against a-chymotrypsin are presented in Table 3.6. These compounds provided a 
valuable insight into the importance ring size has with regards to structure-activity 
relation. 
Compound R 
number 
2.1a Ph 
2.1b Ph 
2.1c PhCH2 
2.1d H 
2.1e H 
2.lf H 
Inhibition 
R' R" 
H H 
H H 
H H 
Ph H 
cyc10hexyl 
CH3 CH3 
Rn'R R" 3 4 
o N 0 
I 
OL 
2.1 
L==S02R'" 
==C(O)R'" 
L kinact 
(s-l) 
S02CH3 0.011 
Ac C 
S02CH3 C 
S02CH3 C 
S02CH3 0.009 
S02CH3 0.006E 
kinactfKI 
(M-is-I) 
100000A 
C 
C 
C 
C 
37E 
Table 3.6 Inhibition of a-chymotrypsin by derivatives of type 2.1 
A Values determined from Tsou plot of [I]/kobs versus [I] 
kobs/[I] 
(M-l s-i) 
7784B 
15845 
D 
452B 
14321B 
F 
B Value obtained from progress curve analysis [IolEo] == 10; [Eo] == 0.073!lM; [S] 
== 117!lM. The lower the value the more potent the inhibitor. 
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C Unable to be calculated due to inactivation of a-chymotrypsin being too rapid at 
[IolEo] = 10 or Tsou plot of [I]/kobs versus [I] having a negative y-intercept. 
D Inhibition too rapid to be measured by progress curve method at [IoIEo] == 10; 
[Eo] == 0.073mM; [S] == 117!lM. 
E Values obtained from Kitz and Wilson plot oft1l2 versus 1/[1] 
F Value (kobs/[I] = 20 M-1s-l) obtained from incubation method analysis [IolEo] = 
25; [Eo] = 3.922!lM; [S] = 117!lM. Note that this value eannot be compared with 
those obtained using the progress curve method. 
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The N-mesyl glutarimide 2.1fwas found to be a poor inhibitor (kinactlKI = 37 M-1s-
1) when assayed using the incubation method. However, the glutarimide 2.le which 
possesses more suitable substitution to interact with the hydrophobic S 1 pocket was 
found to be a more potent inhibitor. This compound was unable to be assayed 
accurately using the incubation method although a lower limit for kinact/KI was 
calculated to be 408 M-1s-l hence 2.le is at least ll-fold more potent than 2.1f. An 
analysis using the progress curve method gave a kobs/[I] value of 14321 M- ts-l hence 
2.1£ is less active than the five-membered succinimide compounds (see Table 3.3). The 
difference in the observed potencies of these compounds lies in consideration of their 
binding affinity for a-chymotrypsin since their kinact values were found to be of the 
same magnitude; KI for the more potent 2.le must therefore be lower than the value for 
2.1£ (KI = 156~M) calculated from a Kitz and Wilson plot of tl/2 versus 11[1]. 
The introduction of an aromatic substituent onto the ring resulted in a dramatic 2 000 
fold increase in inhibitory activity as shown by comparison of kinactlKI values for 2.1£ 
(kinactlKI = 37 M-1s-l) and 2.la (kinactlKJ = 100 000 M-Is·l) which has a favourable a-
phenyl substituent. The kinact value for 2.la was only slightly higher than that for 2.1£ 
hence the dramatic increase in activity is due to increased binding affinity as confirmed 
by the comparison of the KJ values for 2.la (0.1~M) and 2.1£ (156~lM). 
Although no kinact/KI analysis was made for 2.Id comparison of the kobs/[IJ values 
obtained for 2.la (kobJ[I] = 7 784 M-ts-I) and 2.ld (kobs/[I] 452 M-1s-l) indicate that 
the placement of the phenyl substituent at the ~-position leads to an increase in 
inhibitory activity (note that studies have shown that a lower value corresponds to more 
potent inhibition). This may suggest that 2.ld may be able to bind in a different manner 
in the active-site projecting both the phenyl substituent and a portion of the glutarimide 
ring into the SI specificity pocket such that this compound can mimick the p] 
phenylalanine residue of the natural substrate while retaining the correct conformation 
to react with Ser-195. 
As observed in the succinimide series incorporation of an a-benzyl substituent onto 
the glutarimide ring afforded the most potent inhibition observed in the glutarimide 
series. Compound 2.lc totally inactivated a-chymotrypsin at a concentration lO-fold 
excess over enzyme within the mixing period and is therefore of comparable activity to 
the succinimides l.4Ig and h. 
As mentioned previously these potent compounds would require the use of stopped 
flow methods to determine kinact/l<]:. However an indication of their relative potencies 
can be obtained by comparison of the kinact values obtained for the succinimide and 
glutarimide series. With the exception of the "dimeric" inhibitor l.4In whose kinact is 
125 Chapter 3 - a-Chymotrypsin Inhibition Assay 
----------~--------------------------------
of the same magnitude the kinact values of the glutarimide inhibitors are an order of 
magnitude higher. 
Assuming that compounds 1.41g and h, and 2.1c have comparable binding affinity 
for a-chymotrypsin it appears that 2.1c may be the more potent inhibitor due to the 
higher kinact value observed in the glutarimide series. This trend has been reported in 
the comparison of five and six membered haloenol lactones discussed previously 
(Section 1.3, Chapter 1) where the higher inhibitory activity of the six membered 
derivatives was rationalised in the terms that the a-halo ketone reactive species 
unmasked was on a longer tether and therefore closer to His-57 promoting formation of 
the inactive enzyme. 
Suprisingly, the N-acetylglutarimide 2.1h showed inhibitory activity against a-
chymotrypsin. If the mechanism of inactivation of a-chymotrypsin by 2.1h involves thc 
Lossen rearrangement the question arises as to why the related 
N[(acyl)oxy]succinimides did not exhibit similar activity. The differences in activity 
between the N-acyloxy glutarimide and succinimide derivatives could be explained in 
the terms that the glutarimide binds more favourably to a-chymotrypsin and in such a 
way that allows a mode of inhibition to proceed which is unavailable to the 
succinimides. 
In summary, we assayed the inhibitory activity of the series of five- and six-
membered imides represented by structures 1.41 and 2.1 against a-chymotrypsin using 
both the incubation method, for slower inhibitors, and the progress curve method for 
faster more potent inhibitors. 
R 3h4 
oAN~O 
I 
OL 
1.41 
L=S02R' 
= C(O)R' 
Rn'R R" 3 4 
o N 0 
I 
OL 
2.1 
=C(O)R'" 
These results suggest that for potent inhibition to be observed the ring substitution 
must be aromatic or hydrophobic in nature; alkyl type substitution resulted in poor 
inhibition. A benzyl substituent was found to be optimum for activity being equivalent 
to the side chain of phenyalanine the preferred PI residue of natural substrates of a-
chymotrypsin. 
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No activity was observed in the succinimide compounds 1.41o~r, probably due to the 
fact that an acyl group is not a sufficiently good leaving group. Suprisingly, activity was 
observed in the glutarimide example 2.1b suggesting that the six-membered ring has 
favourable binding properties. 
An increase in inhibitory activity in the succinmide series was observed when the R 
substituent of the leaving group (OS02R) was aromatic. It is thought that this R group 
may be interacting favourably with the Sn' subsites of a-chymotrypsin and their 
increased activity owing to increased binding energy. However not all aromatic type 
inhibitors of type 1.41 displayed a favourable enhancement in activity; those derivatives 
with bulkier subtituents e.g. 1.4lf and 1.4li displayed slightly decreased potency 
indicating there are steric limitations to the extent of binding with the Sn' subsites. 
The glutarimides 2.1a, e and f were analysed to have higher kinact values than the 
succinimides 1.41. This is thought to result from an increase in the rate of reaction of 
the reactive isocyanate formed in the Lossen rearrangement with His-57. This is 
explained in the terms that the isocyanate is on a longer tether and hence closer to His-
57 for glutarimides. Due to the glutarirnide compounds possessing higher kinact values it 
is thought that appropriately substituted derivatives, having high binding affinity for a-
chymotrypsin, will display the optimum activity of the inhibitors whose assay has been 
discussed in this chapter. The greater number of substitution sites on the glutarimide 
ling will also make these compounds more amenable to the development of imides as 
potent and selective mechanism-based inactivators of serine proteases. 
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4.1 CHIRALITY AND BIODISCRIMINATION 
Chirality is a property of molecules which defines important aspects of our 
biochemistry and interaction with the environment. It also determines the biological 
activity of molecules finding wider everyday use as pharmaceuticals, agrochemicals, 
and foodstuffs. 
Biological activity arises from the interaction of a compound with a biomolecule 
such as an enzyme or a receptor. These biomolecules are constructed from amino acids 
and carbohydrates - nature's own chiral building blocks - and hence are chiral 
themselves. If the compound is chiral then the type and magnitude of the interaction, 
and therefore the biological response, is related to its stereochemistry. Thus the 
stereoisomers of an organic compound are likely to interact differently with its 
biomolecule.205,206 
This biodiscrimination is manifest throughout nature,207,208 and has long been 
recognised in taste and odour perception209-211 and other physiological responses. 
Perhaps the most striking example is the stereoselective action of the enzymes and 
receptors responsible for the chemical reactions that instill life. The enzymes of our 
body, with few exceptions, metabolize only the (L)-enantiomers of amino acids and the 
(D)-enantiomers of carbohydrates and receptors act on the spatial elements these 
stereochemistries dictate. 
TYPES OF BIODISCRIMINATION 
In general, there are four different ways in which stereoisomers act on their target 
chiral biomolecule.212 Of these four, only three are observed when studying a single 
enzyme system in vitro as in this thesis. In one situation the biological activity resides 
totally with one stereoisomer while another is devoid of activity: for example the (S,S)-
peptidyl haloenol lactone 1.35 is active against a-chymotrypsin (a-CT) and human 
neutrophil elastase (HNE) while the (S,R)-peptidyl haloenollactone 4.1 is inactive at 
the same concentration.79 
)"1" o. Dy"-BU 
o o:lsro 
(S,S) 
1.35 
kobs/[I] = 8 000 M-1s-l/a-CT79 
kob/[I] = 1100 M-1s-1/HNE79 
(S,R) 
4.1 
inactive 
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Alternatively, the stereisomers may both be active but differ in potency. This case is 
illustrated by the reversible inhibition of human neutrophil elastase (HNE) by peptidyl 
trifluoromethylketones (see Section 1.3, Chapter 1 for a discussion). Compound 1.1536 
has the correct (S)-configuration at the a-position to mimick the natural peptide and 
hence is 100-fold more active than the epimer 4.236 which has an unfavourable non-
natural (R)-configuration, and two-fold more active than the racemate 4.3. 
'-..../ 
Cbz-Val-Prer-~~CF3 
H 0 
: CF Cbz-Val-Pro-N~ 3 
H 0 
1.15 4.2 
K j = 0.0008 11M / HNE36 K j = 0.015 11M / HNE36 
Cbz-Val-Pro-~~CF3 
H 0 
4.3 
Ki = 0.0016 11M / HNE192 
Discussion of the biodiscrimination displayed in the above two situations has lent 
itself to the nomenclature proposed by Lehmann et al.213 The more biologically active 
stereoisomer has been named the eutomer; the corresponding less potent or inactive 
isomer is then called the distomer. The ratio of the activities (eutomer:distomer), the so-
called eudismic ratio, is a measure of the degree of stereoselectivity of the biological 
activity. The eudismic ratio for the above example (Kil.1S:Ki4.3) is ca 200 which is a 
value typical of chiral medicinal agents.214 
The remaining biodiscrimination type observed is relatively rare. In this situation 
both stereoisomers may have similar or equal activities as illustrated by the inhibition 
of Type 1 human steroid Sa-reductase by 4.4 and 4.5.215 
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o 
4.4 
Ki,app == 9nM 
Type 1 Steroid Sa-reductase 
o 
4.5 
Ki,app == 10nM 
CI 
Type 1 Steroid Sa-reductase 
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The stereoselective inhibition of serine proteases by mechanism-based inhibitors of 
type 1.41 has been undertaken by Groutas et al. 87e The results for the inhibition of 
human leukocyte elastase by (-)-(R)- and (+)-(8 )-1.41d are shown below. 
Ph-" o~o 
I 
OS02CH3 
(-)-(R) 
1.41d 
k2iKr == 330 M-1s-11 HLE87e 
(+)-(8) 
1.41d 
k2/KI = 1500 M-1s-11 HLE87e 
The eudismic ratio for the above example is equal to five suggesting there is low 
stereo selectivity for the inhibition which has been rationalised in the terms that both 
enantiomers of 1.41d can display the correct spatial orientation to be accomodated in 
the active site. 
Human leukocyte elastase has a long and shallow active site and its substrate 
specificity at Sl has been found to be regulated by substrate length.216 The preferred PI 
residue is valine however the hydrophobic Sl pocket of human leukocyte elastase will 
also accomodate residues such as alanine and phenylalanine with short substrates. With 
extended substrates the specficity demands increase and only those substrates with 
valine as the PI residue are accomodated, in the same manner the stereo selectivity of 
inhibition will increase a commonly observed observation that is known as Pfeiffer's 
rule. 217 The low stereoselectivity of inhibition observed does not mean that human 
leukocyte elastase acts with low stereospecificity; it is thought that with longer 
inhibitors the difference in rates of inhibition for stereoisomers will be larger and a 
higher eudismic ratio observed. 
Groutas et al87e obtained similar results to those above for human leukocyte elastase 
when investigating a-chymotrypsin i.e. (-)-(R)- and (+)-(8)-1.41d were equipotent. 
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This enzyme does not display the broad substrate specificity of human leukocyte 
elastase and invoking Pfeiffer's rule it may have been expected that the two 
enantiomers would display different levels of activity. The stereoselective action of a-
chymotrypsin has been explained in terms of binding requirements to specific structural 
motifs in a model of the active site proposed by Cohen and Milovanovic in a study of 
the absolute steric course of hydrolysis of a number of esters of substituted succinic and 
propionic acids.152 Figure 4.1 depicts the binding of diethyl 2-benzylsuccinate (4.6) in 
the active site proposed by these authors. 
4.6 
JJ. a-chymotrypsin 
a-chymotrypsin active site model 
(R)-4.6 accomodated (8)-4.6 no fit 
Figure 4.1 The binding of diethyl 2-benzylsuccinate 4.6 in Cohen and Milovanovic's 
active site model for a-chymotrypsin 
From Figure 4.1 only (R)-4.6 is hydrolysed by a-chymotrypsin as it is the 
enantiomer that has the correct spatial orientation to bind properly within the active 
site. For this enantiomer, the phenyl ring is juxtaposed so that it can interact favourably 
with the Sl hydrohobic binding pocket while the scissile bond is aligned correctly in 
the hydrolytic site, N. The a-carbethoxymethylene group is in the correct position to 
permit favourable hydrogen bonding with the acylamino binding pocket Am. The a-H 
of (R)-4.6 points toward the interior of the active site at a domain H of restricted 
volume, contiguous with Ar. 
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This binding domain H can only accomodate structural moieties of small size; 
substitution of a substantially larger group decreases reactivity greatly. Hence (8)-4.6 if 
it is to interact correctly with the S 1 hydrophobic pocket places the large a-
carbethoxymethylene group at H which explains the poor reactivity of (8)-4.6 in 
conjuction with the loss of the favourable hydrogen bonding iteraction with the acyl 
amino binding site. 
The stereospecificity of action is lost if the a-carbethoxymethylene group is replaced 
with a group of smaller size and this has been observed with a-chloro and hydroxy 
propionic acid esters218 and cyclised substrates.219 That the enantiopure inhibitors (-)-
(R)- and (+ )-(8)-1.41d exhibit the same potency may be rationalised in the terms that 
the N-mesylate is sufficiently small that both enantiomers can be accomodated in the 
active site. 
A goal of this thesis was to explore the stereoselective inhibition of a-chymotrypsin 
by derivatives of type 1.41, as shown below, where the alkyl sulfonyl group was larger 
than a mesylate so that a difference in the activites betwen the two enantiomers may be 
observed and that the stereoselectivity of the interaction with the Sn' subsites of the 
enzyme could be examined. 
Ph-" 
" O~O 
I 
OH 
(3R) 
2.26 
(3R) 
1.41 
A method for obtaining enantiopure derivatives of type 1.41 therefore was required 
as a step towards accomplishing this goal. N-Hydroxysuccinimides, such as 2.26, are 
key precursors of 1.41 therefore we required an enantioselective synthesis of these 
derivatives. 
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CHIRAL 
Biodiscrimination has had implications for the agrochemical and foodstuffs 
industries: chiral herbicides and plant growth factors display biodiscrirnination, and 
large industries have developed for the stereoselective synthesis of (L)-amino acids as 
food supplements and (D)-glucoses as non nutritive sweeteners.220,221 Chiral medicinal 
agents have been known to exhibit biodiscrimination as long as 80 years ag0222 and 
this phenomenon abounds in the medical field223 and hence has held the greatest 
consequence for the pharmaceutical industry. 
Industry's requirement for chiral pharmaceuticals, agrochemicals and foodstuffs has 
fueled research into the synthesis of enantiopure compounds and subsequently the 
analysis of the enantiomer compositions of molecules. This has had a huge "wash-over" 
effect for academic pursuit as there exist several ways of obtaining chiral, non-racemic 
compounds essential for the study of nature's stereoselective processes, whether that be 
the investigation of the stereospecificity of an enzyme's catalytic action, or mimicking 
her biosynthetic prowess by threading the stereochemical labyrinth of her structurally 
diverse and complicated molecules through asymmetric synthesis. 224 
There exist a number of methods for the preparation of chiral succinates and these 
are discussed briefly in turn. 
CLASSICAL RESOLUTION 
Traditionally, optically pure compounds have been obtained by classical resolution 
techniques at a favourable stage during the synthesis of their racemates. The use of 
enantiomerically pure starting materials and enzymes in synthesis and of the latter in 
kinetic resolutions and the advent of stereoselective synthesis has reduced, though not 
totally, the need for classical resolution. A synthesis purporting all of these design 
principles can still be subject to rabid racemization requiring resolution of 
intermediates and products. 
Earlier in this thesis (Section 2.1, Chapter 2) 2-substituted succinic acids were 
identified as intermediates in the synthesis of 3-substituted N-hydroxysuccinimides key 
precursors in the preparation of the target inhibitors 1.41. These acids also represent a 
favourable target for classical resolution. The resolution of 2-substituted succinic acids 
in particular 2-benzylsuccinic acid 2.13 by the optically active amine C+)-(R)-
methybenzylamine (MBA) followed by the alkaloid strychnine (Scheme 4.1) has been 
carried out by Fredga.225 Succinic acid mono esters featured in one synthesis of 2-
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substituted succinic acids employing Stobbe condensation methodology (Method C, 
Scheme 2.5, Chapter 2) and these also present themselves as targets for classical 
resolution. The resolution of methyl 2-isopropylsuccinate by both enantiomers of 
methylbenzylamine has been achieved.226 
A resolution procedure may prove wasteful if the undesirable enantiomer cannot be 
used in a different application or recycled. The above resolution procedures are 
economical in this sense as both enantiomers of the target inhibitors 1.41 provide 
valuable information regarding the stereospecifics of inhibition of a-chymotrypsin. 
Classical resolution therefore is a competitive route to desired enantiopure inhibitors 
1.41 considering the resolving agents employed, strychnine and methylbenzylamine, 
are both commercially available. 
Classical resolution, however, involves numerous recrystallisations each with 
inherent loss of material, and is lengthy (in terms of time). For example, the resolution 
of racemic 2-benzylsuccinic acid 2.13 (Figure 4.1) as described in the literature,225 
was undertaken using pure 2.13, requiring repeated recrystallisation of the material 
obtained from synthesis (in our experience four recrystallisations from water were 
required). 
The racemic acid 2.13 is treated with two equivalents of (+ )-(R)-methylbenzylamine 
to give the diastereoisomeric salts 4.7 and 4.8. The required separation of these is trivial 
as 4.8 crystallises from the reaction solution, and 4.7 remains in the mother liquor. 
Repeated recrystallisation of salt 4.8 from H20 completes the resolution of (-)-(S)-2-
benzyl succinic acid 2.13 ([a]o = -27.2°) and this is obtained by decomposition of the 
purified salt 4.8 with dilute H2S04 and extractive work-up with Et20. Salt 4.7 is 
decomposed to give impure (+)-(R)-2-benzylsuccinic acid 2.13 which is then further 
resolved by treatment with strychnine, the resulting salt 4.7 requiring no purification to 
give pure (R)~2.13 ([a]D = +27.00 ) which is obtained as described for (S)~2.13. 
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Scheme 4.1 Classical resolution of racemic 2-benzy lsuccinic acid 2.13 by (+)-
methylbenzylamine (MBA) and (-)-strychnine. 
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In addition to developing resolution procedures for 2-substituted succinic acids 
Fredga has undertaken the groundwork in determining the absolute configurations of 
the (+)- and (-)-enantiomers of the acids obtained. The method he has exclusively used 
has been that of quasi-racemates.227 In brief, it has been shown that (+)-2-
benzylsuccinic acid has the same configuration as (+ )-malic acid whose absolute (R) 
configuration has been unequivocably established.228 
The specific rotations obtained by Fredga for the above resolution are considered to 
be the maximum specific rotations for (+ )-(R)- and (-)-(8)-2.13 and have therefore been 
used routinely in the determination of the optical purity of samples prepared using other 
methods as seen below. 
KINETIC ENZYMIC RESOLUTION 
The length of a classical resolution however does not present itself in the resolution 
of racemates by enzymes. On presentation of a racemic substrate the enzyme due to its 
chirality behaves in an stereoselective manner reacting exclusively with one 
stereoisomer leaving the other untouched. As discussed earlier the (+ )-(R) enantiomer 
of racemic diethyl 2-benzylsuccinate 4.6 can only be accommodated in the active site 
of a-chymotrypsin and is hydrolysed to (+)-(R)-ethy12-benzylsuccinate (3.11). The (-)-
(S) enantiomer of 4.6 is left untouched as observed in Scheme 4.2 which depicts the 
enzymic kinetic resolution of 4.6 by a-chymotrypsin. 
Ph"h a-chymotrypsin Ph-" Ph"h 
'" 
> ~ + Et02C C02Et H02C C02Et Et02C C02Et 
4.6 1Sh (R) (8) 
4.10 4.6 
JA JA 
Ph-" Ph"h ", 
~ 
H02C C02H H02C C02H 
(R) (8) 
2.13 2.13 
Scheme 4.2 A, NaOEt, EtOH, rt 
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Both (R)-4.10 and (S)-4.6 can be hydrolysed with ethanolic sodium hydroxide to 
give the corresponding (R)- and (S)- acids 2.13 whose rotations ([a,]25D = +27° and 
[a.]25D -270 respectively) were found to be comparable to the definitive rotations 
determined by Fredga above; (R)-2.13 ([a,]25D = 27.00) and (S)-2.13 ([a,]25D ::= -27.2°) 
indicating that the products obtained by the enzyme kinetic resolution were of high 
purity. 
This resolution procedure has the potential to return amounts of both enantiomers of 
the racemic substrate in a day period. However high concentrations of a,-chymotrypsin 
have to be used making this method prohibitive considering the supply of this enzyme 
in our laboratory and the hydrolysis of 4.6 is slow and with no suitable pH-Stat 
apparatus available, the 18h duration of the hydrolysis course to be followed manually 
makes this approach attractive to only an insomnic chemist. 
Enantiopure inhibitors can then be prepared from the enantiopure 2-benzylsuccinic 
acid obtained from the above classical and enzymic resolutions employing the 
methodology of Scheme 4.3 used in the synthesis of racemic inhibitors of type 1.41 
discussed in Chapter 2. The reactions of Scheme 4.3 which depicts the representative 
synthesis of (S)-1.41d have been shown to be devoid of racemization by Groutas et 
al87e who found the product inhibitors prepared by this route to be enantiopure by 
chiral shift reagent determination.229 
(S) 
2.13 
Phb 
o N 0 
I 
OR' 
(S) 
C [ 2.25 R' ::= CH2Ph 
y... 2.26 R'::= H 
D 
Scheme 4.3 A AC20, reflux 
B H2NOCH2Ph, toluene, reflux 
C H2/10% Pd-CITHF 
D CH3S02Cl, pyridine, CH2Ch 
Ph~ 
oJ-..o~o 
(S) 
2.27 
B 
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ASYMMETRIC SYNTHESIS 
Asymmetric synthesis provides the chemist with the power to employ synthetic 
methods that not only result in the desired transformations of starting materials to 
products but control the absolute stereochemistry of the stereogenic centres which are 
created as a result of the synthetic operation. 
An asymmetric synthesis of chiral succi nates is therefore more flexible than the 
previous methods discussed. Methods that have been employed include the synthesis of 
chiral succinates from naturally occurring substrates,230 a strategy widely known as the 
chiron approach.231 This method has been used in the synthesis of imide containing 
psuedo peptide sequences 2.37 from (L)-phenylalanine (4.11). The stereochemistry 
residing in 4.11 is incorporated into the key intermediate 2.36 which mediates the 
stereochemistry in the final product 2.37. However, to its disadvantage the chi ron 
approach often involves multi-step syntheses. 
H2NXC02H 
( H 
Ph 
4.11 2.36 
o 
-~:Q-OS02R' 
Ph 0 
2.37 
Scheme 4.4 Synthesis of 3-benzylsuccinimide containing pseudo peptides 
The asymmetric hydrogenation of unsaturated succinate derivatives has been 
undertaken232 however methods based on the principle of relayed asymmetric 
induction have proved popular. In this process asymmetric information is introduced to 
the racemic substrate before the reaction where the new asymmetric centre is created 
and then the chiral originator, a so-called chiral auxiliary is removed. Two auxiliaries 
that have furnished short syntheses of chiral alkyl succinates are iron acyl complexes233 
and the chiral oxazolidinones developed by Evans. 234 
Evan's chiral oxazolidinones prepared from naturally ocurring amino acids such as 
valine and phenylalanine are readily available. Of the chiral auxiliaries derived from 
these two amino acids those prepared from phenylalanine are crystalline not requiring 
the extra purification steps associated with the valinol derived auxiliaries and contain a 
good chromophore facilitating TLC analysis. The phenylalanine oxazolidinones are 
easily attached to the racemic substrate and recycled and hence were the chiral auxiliary 
of choice presenting an attractive route to the desired chiral alkyl succinate 
intermediates. 
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The mode of asymmetric induction by Evans chiral auxiliaries lies in the 
consideration of enolate chemistry. For a reaction at the a-position to be stereos elective 
several conditons have to be fulfilled among the most important being the geometry of 
the enolate formed. Factors which can control the stereoselectivity of enolate formation 
include choice of base, solvent, temperature and metal counter ion but most importantly 
from the viewpoint of this thesis the chiral auxiliary. In this respect the Evans 
oxazolidinones are attractive in that they give exclusively (Z)-enolates. 
A second factor in determining the stereochemical outcome in the reaction is that the 
chiral auxiliary imposes a strong facial bias for the approach of the eletrophilic 
alkylating agent towards the enolate. It is here the substitution present the chiral 
auxiliary comes into playas the approach of the electrophile occurs on the less hindered 
face of the enolate. 
Alkylation and aldol additions of N-acyl compounds derived from chiral 
oxazolidinones proceed with high diastereoselectivity as illustrated by relevant 
literature examples of the synthesis of chiral succinates. In 1981 Evans235 prepared 
(2R)-benzylsuccinic acid employing the aldol addition of a N-acyloxazolidinone boron 
enolate derived from(L)-valinol. The key aldol adduct was prepared in 99% 
diastereoisomeric excess as determined by gas capillary chromatography which was 
degraded to give (2R)-benzylsuccinic acid whose optical purity was judged to be 98% 
by comparison to the maximum specific rotation obtained by Fredga.225 
In 1988, Fadel and Salaun236 reported the preparation of chiral succinic acid diesters 
employing the distereoselective alkylation (>95% as determined by IH NMR) of (L)-
valinol derived N-acyloxazolidinones. The enantiomeric excess of the esters was 
determined by chiral shift reagent to be >95%. 
In 1993, Crimmins et al237 described a stereoselective synthesis (>95% 
diastereoisomeric excess) of succinic acid mono esters employing sodium base 
mediated alkylation of a chiral N-acyloxazolidinone derived from (L)-phenylalanine. 
This methodology was repeated in 1998 by Levy et al226 and McClure et a1238 who 
reported the synthesis of chiral succinate derivatives with high diastereoselectivity. 
The trend in these examples illustrates how Evans oxazolidinones are widely utilised 
for the synthesis of chiral compounds and that the stereochemistry of these reactions 
has been so rigorously established that present day synthetic communications rarely 
involve a critique on the stereoselectivity of these reactions-an example being patents 
filed for the synthesis of renin inhibitors using oxazolidinone methodology.239 
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4.3 SYNTHESIS AND INHIBITORY ACTIVITY OF 
AN ENANTIOPURE N-[(ALKYLSULFONYL)OXY] 
SUCCINIMIDE 
To incorporate the Evans oxazolidinone methodology into a synthesis of an 
enantiopure inhibitor of type 1.41 a retrosynthetic analysis was carried out. The 
disconnection of (R)-l.4ld serves as a representative example and is shown below 
(Scheme 4.5). 
Ph-" o~o 
Ph-" 
I 
OS02CH3 
(R) 
l.4ld 
o~o 
Ph-" 
h o X X 0 
4.12 
X=OH, OR 
I 
OH 
(R) 
2.26 
Scheme 4.5 Retrosynthetic analysis of (R)-l.4ld 
The retrosynthetic analysis proceeds with disconnections discussed earlier in the 
synthesis of the racemic counterpart. Disconnection of the bond between the oxygen 
and the reactive moiety L of (R)-1.41d gives (R)-3-substituted N-hydroxysuccinimide 
(R)-2.26 and alkylsulfonic and alky1carboxylic acid derivatives as reagents. 
Chapter 4 - Enantiopure N-[(sulfonyl)oxy]succinimides and inhibition 140 
Disconnection of (R)-2.26 proceeds by cleavage of the imide bonds, as indicated, to 
give hydroxylamine and the chiral 3-alkylsuccinate reagent 4.12. 
Retrosynthetic analysis of the key chiral succinate reagent 4.12 proceeded as shown 
in Scheme 4.6. Dissection of 4.12 as indicated gives the two synthons 4.13 and 4.14 
which correspond to the chira12-benzylpropionate reagent 4.15 and bromo acetate esters 
4.16. Disconnection of 4.15 gives the chiral auxiliary 4.17 and 3-phenylpropionyl 
chloride 4.18. 
(NH 
o-{ 
o 
4.17 
III 
4.15 
Ph-, 
\ ~ o;:~o 
X X 
4.12 
X=OH,OR 
4.18 
+~ 
X 0 
4.14 
III 
Scheme 4.6 Disconnection of 4.12 using a chiral propionate synthon 
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The starting point of the synthesis of an enantiopure inhibitor was the preparation of 
the chiral oxazolidinone 4.17 in two steps (Steps A-B of Scheme 4.7) from (L)-
phenylalanine 4.11. 
A B 
4.11 4.19 
o 
A 
o NH 
~Ph 
4.17 4.15 
Scheme 4.7 A 1) BF3.0Et, 0.75h, rt, 2h reflux, 2) BH3.S(CH3h, 12.25h rt, 
11.25h reflux, 3) 5N NaOH, overnight 
B diethyl carbonate, K2C03, 4h, 136°C 
C 1) n-BuLi, THF, 0.5h, -78 °C 2) 3-phenylpropionyl chloride, overnight 
-78°C rt 
An initial preparation of (L)-phenyalaninol 4.19 was carried out using lithium 
aluminium hydride reduction of phenylalanine. Work up of this reaction was hindered 
by a persistent emulsion, which was removed by filtration through ceHte but probably 
contributed to the low observed yield for the reaction (10% ). 
The low yield prompted the use of another method and hence the synthesis of (L)-
phenylalaninol was carried out by borane reduction of (L)-phenylalanine according to 
the literature procedure (Step A, Scheme 4.7).240 Thus (L)-phenylalanine was treated 
with boron trifluoride etherate followed by borane-dimethyl sulfide (1.15 equiv.). 
Aqueous alkali was added and the resulting reaction slurry refluxed overnight. 
Extractive work-up gave (S)-phenylalaninol 4.19 in 91 % yield. Little emulsion was 
observed with this method and although this intricate procedure was lengthy (three days 
in total) and involved hazardous reagents and conditions a higher yield was observed. 
An added advantage is that borane reductions typically proceed with less 
racemisation.240 
A mixture of 4.19 and diethyl carbonate (2 equiv.) and K2C03 (0.5 equiv.) was 
heated for 4h at 136 °C to give the oxazolidinone chiral auxiliary 4.17 in 98 % yield. 
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However when this reaction was repeated the results above proved difficult to 
reproduce; charring of the reaction mixture occurred on heating which on work-up gave 
a crude brown mass which proved difficult to purify by recrystallisation due to oiling 
problems. However we found the sucess of the subsequent acylation step such that 
these unfavourable samples of 4.17 could be used without hindering the yield of the 
reaction. 
The chiral oxazolidinone 4.17 was acylated following literature directions239,241 by 
treatment with n-BuLi (1.05 equiv.) followed by 3-phenylpropionyl chloride (1.1 
equiv.), itself obtained from treatment of 3-phenylpropionic acid with SOCl2 (1.2 
equiv.) under refluxing conditions, to give crude 4.15. This was purified by flash 
chromatography to give pure 4.15 as a white solid in 83% yield. The sucess of this 
reaction depended much on the quality of the n-BuLi and thus the reagent was 
frequently titrated to determine an accurate active concentration. The reaction was 
repeated in similar high yields illustrating the ease in which these compounds can be 
prepared highlighting the advantageous use of chiral auxiliaries derived from 
phenylalanine. 
The key stereoselective reaction of the synthetic scheme was then carried out by 
treating 4.15 with LDA at -78°C to give the corresponding chelated lithium enol ate 
4.17 which was alkylated by excess ethyl bromo acetate as the reaction solution was 
allowed to warm to room temperature overnight (Scheme 4.8). 
4.15 
(S,R) 
4.21 
+ 
(S,S) 
4.22 
4.20 
B 
Scheme 4.8 A 1) LDA -78°C Ih 2) ethylbromoacetate, overnight, -78°C - rt 
.. 
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Work-up gave a brown residue which was purified by flash chromatagraphy. Proton 
NMR analysis of this product gave a spectrum consistent with the predicted (S,R) 
diastereoisomer 4.21 but also indicated the presence of a second component in ca 5% 
by 1 H NMR. This was determined to be either the minor diastereoisomer 4.22 or 
starting material 4.15. Homonuclear decoupling experiments were carried out to make a 
definitive identification especially concentrating on locating a second triplet and quartet 
which would only be attrituable to the minor diastereoisomer 4.22. These experiments 
proved difficult to analyse due to overlapping signals especially the methylene protons 
of the ethyl ester and those of the oxazolidinone ring of 4.21 since the irradiations in 
this region of the spectrum (3 4.00ppm) were to be of important diagnostic value. 
Confirmation of the presence of staring material in the alkylation product was 
obtained by comparison to an authentic spectrum of 4.15. Of note, the l3e NMR 
spectrum revcaled no presence of the minor diastereoisomer 4.22. Further evidence for 
the presence of 4.15 in the alkylation product was obtained from LiOH/30% H202 
hydrolysis of a sample of the alkylation product. Proton NMR analysis of the product 
obtained indicated the presence of 3-phenyl propionic acid presumably arising from 
hydrolysis of 4.15. 
Attempts were made to further purify the alkylation product by repeating the 
chromatography lowering the polarity of the eluting solvent, using more silica, and 
collecting smaller fractions. However no effective separation of 4.15 and 4.21 could be 
effected. 
The presence of starting material in the alkylation product suggested that formation 
of the lithium enolate 4.20 had not been quantative. Possible causes included not 
maintaining the reaction at -78 oe during enolisation such that the enol ate formed could 
be undergoing decomposition via a ketene pathway. A product of this decomposition 
would be the chiral oxazolidinone 4.17 however inspection of the 1 H NMR spectrum of 
the crude product for the NH resonance diagnostic for 4.17 indicated its absence. This 
placed the quality of the LDA into question and consequently a new solution was 
employed which was then titrated according to literature procedure242 and found to be 
1.8M a significant deviation from the quoted 2.0M. 
The alkylation procedure was repeated and in addition to purification by 
chromatography the product was recrystallised. The white solid obtained possessed a 
sharp melting point (60-62 OC) however 1 H NMR analysis indicated the presence of the 
disastereoisomers 4.21 and 4.22 in the ratio of 10: 1, by examining the integrals of the 
resonances assigned as the methyl protons of the ethyl esters of this diastereoisomeric 
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pair, equivalent to a diastereoisomeric excess of 91 % (see Figure 4.2 for the 
appropriate IH NMR spectrum). 
The assignment of the spectrum displayed in Figure 4.2 was undertaken by carrying 
out several homo nuclear decoupling experiments aided by comparison with spectra 
obtained for the chiral oxazolidinone 4.17 and N-acyloxazolidinone 4.15. The spectrum 
can be divided into three parts which at several points overlap. The triplets (0-1.25 
ppm) according to the methyl protons of the ethyl esters of the diastereoisomers 4.21 
and 4.22 are easily distinguished and due to their chemical equivalence, unlike the 
resonances of the diastereotopic protons featured in the rest of the spectrum, appear as a 
triplet. Further downfield (02.4-3.3 ppm) are signals resulting from the merging of two 
spin systems made up of a series of doublets of doublets. The first doublet of doublets 
downfield is due to the one of the benzylic protons of the 4-benzyl substituent of the 
oxazolidinone ring. The other proton of this type then merges with the resonances for 
the benzylic protons of the 2'-benzyl substituent which in turn merge with the 
resonances for the methylene protons in the a-positon relative to the carbonyl of the 
ethyl ester. The protons of the oxazolidinone ring overlap with the quartet of the ethyl 
ester at 0-4.0ppm. Of the two protons at the 3-postion of the oxazolidinone ring one is 
a triplet due to coupling constants around this ring being of the same magnitude. The 4-
H of the oxazolidinone ring overlaps with the 2'-H at 0-4.5 ppm which is shifted 
considerably downfield from the spin system it is a part of. 
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Figure 4.2 Selected region of IH NMR spectrum for product obtained on alkylation of 
4.15 by ethyl bromoacetate 
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To further probe the nature of the alkylation reaction the t-butyl ester 4.23 was 
prepared. The purpose of its preparation lay in generating a simpler spectrum which 
could give a clearer picture as to the presence of the minor diastereoisomer. It was also 
considered that the increased bulk of the t-butyl ester relative to the ethyl ester may 
increase the diastereoisomeric excess observed for this reaction. 
A 
.. 
4.15 
o 0 
O)lN¥Ph 
~Ph~C02t-Bu 
(S,R) 
4.23 
(S,S) 
4.24 
Scheme 4.9 A, 1) LDA -78°C 1h 2) tert-butyl bromoacetate, overnight, -78°C rt 
Hence the N-acyloxazolidinone was treated with LDA (1.2 equiv.) and the resulting 
anion was alkylated with t-butyl bromoacetate to give a crude product which was 
purified by flash chromatography to give a white solid in 44% yield. This white solid 
was further purified by recrystallisation to a give a product that as observed with the 
ethyl ester had a sharp melting point (105-7 DC). Proton NMR analysis of this product 
provided a spectrum consistent with formation of 4.23. Inspection of the region of the 
spectrum for 4.23 displayed in Figure 4.3 indicated no presence of the minor isomer 
4.24. 
The region of the spectrum for 4.23 displayed in Figure 4.3 contains the same 
featues as that discussed for the spectrum of 4.22. A series of doublets of doublets (0 
2.35-3.3 ppm) precedes the two protons at the 3-position of the oxazolidinone ring 
further downfield. The coupling existing between the protons of the oxazolidinone ring 
is made clearer in the case of the t-butyl ester confirming that two of the constants are 
of the same magnitude. As observed in the spectrum of 4.23 the NCH proton of the ring 
and that at the 2' position overlap. 
Further confirmation of the alkylation product containing only the major 
diastereoisomer 4.23 was provided by inspection of the alkyl region of the l3C NMR 
spectrum (see Figure 4.4), which showed no signs of the minor diastereoisomer 4.24. 
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Figure 4.3 Selected region of IH NMR spectrum of product obtained on alkylation of 
4.15 by tert-butyl bromoacetate 
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The absolute stereochemistry of the ethyl ester 4.21 was determined by subsequent 
LiOH/30% H202 hydrolysis to give 4.25 (Scheme 4.10) whose measured positive 
specific rotation ([a]D24 = 20.30 (c = 1.6, EtOAc» correlates to the (R) enantiomer on 
the basis of the work of Fredga discussed earlier. 
(S,R) 
4.21 
A 
Scheme 4.10 A, LiOH, 30% H202, lh, 0-5 °C 
.. 
(R) 
4.25 
The synthesis of (R)-2.26 then proceeded using methodology developed in the 
synthesis of racemic 2.26 (Scheme 4.11). DCC/HOBt mediated coupling of 0-
benzyloxyamine to (R)-4.25 followed by reflux in DCE gave (R)-2.25 ([aJ21D = -67.80 
(c =4.5, EtOAc) in 58% yield over two steps. Hydrogenolysis in the presence of 10% 
Pd-C then gave (-)-(R)-3-benzyl-N-hydroxysuccinimide, (R)-2.26, ([a]24n = -78.00 (c = 
3.0, EtOAc) in 91 % yield. 
o 
HO~Ph 
(R) 
4.25 
A .-r
Ph 
O,)..N~O 
I 
OR' 
(R) 
B [ 2.25 R' CH2Ph 
'-+- 2.26 R' = H 
Scheme 4.11 A 1) HCl.H2NOCH2Ph, Et3N, DCC, HOBt, CH2CI2, overnight, 0-5 °C-
rt 2) reflux, DCE, 20h 
B H2, lO% Pd-C, THF 
To stringently determine the optical purity of (R)-2.26 the optical purity or 
enantiomeric excesses of the intermediates in the synthesis of (R)-2.26 would have to 
be determined. Although Step B of Scheme 4.11 has been reported to proceed free of 
racemisation87e no such study has been made for the reactions of Step A. A definitive 
analysis of the optical purity of (R)-2.26 could be obtained from coupling to a chiral 
amino acid and inspection of the diastereoisomeric excess obtained or by chiral shift 
determination. However the high diastereoisomeric excess (>90 %) observed in the 
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alkylation of 4.15 by ethyl bromoacetate, and the high optical rotations observed 
indicated that (R)-2.26 had been obtained in good optical purity. 
To examine the stereospecificity of action of an inhibitor of type 1.41 we needed to 
chose an inhibitor which had good binding affinity to a-chymotrypsin so that the 
stereoselectivity of action was high (invoking Pfeiffers rule)217 and of a magnitude that 
there would exist a measurable difference in the activities between the racemate and the 
enantiopure derivative. The R substituent also had to be of greater size than methyl, as 
both (+)-(R)- and (-)-(S)-1.41d exhibited the same potency towards a-chymotrypsin 
which has been rationalised in the terms that the methyl substituent is sman enough to 
allow both enantiomers to be accomodated in the active site. 
Of the race mates whose inhibitory activity was discussed in Chapter 3 compound 
1.41f suited our needs. This compound was shown to have high binding affinity 
towards a-chymotrypsin and inhibited this enzyme at a measurable rate compared to 
other aromatics which were of such potency that they could not be measured using the 
progress curve method. The trans-styryl substituent is larger than the methyl substituent 
and it was therefore predicted that there would be an observed difference in actvity 
between (R)-1.41f and its racemate. 
Ph-" 
" O~O 
I 
OR 
(R) 
2.26 
A 
(R) 
1.41f R = trans-styryl 
1.41d R = CH3 
Scheme 4.12 A, trans-styrylsulfonyl chloride, pyridine, overnight 50 °C 
The inhibitory activity of (R)-1.41f against a-chymotrypsin was then assayed using 
the progress curve method. When experiments were carried out at an inhibitor 
concentration at 20-fold excess over enzyme a difference in the activity of (R)-1.41f 
and its racemate was observed. At this concentration the racemate was found to 
inactivate a-chymotrypsin totally within the mixing period whereas the (R)-enantiomer 
gave a typical progress curve indicating the enzyme was still active. These preliminary 
inhibition studies indicate that the the racemate is more potent than the (R)-enantiomer. 
These preliminary inhibition studies indicate that the the racemate is more potent 
than the (R)-enantiomer. This result suggests that the (S)-enatiomer is also active, and 
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of greater potency than the (R)-enantiomer enriching the activity of the racemate. It 
appears also that both enantiomers are active towards a-chymotrypsin. On the basis of 
kobs/[I] values the less active (R)-enantiomer (kobs/[I] = 6 944 M-1s-l) still compares 
favourably with the succinimide and glutarimide inhibitors discussed in Chapter 3 
being equipotent to the aromatic succinimide 1.41k (kobsl[I] = 6 427 M-1s-l). The 
observed activity of (R)-1.4lf reflects the high binding affinity to a-chymotrypsin that 
compounds exhibiting aromatic substitution possess. 
For a definitive analysis of the stereoselectivity of inhibition of a-chymotrypsin by 
compound 1.4lf and other inhibitors of this type a route to the (S)-enantiomer of the 
important N-hydroxysuccinimide precursor 2.26 is required. 
As depicted in Figure 4.13 this may be achieved by using (R)-phenylalanine 
(Strategy 1) as the starting material or by using a different metal counter ion (Strategy 
2) so that the enolate is not chelated. Both have the effect of inducing the opposite 
sense of alkylation to the route described above. 
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Figure 4.13 Strategies for the synthesis of (S)-2.26 
A route towards (8)-2.26 employing Strategy 1 would require the synthesis of the 
(R)-N-acyloxazolidinone 4.26 using the lengthy borane reduction of (R)-phenylalanine 
and subsequent treatment with diethyl carbonate and acylation steps described for the 
preparation of the (S)-N-acyloxazolidinone 4.15. An improved route to chiral 
oxazolidinones came to our attention during the above work which involved a one-pot 
two-step synthesis.243 Employment of such methodology would lead to a short 
synthesis of (S)-2.26. 
A route to (S)-2.26 using Strategy 2 was more practical as it made use of reagents 
already prepared above. 
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An attractive alternative synthesis of chiral succinates would be one where a number 
of derivatives could be prepared by substituting the alkylating agent used. To achieve 
this goal a different type of chiral enolate (4.31) to 4.27 and 4.29 was employed. 
A 
4.17 
4.32 
.. 
3 steps 
'--------,> 
4.31 
(S) 
2.26 
B 
X " 
Scheme 4.14 A, 1) n-BuLi, THF, O.5h, -78 DC 2) 3-carbomethoxy-propionyl chloride, 
overnight -78 DC - rt 
B 1) TiCI4, Hunigs Base, 2) PhCH2Br 
Acylation of the chiral oxazolidinone with 3-carbomethoxy-propionyl chloride, 
prepared according to literature procedure,244 gave the N-acyloxazolidinone 4.32. 
Attempted enolisation of this by TiC14 and Hunigs base and subsequent alkylation with 
benzyl bromide gave a product whose IH NMR indicated the presence of a mixture of 
alkylated products and starting material. The mixture of the alkylation products may be 
explained in terms that the ester also activates the P-position towards alkylation as well 
as the desired a-position. Hence future development of this route may involve methods 
of directing the alkylation to one position. 
In summary a synthetic route to enantiopure N-[(sulfonyl)oxy]imide inhibitors of 
type 1.41was undertaken employing well established Evans oxazolidinone chemistry. 
An appropriately substituted racemic propionate substrate was attached to a chiral 
oxazolidinone to give a key N-acyloxazolidinone. This was treated with LDA to give 
the corresponding lithium enolate which was alkylated by both ethyl bromo acetate and 
tert-butyl acetate, reactions which proceeded with high stereoselectivity as evidenced 
by both 1 Hand l3C NMR. Hydrolysis of the alkylation product obtained with ethyl 
bromo acetate with LiOH/30% H202 gave enantiopure (R)-succinic acid mono ethyl 
ester. Employing methodology developed in the synthesis of racemic inhibitors the key 
enantiopure N-hydroxysuccinimide precursor (R)-2.26 was prepared and then coupled 
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to trans-styryl sulfonyl chloride to give an enantiopure inhibitor (R)-1.4lf with 
sufficient sterically demanding substitution that a difference in inhibitory activities 
between itself and its racemate may be observed. Preliminary inhibition studies 
undertaken employing the progress curve method indicated that the racemic inhbitor 
1.4lf was more potent than (R)-1.4lf suggesting that the (S)-enantiomer is the more 
active of the two enantiomers. 
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5.1 DESIGN AND PROPOSED MECHANISM OF 
INHIBITION 
The glutarimide and succinimide based inhibitors 1.41 and 2.1 which were discussed 
in previous chapters, all operate with the same mode of inactivation. The key step in 
their proposed mechanism of inactivation is a Lossen rearrangement of an N-acyl or 
sulfonyloxy carboxamide to give a reactive electrophilic isocyanate that reacts further 
with the enzyme to give a doubly bound inactive enzyme-inhibitor complex (see 
Section 1.3, Chapter 1). 
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= C(O)R' 
Other classes of mechanism-based inhibitors operate by presenting a reactive species 
other than isocyanate in the active site of the enzyme, for example halo enol and ynenol 
lactones contain a-halo ketones and allenones respectively (see Section 1.3, Chapter 1). 
With the goal of designing new classes of mechanism-based imide inhibitors we aimed 
at incorporating electrophilic species previously observed to be involved in mechanism-
based inhibition into the succinimide and glutarimide skeletons. 
Halomethyl coumarins of type 1.27, are known mechanism-based inhibitors of serine 
proteases. These operate by unmasking a 4-hydroxybenzylhalide which decomposes to 
give a reactive quinone methide which alkylates His-57 inactivating the enzyme. The 
functionalised 3,4-dihydroquinoline 1.29 was proposed to inactivate serine proteases by 
unmasking a quinone imine methide but it was found to be inactive probably because 
the cis-Iactam ring was not hydrolysed by the enzyme. However incorporation of the 
latent methide of 1.29 into a macrocyclic peptide possessing the correct trans 
configuration resulted in a series of active inhibitors represented by 1.30. 
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Based on the knowledge that imides readily undergo enzyme induced ring opening, 
the imides 2.2 and 5.1 containing the latent quinone imine methide were proposed to be 
able to liberate activity on hydrolysis. The compounds would then be potentia] 
mechanism-based inhibitors of serine protea'ies. 
R~" 
o~NAo 
~ X 
2.2 5.1 
The proposed mechanism of the release of latent reactivity (Scheme 5.1), shown for 
2.2, would proceed with accommodation of the imide inhibitor in the active site of the 
enzyme through favourable interaction of the imide ring substitution with the S 1 pocket 
of the enzyme to give the Michaelis enzyme -inhibitor complex 6.2. Ser-195 induced 
opening of imide ring to gives the acyl enzyme species 6.3. Charge transfer through the 
aromatic ring as shown with release of the leaving group results in a reactive quinone 
imine methide tethered in the active site of the enzyme, see structure 5.4. This will then 
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Scheme 5.1 Proposed mechanism of inactivation of a-chymotrypsin by representative 
inhibitor 2.2 
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undergo reaction with an enzyme nucleophile such as His-57 to give the likely inactive 
enzyme species 5.5. The quinone imine methide may also undergo hydrolysis to give 
5.6 and liberating free enzyme in a turnover pathway. 
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5.2 SYNTHESIS 
A retrosynthetic analysis of 5.1 (Scheme 5.2) identified a synthetic strategy similar 
to that used for the preparation of substituted racemic N-hydroxyglutarimides and 
succinimides discussed in Chapter 2. The first disconnection of 5.1 involves a 
functional group interconversion to the N-(4-hydroxymethyl)phenyl imide 5.7. 
Disconnection of the imide ring then follows, as shown, to give the diacid derivatives 
2.7 and 2.8 and p-hydroxymethylbenzylamine 5.8 as reagents. It was considered 
therefore that the synthesis of the target inhibitors of types 2.2 and 5.1 could be 
wrought using the methodology developed for preparation of the related N-
benzyloxyimides (see Chapter 2) replacing 0 -benzyloxyamine with p-
hydroxymethylaniline, or a potential analogue. 
R 
h o N 0 
~ X 
X = leaving group 
5.1 
UFOI 
R 
h o N 0 
~ OH 
5.7 
U 
Rn R o~o NH2~ H02C C02H _ OH 
2.8 2.7 5.8 
Scheme 5.2 Retrosynthetic analysis of representative imide 5.1 
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The preparation of 4-hydroxymethylaniline 5.S (Scheme 5.3) was undertaken by a 
two step reduction of 4-nitrobenzaldehyde 5.9. Reaction of this with an alkaline 
solution of sodium borohydride gave 4-nitrobenzyl alcohol 5.10 which was then 
reduced with hydrogen and Adam's catlayst to give 5.S. 
A B 
.. 
5.9 5.10 
5.S 
Scheme 5.3 A, alkaline N aBH4 
B, H2, Pt02, EtOH 3d 
The synthesis of 5.11 was then attempted from the corresponding anhydride 2.27 
using a number of reaction conditions. A first attempt involved refluxing a solution of 
the anhydride in benzene with a slight excess of 5.S proved unsuccessfuL Solubility 
problems were encountered and unreacted anhydride was recovered on work-up. Two 
approaches were employed to find a solution to these problems and effect a synthesis of 
5.11. The first involved optimising the reaction conditions and the second was based on 
employing a protected form of the amine. 
Ph~ 
oAo~o 
2.27 
+ 
5.S 
Scheme 5.4 Attempted preparation of novel succinimide inhibitor 5.11 
5.11 
Following the first approach subsequent reactions were attempted in toluene and 1,2-
dichloroethane, however, only starting material and decomposition products were 
obtained. Additional reactions carried out with the addition of molecular sieves to the 
reaction mixture designed to scavenge water were also unsuccessful. The reaction was 
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also attempted with two equivalents of p-hydroxymethylaniline and in pyridine 
however this was method was also unsuccessful. 
Considering the prior success of these reactions when using O-benzyloxyamine 
focus turned to consideration of using a protected form of the aniline 5.8 such that the 
modified properties may facilitate the reaction. The choice of an acetate protecting 
group was influenced by the desire to also incorporate a leaving group at this position 
so that a potential inhibitor may be obtained. The attempted synthesis of 5.14 is shown 
below (Scheme 5.5). 
02N~ A 02N~ .. 
OH OAc 
5.10 5.12 
fB Ph=n 
+ H2N~ 
o 0 0 OAc 
2.27 5.13 
Scheme 5.5 A AC20, pyridine, overnight, rt 
B Pt02, BtOH, overnight 
Ph=n 
o N 0 
c:::> ~ OAc 
5.14 
The starting material for the above synthesis 4-nitrobenzylalcohol 5.10 was 
acetylated by reaction with acetic anhydride in pyridine to give p-nitrobenzylacetate 
5.12. Subsequent hydrogenation to give 4-acetoxymethylaniline 5.13 the key precursor 
to 5.14 however was unsuccessful with the molecule fragmenting during the reaction as 
indicated by the presence of 4-nitrotoluene in the isolated product as analysed by IH 
NMR. 
With the proposed routes to the desired succinimide inhibitors 5.1 unsuccessful, 
focus turned to the preparation of a glutarimide derivative of type 2.2. A mild method 
for the preparation of N-substituted glutarimides involves the reaction of amines with 
the appropriate acids mediated by coupling reagents such as dicyclohexylcarbodiimide 
(DCC)246 and 1-(3-dimethylamino)-propyl)-3-ethyl-carbodiimide hydrochloride 
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(EDAC) 159 which was used in a successful preparation of a N -benzyloxyglutarimide 
(see Section 2.4, Chapter 2 for a discussion) following the directions of Zhu et al.159 
The method of Zhu et al159 was then applied to the synthesis of 5.15 (Scheme 5.6). 
This was undertaken by the EDAC mediated coupling of the amine 5.8 to 3,3-
dimethylglutaric acid 2.44e in the presence of triethylamine. Work-up of the reaction 
mixture gave a crude solid which was purified by flash Si02 chromatography to give 
pure 5.15 in 12% yield. 
H3XH3 
O~ ~O 
A 
OH OH 
2.44e 
5.15 
Scheme 5.6 A, EDAC, HOBt, Et3N, 6.8, overnight 0-5 DC - rt 
Compound 5.15 was then assayed against a-chymotrypsin (Figure 5.1) using the 
incubation method as described in Chapter 3 to make a preliminary determination of the 
inhibitory activity. 
The activity versus time profile of compound 5.15 (Figure 5.1) indicates that over a 
period of thirty minutes there is no net loss of activity. However as the inhibitor 
concentration was increased to 50-fold excess over enzyme it appears there is an initial 
loss of enzyme activity followed quickly, however by a regain in enzyme activity. This 
suggests that compound 5.15 is acting as a transient alternate substrate inhibitor of a-
chymotrypsin in which the acyl-enzyme species (structure 5.3 of Scheme 5.1) inhibits 
the enzyme for a period equal to its lifetime. This description of the activity displayed 
by 5.15 is tentative for as discussed previously the error involved in incubation method 
measurements is significant 20%). 
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Figure 5.1 Time dependent inactivation of a-chymotrypsin by 5.15. a-Chymotrypsin 
(4J.lM) was incubated with 6.15 (A, 1OJ.1M; B, lOOJ.lM; C, 200J.lM) and enzymic activity 
assayed using either N-Succ-(Alah-Pro-Phe-p-nitroanilide (A, 117J.lM) or BTEE (B, C, 
117J.lM). 
Study of the mechanism of inactivation proposed for these compounds (Scheme 5.1) 
indicates design efforts to enhance the activity of these compounds will be based on 
increasing the rate of formation of the initial Michaelis inhibitor enzyme complex (KI) 
and the rates of formation of the reactive quinone methide and alkylation of the active 
site imidazole ring of His-57. Modification of the substituents on the imide ring to 
mimic the substitution present in a natural substrate of a-chymotrypsin would be 
expected to enhance activity. The a or ~ substituents of the ring are supposed to interact 
with the S 1 subsite of a-chymotrypsin and hence it is forecast that the introduction of 
aromatic substituents on the ring would lead to increased activity. This SAR trend was 
observed in the N-[(methanesulfonyl)oxy]glutarimide series assayed in Chapter 3. The 
glutarimide inhibitor 2.1f, which possesses dimethyl substitution was found to be a poor 
inhibitor of a-chymotrypsin (kobs/[I] = 25 M-1s·l) when assayed by the incubation 
method, whereas compound 2.1d, which possesses aromatic substitution was too potent 
to be measured accurately by the incubation method. On this basis, it is perhaps not 
suprising that 5.15 did not show significant activity. 
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The inhibitory activity may also be enhanced by increasing the rate of formation of 
the quinone imine methide. This may be accomplished by substituting the OH group of 
5.15 with a better leaving group. Determination of a good leaving group can be made 
by comparison of the relative strengths of the parent acids hence it was supposed that 
incorporation of X = halogen into structure 5.15 in the place of the hydroxy goup would 
result in more potent inhibitors (compare the strengths of HCl and H20). This trend has 
been observed in the series of saccharin inhibitors of type 1.48 developed by Groutas et 
al99 as seen by comparing the inhibitory activities of 1.48b and 1.48a. 
1.48 
1.48aL=OH 
inactive99 . 
1.48b L = Cl 
kobsf[I] > 49 000 M"ls-l; HLE99 
1.48c L = F 
kobsf[I] > 4 750 M-1s-1; HLE99 
These SAR considerations suggested that compound 5.17 may be a more potent 
inhibitor of a-chymotrypsin than 5.15, because it has both more suitable substitution to 
interact favourably with a-chymotrypsin and a better leaving group. Hence 5.17 
became a synthetic target. EDAC mediated coupling of 4-hydroxymethylaniline 5.8 to 
the commercially available 3-phenylglutaric acid (Scheme 5.7) gave a solid that on 
analysis by thin layer chromatography (TLC) was found to be unsuitable for 
purification by flash Si02 chromatography. Purification was then carried out following 
the directions of Seth et al.246 The solid was dissolved in 5% aqueous sodium 
carbonate and this aqueous solution was washed with dichloromethane to remove 
impurities such as 5.8. Acidification of the aqueous layer and organic extraction gave 
5.16 which was further purified by recrystallisation. 
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Scheme 5.7 A, EDAC, HOBt, 5.8, Et3N, 0-5 °C rt overnight 
Chlorination of 5.16 to afford 5.17 was then attempted using the method adopted by 
Groutas et al99 in the preparation of 1.48b from N-hydroxymethylsaccharin 1.48a. A 
solution of 5.16 in ether was treated with thionyl chloride (5 equiv.) for two days at 
room temperature however 1 H NMR analysis of the product indicated the reaction was 
unsuccessful and an altenative procedure was sought. 
000 000 
~ > ~ OH CI 
5.16 5.17 
The chlorination of primary alcohols using CC14-PPh3 has been well documentecJ247 
and was attractive as the reaction is both mild and rapid. A trial chlorination of 6.15 
was undertaken employing this methodology however this too was unsuccessful. 
Although only preliminary results, the lack of success observed in these reactions may 
be due to the inherent reactivity of 5.17. This may undergo ring-opening to give the 
quinone imine methide which reacts with any nucleophiles present in the reaction 
mixture. Proton NMR analysis of the product isolated from the attempted chlorination 
using thionyl chloride indicated the presence of a charateristic triplet and quartet of an 
ethyl ester perhaps formed from reaction of the methide with ethanol. 
In summary we have developed a preliminary synthetic approach to a glutarimide 
designed to liberate reactivity on hydrolysis. Initial studies have failed to identify an 
inhibitor of a-chymotrypsin. The lack of inhibitory activity may be reasoned in that this 
Chapter 5 - SubstitutedN-[(4-hydroxyme!hyl)phenyl]imides: Novel inhibitors 167 
glutarimide does not act as a substrate of a-chymotrypsin and therefore cannot undergo 
the required ring-opening necessary to unmask the quinone imine methide. Considering 
the structure of the acyl enzyme intermediate in the formation of the methide the lone 
pair on the nitrogen may not be available to move through the aromatic ring to displace 
the leaving group as it is delocalised by the neighbouring carbonyl group. 
Attempts to introduce activity into this series involved incorporation of ring 
substitution able to interact with a-chymotrypsin and improving the leaving group. 
Synthesis of a compound purporting both these features was unsuccessful maybe due to 
the irony that the synthesis is undone by the activity it is trying to create. 
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6.1 GENERAL 
Melting points (mp) were measured using an Electrothermal apparatus and are 
uncorrected. Optical rotations were measured on a JASCO J-20C recording 
spectropolarimeter at the Na line (J... = 589nm). The specific optical rotation at the stated 
temperature [a]TD is given in units of lO-I degcm2 g-l with the sample concentration, 
c, in the indicated solvent given in units of g lOOcm-3. 
IR spectra were recorded on a Schimadzu FTIR-8201PC spectrophotometer. 
Samples were run as KBr discs (KBr), Nujol mulls between KBr plates (NujollKBr), 
CHCb and CDCl3 solutions, or as a CHCb film between NaCI plates (CHCI3/NaCI). 
Data is presented as the wavenumbers (cm-I) at which the maxima absorptions of 
diagnostic value occur. 
Proton (300MHz) and 13C (75MHz) nuclear magnetic resonance (NMR) 
spectroscopy was performed with either a Varian CFT300 or XL300 spectrometer. 
CDCI3, with Me4Si as an internal standard, a mixture of CDCb and a small amount of 
DMSO-d6 (CDC13IDMSO-d6), DMSO-d6, and D20 (lH NMR only) were used as 
solvents. 
Proton CDCl3 and CDCI3IDMSO-d6 spectra were referenced to the (CH3)4Si signal 
at a chemical shift (0) of 0.00 parts per million (ppm) and 13C NMR spectra to the 
central peak of the CDCl3 triplet at 0 77.0ppm. Proton DMSO-d6 spectra were 
referenced to the residual (CH3hSO signal at 0 2.50ppm and 13C NMR spectra to the 
central peak of (CH3hSO quintuplet at 0 39.6. Proton D20 spectra were referenced to 
the residual H20 signal at 0 4.70ppm. 
Proton NMR data are recorded as follows: chemical shift in parts per million (0) 
accurate to two decimal places (multiplicity (s: singlet, d: doublet, t: triplet, q: quartet, 
m: multiplet, dd: doublet of doublets, ABq: AB quartet, etc., b indicates some 
broadening of the signal), integrated intensities, coupling constant(s) in Hz accurate to 
one decimal place, and assignment as the underlined proton(s) within the given 
structural fragment). Data for 13C NMR are recorded as the chemical shifts observed 
accurate to one decimal place. If required, 2D NMR experiments were carried out using 
a Varian CFT300 spectrometer to aid assignment. 
Mass spectra were obtained using a Kratos MS80RF Aspectrometer operating at 
70eV. The molecular ion (M+) only, if present, is reported accurate to four decimal 
places when using High Resolution Mass Spectrometry (HRMS) in the indicated 
operated mode +CI (Chemical Ionisation), +EI (Electron Ionisation) or FAB (Fast Atom 
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Bombardment). If the molecular ion was sufficiently weak so as not to be recorded 
significantly high mass ions and the more intense low mass ions accurate to one 
decimal place are reported. The molecular ion (M+), if present, significantly high mass 
ions and the more intense low mass ions accurate to the nearest mass unit are reported 
when using Low Resolution Mass Spectrometry (LRMS) in the indicated operation 
mode as above. Data are presented in the folowing order: mlz value, the attributed 
fragmentation; relative intensity as a percentage of the base peak. 
Elemental analyses were performed by the Campbell Microanalytical Laboratory, 
University of Otago, Dunedin. 
Solvents were freshly dried and distilled according to the following well established 
procedures248,249 and then stored in N2 immediately prior to use. Tetrahydrofuran 
(THF) , and diethyl ether (ether, Et20) were purified by distillation from sodium 
benzophenone ketyl. Ethanol (EtOH) and Methanol (MeOH) were purified by 
distillation from magnesium ethoxide or methoxide respectively. Benzene, 
dichloromethane (CH2Clz) and toluene were purified by distillation from CaH2. N,N-
Dimethylformamide (DMF) was dried by the method of Burfield and Smithers.250 
Petroleum ether refers to the fraction of boiling range 50-70 oC. Reagents were purified 
prior to use according to literature procedures.249 The commonly used bases N,N-
diisopropylethylamine (Hunigs base), pyridine, and triethylamine (Et3N) were purified 
by distillation from CaH2 or P205. 
Organic reactions requiring anhydrous conditions were performed with solvents and 
reagents as prepared above under a dry N2 atmosphere with glassware baked in an oven 
set at 110 °C overnight then assembled hot and 'flame' dried with a bunsen burner or 
heat gun under N2 or vacuum immediately prior to use. Reaction temperatures refer to 
the external bath temperature, A reaction carried out at room temperature (rt) refers to a 
temperature of ca 20 °C. A workup procedure carried out in the usual manner involved 
separation of the organic extract or phase, drying with Na2S04 or MgS04, filtration to 
remove the dessicant and then evaporation of the bulk of the solvent using a rotary 
evaporator, the last traces being removed under high vacuum, Flash chromatography 
was conducted according to the method of Still et al 251 using Merck 60 PF254 type 
silica geL 
Diethyl benzyl malonate (2.10), 2-phenylsuccinic acid (2.30), 3-phenylglutaric acid 
(2.44c), 2-phenylglutaric anhydride (2.43a), ~-tral1s-styryl sulfonyl chloride, 2-
naphthalene sulfonyl chloride, 4,4'-biphenyldisulfonyl chloride were obtained from 
Aldrich Chemical Company, Milwaukee, USA. 2-Phenylglutaric anhydride 2.43a was 
purified by treatment with AC20 before use. 3-Chlorosulfonyl benzoic acid and 1,3-
bis(chlorosulfonyl)benzene were obtained from Maybridge Chemical Co. Ltd, Tintagel, 
Cornwall, UK. 
4,4-Cyc1ohexyl-3,5-dicyanoglutarimide (2.48b) was generously gifted by Dr. R. H. 
McKeown. 
6.2 CHAPTER 2 EXPERIMENTAL 
SYNTHESIS OF 2-SUBSTITUTED SUCCINIC ACIDS 
Method A: Malonate Ester Route 
DiethyI2-carboethoxy-2-benzylsuccinate (2.11)152 
A solution of sodium ethylate was prepared by slowly dissolving sodium (2.332g, 
O.lOlmol) in EtOH (3SmL). Diethyl benzyl malonate (2.10) (24.890g, O.lOOmol) and 
ethyl bromoacetate (11mL, 16.566g, 0.099mol) were added slowly in succession. The 
resulting solution was refluxed for 14.25h, concentrated, made slightly acidic (pH=6, 
Universal Indicator Paper) with 3N H2S04 and extracted with Et20. The Et20 extract 
was worked up in the usual manner to give a yellow oil (28.49g) containing a 4:5 
mixture, by IH NMR, of unreacted 2.10 and 2.11. This crude product was used without 
further purification. IH NMR 2.11 (CDCl3) 01.17-1.29 (m, 9H, 3xOCH2CH3), 2.85 (s, 
2H, CH2C02Et), 3.39 (s, 2H, CH2Ph), 4.12-4.24 (m, 6H, 3xOCH2CH3), 7.08-7.26 (m, 
5H, ArH). 
2-Carboxyl-2-benzylsuccinic acid (2.12)152 
The above crude product (28.49g) was boiled under reflux with KOH (21.338g, 
0.380mol) in EtOH (120ml) for 4h. The reaction mixture was diluted with H20 (55ml), 
and extracted with Et20. The aqueous layer was acidifided (pH=I, Universal Indicator 
Paper) with 6M HCI, and extracted with Et20. The extracts were worked up in the usual 
manner to give a brown residue (l3.127g) containing a 12:15 mixture, by IH NMR, of 
benzyl malonic acid (from the hydrolysis of 2.10 present in the starting material) and 
2.12: IH NMR 2.12 (CDCb) 02.85 (s, 2H, CH2Ph), 3.33 (s, 2H, CfuC02H), 7.14-7.58 
(m, SH, ArH), 9.66 (bs, 3H, 3xCOllI). 
2-Benzylsuccinic acid (2.13)152 
The above mixture (l3.127g) was heated in an oil bath set at 160-170 DC for 2.25h. 
The reaction mixture was allowed to cool to rt and then refridgerated. The resultant 
brown mass was treated with boiling H20 to give an immiscible mixture consisting of 
an upper aqueous phase and lower brown oil. The aqueous phase was decanted and 
allowed to cool to rt during which 2.13 crystallised as a white solid. More acid was 
obtained by repeated treatments and concentration of the mother liquors. Total yield 
(3.307g, overall yield 17%); mp 160-1 °C (H20, glittering white rectangular plates) 
lit.252 mp 160-1 °C; IR (KEr) 'Umax 3022.1 (OH), 1697.8 (C=O) em-I; IH NMR 
173 
(CDCbIDMSO-d6) 6 2.31 (dd, IH, .J = 4.9, 17.1Hz, HCHPh), 2.58 (dd, IH, .J = 8.3, 
16.6Hz, HCHPh), 2.78 (dd, IH, .J = 4.9, 1O.2Hz, HCHC(O)), 3.01-3.08 (m, 2H, 
HCHC(O) and CH), 7.18-7.30 (m, 5H); HRMS (+EI, M+) ca1cd. 208.0736, found 
208.0736. 
Method B: Amide base alkylation of succinimide 
2.Benzylsuccinimide (2.14)144 
Liquid NH3 (60mL) was transferred to a three necked reaction flask cooled to -78 °C 
(dry-ice/acetone bath) equipped with a dry-ice/acetone condenser and a droppping 
funnel. A small amount of Na was added followed by FeN03.9H20 (90mg). After the 
blue colour was discharged to give a charcoal like reaction solution, Na (total amount 
added 1.634g, 0.071mol) was then added portionwise to give a grey suspension of 
NaNH2. This was stirred for a Ih at -78 °C after which succinimide (3.178g, 0.032mol) 
was added portionwise and the resulting grey suspension stirred for a further hour. The 
dropping funnel was charged with a solution of benzyl bromide (3.826mL, 5.490g, 
0.032mol) in anhydrous Et20 (lOmL) and this was added rapidly to the reaction 
suspension. The dropping funnel was rinsed with an additional quantity of Et20 (ImL) 
and the resulting pale yellow suspension stirred for Ih and the reaction quenched by 
pouring the reaction mixture into a beaker containing NH4CI (5.649g, 0.106mol, 3.3 
equiv.). The NH3 was allowed to evaporate while being replaced by the slow addition 
of El20 (50mL). A mixture of conc HCI (27mL) and ice (250mL) was added and the 
resulting mixture was stirred until the ice melted. The Et20 phase was separated and the 
aqueous phase extracted with Et20. The organics were combined and washed with H20 
and worked up in the usual manner to give a creamy yellow solid. This was dissolved in 
Et20 and extracted thoroughly with 5% aqueous NaOH. The alkaline extracts were 
washed with Et20 and then acidified (pH=I, Universal Indicator Paper) with 6N HCI 
and then extracted with Et20. Work-up in the usual manner gave a white solid (755mg, 
12%): mp 81-4 °C (lit. 144 mp 92.5-95 OC); IR (KBr) umax 3170.8 (NH) , 1776.3 and 
1705.0 (C=O) cm-1; IH NMR (CDCI3) 62,48 (dd, 1H, .J = 4.9, 1805Hz, HCH2Ph) 2.71 
(dd, IH,.J = 8.8, 1805Hz, HCHPh) 2.84 (dd, IH,.J = 9.5, 14,4Hz, HCHC(O)) 3.13-3.25 
(m, 2H, HCHC(O) and CHC(O)), 7.17-7.34 (m, 5H, ArH); 13C NMR (CDCb) 634.4, 
36.1,42.7, 127.0, 128.8, 128.9, 137.1, 180.1, 189.6; LRMS m/z (+EI) 189 (67, M+), 
161 (3), 146 (17),117 (2), 103 (5), 91 (100),78 (8), 65 (13),51 (8). 
2-Benzylsuccinic acid (2.13) 
2.14 (684mg, 4mmol) was refluxed with 6N HCI (15mL) for 26h. The reaction 
solution was allowed to cool to rt during which a white solid cystallised. This reaction 
mixture was evaporated to dryness and sufficient Et20 and saturated aqueous NH4Cl 
solution were added to dissolve the white solid. The Et20 phase was worked up in the 
usual manner to give 2.13 as a white solid (760mg, quantitative yield): mp 152-155 oC 
(lit. 252 mp 160-1 oc). Spectral data as given above. 
Method C: Stobbe Condensation Route 
Ethyl2-benzylidenesuccinate (2.17)157d 
A solution of sodium ethoxide was prepared by slowly dissolving sodium (1.476g, 
0.064mol, 1.23 equiv.) in EtOH (25ml) under a N2 atmosphere. Diethyl succinate 
(8.6ml, 9.004g, 0.052mol) was added dropwise and the resulting milky mixture heated 
until reflux at which point benzaldehyde (5.3ml, 5.533g, 0.052mol) was added 
dropwise. The resulting yellow reaction mixture was refluxed for 12h. The now brown 
reaction mixture was concentrated and dissolved in H20 (lOOmL) and then extracted 
with Et20 (2xlOOmL). The aqueous layer was acidified (pH:l, Universal Indicator 
paper) with 6N HCI (20mL) and this was extracted with Et20 (2x100mL). The organic 
extracts were worked up in the usual manner to give crude ethyl 2-benzylidenesuccinate 
2.17 as a viscous brown syrup (9.262g, 76%): IH NMR 0 1.35 (t, 3H, J 7.1Hz, 
CH2CH3), 3.58 (s, 2H, CH2C02H), 431 (q, 2H, J: 7.1, 7.3Hz, CH2CH3), 7.34-7.44 
(m, 5H, ArH), 7.93 (bs, 1H, NH); 13C NMR 0 14.1, 33.6, 61.4, 125.5, 128.7, 129.0, 
134.7,1423,167.4,177.2; HRMS (+EI, M+) calcd. 234.0893, found 234.0892. 
Ethyl 2-benzylsuccinate (2.18) 
A solution of ethyl 2-benzylidenesuccinate 2.17 (9.144g, 0.039mol) in EtOAc 
(20mL) was hydrogenated in the presence of 10% palladium on carbon (1. 141g) for 
19h. The reaction mixture was filtered through a column packed with both celite and 
Na2S04. The fUter cake was washed with a small quantity of EtOAc and the filtrate and 
washings were combined and evaporated to give 2.18 as a yellow oil (5.541g, 60%): IH 
NMR (CDCI3) 0 1.18 (t, 3H, J = 7.1Hz, OCH2CH3), 2.43 (dd, 1H, J: 4.4, 17.1Hz, 
HCHPh), 2.66-2.81 (m, 2H, HCHPh and HCHC(O», 3.01-3.13 (m, 2H, HCHCeO) and 
CHC(O», 4.12 (q, 2H, J = 6.8, 7.4Hz, OCfuCH3), 7.14-7.31 (m, 5H, ArH); 13C NMR 
o 14.0,34.7,37.6,42.8,60.8, 126.7, 128.5, 129.0, 138.0, 174.0, 177.8. 
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2-Benzylsnccinic acid (2.13)152 
A solution of ethyl 2-benzylsuccinate 2.18 (2.416g, O.OlOmol) in 1: 1 EtOHIH20 
(20mL) with KOH (2.23g, 0.040mol, 4 equiv.) was refluxed for 5h. The reaction 
solution was concentrated and extracted with EtOAc. The aqueous layer was acidified 
(pH=l, Universal Indicator paper) with 6N HCI and then extracted with EtOAc. The 
organic extracts were worked up in the usual manner to give 2.13 as a white solid 
(1.745g, 82%). Spectral data data as given above. 
THE SYNTHESIS OF 2-SUBSTITUTED SUCCINIC ACID 
ANHYDRIDES 
2·Phenylsnccinic anhydride (2.30) 
A mixture of 2-phenylsuccinic acid 2.29 (5.000g, 26mmol) and acetyl chloride 
(l0.5mL, 11.592g, 129mmol) was refluxed for lh. The excess acetyl chloride was 
evaporated and the resultant liquid distilled at reduced pressure to give a pale yellow 
solid. Recrystallisation from toluene/petroleum ether gave 2.30 as a white solid (3.123g, 
69%): mp 51-3 °c (lit.166 mp 53-5 OC); IR (KBR) 'Umax 1867.0 and 1791.7 (C=O) cm-I; 
IH NMR (CDCI3) 83.13 (dd, IH, J = 6.9, 19.1Hz, HCH), 3.47 (dd, 1H, J = 10.3, 
19.1Hz, HCH), 4.35 (dd, IH, J = 6.8, lO.2Hz, CH), 7.26-7.29 (m, 2H, ArH), 7.40-7.45 
(m, 3H, ArH); 13C NMR (CDCb) 8 36.5, 46.5, 127.4, 128.6, 129.4, 134.7, 169.9, 
172.0. 
2.Benzylsnccinic anhydride (2.27)84 
A mixture of 2-benzylsuccinic acid (2.13) (2.055g, O.OlOmol) and AC20 (9.6ml, 
10.387 g, 0.102mol, 10.2 equiv.) was refluxed for 1h. Evaporation of solvent gave a 
crude white solid which was triturated with ice-cold petroleum ether to give 2.27 as a 
white solid (1.766g, 94%): mp 97-9 oC (lit. 84 mp 95-7 OC); IR (CDCb) 'Umax 1868.9 
and 1785.0 (C=O) cm- I; IH NMR (CDCb) 82.72 (dd, 1H, J= 6.3, l8.5Hz, HCHPh), 
2.95 (dd, 1H, J = 5.3, 14.1Hz, HCHPh), 3.02 (dd, 1H, J = 8.3, 14.2Hz, HCHC(O», 
3.24 (dd, 1H, J = 4.9, 14.2Hz, HCHC(O», 3.40-3.50 (m, 1H, CH), 7.17 (d, 2H, J = 
6.3Hz, ArH), 7.27-7.38 (m, 3H, ArH); 13C NMR (CDCI3) 832.9, 36.0,42.1, 127.6, 
135.8,169.6,173.1,128.9,129.1; HRMS (+EI, M+) calcd. 190.0630, found 190.0630. 
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THE SYNTHESIS OF 3-SUBSTITUTED N·BENZYLOXY 
SUCCINIMIDES 
General Method: From anhydride 
A dispersion of O-benzyloxyamine (l equiv.) and the respective anhydride (stated 
amount) in toluene or xylenes (stated volume) dissolved on heating until reflux and the 
resulting solution was refluxed with azeotropic removal of H20 for the stated time. The 
solvent was evaporated to yield either a crude solid or more typically a brown residue. 
Either was dissolved in EtOAc and washed with 10% aqueous NaHC03 and H20. The 
organic phase was worked up in the usual manner to give the title compounds. These 
were purified by recrystallisation from the stated solvent system. 
3-Phenyl-N -benzyloxysuccinimide (2.31) 
By General Method: a dispersion of O-benzyloxyamine (154mg, 1.3mmol, 1.2 
equiv.) and 2-phenylsuccinic anhydride 2.30 (200mg, 1.1mmol) in toluene (2.5mL) 
dissolved with heating and the resulting solution was refluxed with azeotropic removal 
of H20 for 7h. Work-up gave 2.31 as a pale yellow solid (223mg, 70%): mp 111°C 
(1:1:2 Et20/pentanelEtOAc, pale yellow-white crystals); IR (KBr) 'Urn ax 1718.5 and 
1201.6 (C=O) cm-I; IH NMR 3 2.60 (dd, IH, J = 4.3, 18.5Hz, HCHC(O)), 3.03 (dd, 
IR, J = 9.3, 18.1Hz, HCHC(O», 3.84 (dd, IH, J = 4.4, 9.3Hz, CH), 5.16 (s, 2H, 
OCH2Ph), 6.95-6.98 (m, 2H, ArH), 7.26-7.28 (m, 3H, ArH), 7.34-7.36 (m, 3H, ArH), 
7.45-7.48 (m, 2H, ArH); 13C NMR (CDCI3) 3 34.3, 42.8, 78.2, 127.1, 127.8, 128.4, 
128.9, 129.3, 129.9, 1333.0, 136.3, 170.2, 171.8. Anal. Calcd. for C17R 15N03: C, 
72.59; H, 5.37; N, 4.98. Found: C, 72.45; H, 5.41; N, 5.13. 
3-Benzyl-N -benzyloxysuccinimide (2.25)84 
By General Method: a dispersion of O-benzyloxyamine (0.370g, 3.0mmol, 1.07 
equiv.) and 2-benzylsuccinic anhydride 2.27 (525mg, 2.8mmol) in xylenes (6mL) 
dissolved with heating and the resulting solution was refluxed with azeotropic removal 
of H20 for 18.25h. Work up gave a white solid which wa recrystallised from 
toluene/petroleum ether to give 2.25 as a white solid (635mg, 78%): mp 90-1 °C (lit.84 
mp 130-2 °C); IR (KBr) 'Urnax 1785.9 and 1719.5 (C=O) cm-I; IH NMR (CDCI3) 3 
2.35 (dd, IH, J= 4.4, 18.1Hz, HCHPh), 2.60 (dd, IH, J= 8.8, 18.1Hz, HCHPh), 2.70 
(dd, IH, J = 8.8, 18.1Hz, HCHC(O», 2.98-3.07 (m, IH, CH), 3.13 (dd, IH, J 4.4, 
13.7Hz, HCHC(O)), 3.40-3.50 (ABq, 2H, J = 9.8Hz, OCfu), 7.13 (d, 2H, J = 6.3Hz, 
ArH), 7.23-7.45 (m, 3H, ArH); 13C NMR (CDCh) 3 30.5, 36.2, 38.3, 78.6, 127.3, 
177 
128.5,128.9,129.1, 129.4, 130.0, 133.2, 136.3, 170.4, 173.3; HRMS (+CI, MH+) calcd. 
296.1287, found 296.1287. 
Alternatively 2.25 was prepared in the following manner from ethyl 3-benzylsuccinate 
2.18. 
A solution of ethyl 2~benzylsuccinate 2.18 (193mg, 0.81mmol) in CH2Cl2 (2mL) 
was added to a solution of O-benzyloxyamine hydrochloride (130mg, 0.81mmol) and 
Et3N (141.2/lL, 103mg, 1.02mmol, 1.26 equiv.) in CH2Ch (2mL) that had been stirring 
for 10 min under N2 at 0-5 °C (ice-salt bath). HOBt (11Omg, 0.81mmol) and then DCC 
(l65mg, 0.80mmol) were added successively and the resulting yellow solution was 
stirred for 21h while the temperature was allowed to come to rt. The reSUlting white 
slurry was filtered to remove the white DCU solid formed during the reaction and this 
was washed with a small quantity of CH2Ch. The filtrate and the washings were 
combined and evaporated to give a brown residue. This was taken up into the minimum 
amount of EtOAc and the suspended DCU was filtered and washed with a small 
quantity of EOAc and the filtrate and washings were combined and washed with H20 
(lOmL) and worked up in the usual manner to give a brown residue (287mg). A sample 
(233mg) of this was purified by flash Si02 chromatography eluting with 1:3 
EtOAc/petroleum ether to give 3-benzyl-N-benzyloxysuccinimide 2.25 as a white solid 
(33mg) with physical data identical to that given above, and then eluting with EtOAc to 
give 3-(carboethoxy)-3-benzylpropionyl-N-benzyloxyamide 2.24 as a white solid 
(109mg): mp 90-91 oC; IH NMR (CDCb) 8 1.18 (t, 3H, J = 7.1Hz, OCH2C.tb), 2.81 
(dd, tH, J = 7.8, 13.7Hz, HCHPh), 2.97-3.03 (m, 2H, HCHPh and HCHC(O», 3.17-
3.65 (m, 2H, HCHC(O) and CHC(O», 4.09 (q, 2H, J = 6.8, 7.3Hz, OCH2CH3), 4.86 
(bs, 2H, OCH2Ph), 7.15-7.37 (m, 1OH, ArH), 8.16 (bs, tH, NH). 
A solution of 2.24 (92mg, 0.27mmol) andp-TsOH (26mg, 0.14mmol, 0.5 equiv.) in 
1,2-dichloroethane (DCE) (5mL) was refluxed with azeotropic removal of EtOH for 
13h. The solvent was evaporated to give 2.25 as a pale brown solid (l06mg, quantative 
yield). Total yield 2.25 t39mg, (85%). Spectral data as above. 
THE SYNTHESIS OF 3-SUBSTITUTED N -HYDROXY 
SUCCINIMIDES 
Method A: From 3-substitutedN -benzyloxysuccinimide 
A solution of the respective substituted N-(benzyloxy)succinimide (stated amount) in 
the stated solvent (stated volume) was hydrogenated in the presence of the indicated 
palladium catalyst (stated amount) for the stated time. The reaction mixture was filtered 
through celite and Na2S04 and this cake washed with a small quantity of solvent. The 
filtrate and washings were combined and evaporated to give the title N-
hydroxysucccinimides. These were purified, if required, by either chromatagraphy or 
recrystallisation using the stated solvent system. 
Method B: From 2-substituted succinic acid anhydride 
The respective anhydride (stated amount) was added to a solution of hydroxylamine 
hydrochloride (1.2 equiv.) and K2C03 (0.6-1equiv.) in distilled H20 (stated volume). 
This mixture was refluxed for the stated time. The hot solution was acidified (pH= 1, 
Universal Indicator Paper) with 10% or conc. HCI, allowed to cool to rt, and then 
extracted with EtOAc. The combined extracts were worked up in the usual manner to 
give the titleN-hydroxysuccinimide. 
3-Phenyl-N-hydroxysuccinimide (2.32) 
By Method A: a solution of 3-phenyl-N-benzyloxysuccinimide 2.31 (40mg, 
0.14mmol) in THF (lmL) was hydrogenated for 4.25h in the presence of 10% 
palladium on carbon (5mg). Work-up gave a yellow oil which was purified by radial 
chromatography eluting with 1:4 EtOAc/petroleum ether to give 2.32 as a pale yellow 
oil (14mg, 53%): mp 109-111 oC (EtOAc/petroleum ether, white crystals); IR 
(CHCI3/NaCI) umax 3118.7 (OH), 1787.9 and 1693.4 (C=O) cm- l ; lH NMR (DMSO-
d6) 02.73 (dd, 1H, J= 4.4, 17.5Hz, HCH), 3.17 (dd, 1H, J= 9.2, 18.0Hz, HCH), 4.14 
(dd, 1H, J = 4.4, 8.8Hz, CH), 7.31-43 (m, 5H, ArH), 10.78 (bs, lH, NOH); l3C NMR 
(CDC13) 034.2,42.8,127.7,128.0,129.0,137.9,171.8,173.5; LRMS (+EI, mlz) 191 
(M+, 18), 175 (25), 121 (35), 104 (100), 78 (45), 51 (55). Anal. Calcd. for ClOH9N03: 
C, 62.83; H, 4.74; N, 7.33. Found: C, 62.67; H, 4.68; N, 7.36. 
By Method A: a solution of 3-phenyl-N-benzyloxysuccinimide 2.31 (40mg, 
0.14mmol) in MeOH (7.5mL) was hydrogenated at 50psi for 8.5h in the presence of 5% 
palladium on BaS04. Work up gave a pale yellow oil which was purified by radial 
chromatography eluting with 1:4 EtOAc/petroleum ether to give a colourless oil. This 
was recrystallised from EtOAc/petroleum ether to give 2.32 as a white solid (lOmg, 
37%): mp 108-9 oC. Physical data as given above. 
By Method B: 2-phenylsuccinic anhydride 2.30 (500mg, 2.9mmol) was added to a 
solution of hydroxylamine hydrochloride (237mg, 3.4mmol, 1.2 equiv.) and K2C03 
(236mg, 1.7mmol, 0.6 equiv.) in distilled H20 (7.SmL). This mixture was refluxed for 
5h. Subsequent work up as described gave 2.32 as a pale yellow-white solid (440mg, 
82%). Physical data as above. 
3-Benzyl-N -hydroxysuccinimide (2.26)84 
By Method A: a solution of 3-Benzyl-N-benzyloxysuccinimide 2.25 (202mg, 
0.7mmol) in 1:1 MeOHlEtOH (7mL) hydrogenated in the presence of 10% palladium 
on carbon (71mg) for 19.5h. Work up as described gave 2.26 as a white solid (86mg, 
61%): mp 105-110 °c (lit. 84 mp 120-1°C); IR (KBr) 'Umax 3224.8 (OH) , 1770.5 and 
1697.2 (C=O) em-I; IH NMR (CDCI3/DMSO·<h) 3 2.13 (dd, 1H, J = 4.4, 18.1Hz, 
HCHPh) 2.41 (dd, 1H, J = 8.8, IS. 1Hz, HCHPh) 2.62 (dd, IH, J = S.6, 13.5Hz, 
HCHC(O» 2.83-2.91 (m, 1H, CHC(O», 2.97 (dd, 1H, J = 4.4, 13.7Hz, HCHC(O», 
6.92-7.25 (m, 5H, ArH): 13C NMR (CDCI3IMSO-d6) 330.3,35.9, 38.0, 126.7, 128.5, 
128.7,136.6,171.3,174.1; HRMS (+EI, M+) calcd. 205.0739, found 205.0739. Anal. 
Calcd for CUHllN03.l/2H20: C, 61.66; H, 5.65. Found C, 62.08; H, 5.21. 
By Method A: a solution of 3-benzyl-N-benzyloxysuccinimide 2.25 (5.565g, 
19mmol) in THF (SOmL) was hydrogenated in the presence of 10% palladium on 
carbon (1.S96g). Work-up as described gave 2.26 as a white solid (2.780g, 72%): mp = 
119-120 °C (lit. 84 mp = 120-1 °C). Physical data as above. 
By Method B: 2-benzylsuccinic anhydride 2.27 (266mg, 1.4mmol) was added to a 
solution of hydroxylamine hydrochloride (201mg, 2.8mmol) and anhydrous K2C03 
(20Omg, 1.4mmol, 1 equiv.) in H20 (7mL) and the resulting mixture refluxed for 1.75h. 
Acidification with three drops of conc. HCI and subsequent work up gave 2.26 as a 
white solid (299mg, 51 %): mp 11O-17°C (lit. 84 mp = 120-1 °C ). Physical data as 
above. 
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THE SYNTHESIS OF 3-SUBSTITUTED N-[(ALKYL AND 
ARYLSULFONY]OXY] SUCCINIMIDES 
Method A: Sulfonylation at 0-5 oC then rt 
The appropriate sulfonyl chloride (1.5 equiv.) was added slowly to a solution of the 
N-hydroxysuccinimide (stated amount) and either Et3N or i-PrNEt or pyridine (1.1 
equiv.) in CH2Ch or toluene (stated volume) stirring under N2 at 0-5 oC (ice-salt bath). 
Stirring was continued for the stated time after which the ice-salt bath was removed and 
the reaction mixture allowed to come to rt while stirring over the stated period. In 
preparations where CH2Ch had been used as the solvent, the reaction solution was 
diluted and then washed with H20, 10% HCI or 10% aqueous citric acid, and 10% or 
saturated aqueous NaHC03. The organic phase was worked up in the usual manner to 
give the title compound. In preparations where toluene had been used the reaction 
solution was evaporated and the resulting residue dissolved in EtOAc and worked up in 
the same manner as described for a reaction carried out in CH2Ch. Further purification 
if required was carried out as described per compound. 
Method B: Sulfonylation at rt 
The appropriate sulfonyl chloride was (1-1.5 equiv.) was added slowly to solution of 
N-hydroxy imide (stated amount) and either Et3NH or iprNEt (1.1 equiv.) or pyridine 
(2 equiv.) in CH2Ch or toluene (stated volume) stirring at rt in N2. Stirring was 
continued for the stated time. Work up was carried out as described for Method A. 
Method C: Sulfonylation at 50 °c 
The appropriate sulfonyl chloride (l equiv.) was added to a solution of N-
hydroxyimide (stated amount) and pyridine (2 equiv.) in toluene (stated volume) 
stirring at 40 °C. The temperature was elevated to 50 °C and stirring was continued for 
the stated time. The reaction solution was then allowed to cool to rt and work up carried 
out as per Methods A and B. 
3-Benzyl-N-[(methanesulfonyl)oxy]succinimide (1.41d)84 
By Method B: MeS02Cl (l6.3J.1L, 24mg, 0.21mmol) was added to a solution of 3-
benzyl-N-hydroxysuccinimide 2.26 (44mg, 0.21mmol) and pyridine (33.9~L, 33mg, 
0.42mmol, 2 equiv.) in toluene (lmL). Stirring was continued for 12h. Work up in the 
manner described for a reaction carried out in toluene gave a white solid (59mg, 
quantatative yield); mp 70-1°C (lit. 84 mp 70-1°C); 1 H NMR (CDCb) 8 2.55 (dd, 1H, J 
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= 4.2, 16.1Hz, HCHPh), 2.80 (dd, 1H, J::: 8.6, 18.4Hz, HCHPh) 2.93 (dd, lH, J::: 10.3, 
15.1Hz, HCHC(O)) 3.22-3.30 (m, 2H, HCHC(O)) and CHC(O)), 3.40 (s, 3H, CH3)2.97 
(dd, IH, J::: 4.4, 13.7Hz, HCHC(O»), 7.18 (d, 2H, J::: 7.6Hz, ArH), 7.26-7.36 (m, 3H, 
ArH):13C NMR (CDCb) cS 30.4, 36.0, 38.4, 40.9, 127.3, 129.0, 135.9, 168.2, 171.2: 
HRMS (+EI, M+) calcd. 283.0515, found 283.0515. 
3-Phenyl-N -[ (methanesulfonyl)oxy ]succinimide (1.41e) 
By Method A: CH3S02CI (60IlL, 90mg, 0.78mmol, 1.5 equiv.) was added to a 
solution of 3-phenyl-N-hydroxysuccinimide 2.32 (100mg, 0.52mmol) and i-PrNEt 
(lOOIlL, 74mg, 0.57mmol, 1.1 equiv.) in CH2Cl2 (2mL). Stirred 0-5 °C for 20 min and 
then at rt for 30 min. Work up gave 1.41e as a pale yellow solid (138mg, 98%): mp 
169-70oC (toluene/petroleum ether, white crystals); IR (CHCb/NaCl) 'Umax cm- I 
1747.4 and 1720.4 (C:::O), 1421.4 and 1209.3 (-OS02-) cm-I; IH NMR (CDC13) cS 2.92 
(dd, IH, J ::: 4.4, 18.6, HCHC(O»), 3.35 (dd, IH, J ::: 10.0, 18.6Hz, HCHC(O», 3.47 (s, 
3H, CH3), 4.15 (dd, IH, J::: 4.4, 9.2, CHC(O», 7.25-7.28 (m, 2H, ArH), 7.35-7.43 (m, 
3H, ArH); 13C NMR (CDCI3) cS 34.6, 41.3, 43.1, 127.5, 128.6, 129.5, 135.7, 167.9, 
169.9: HRMS (+EI) (M+) calcd. 269.0358, found 269.0358. 
3-Benzyl-N-[(trans-styrylsulfonyl)oxy]succinimide (1.41f)87a 
By Method A: trans-styryl sulfonyl chloride (197mg, 0.97mmol, 1.5 equiv.) was 
added to an ice-cooled solution of 3-benzyl-N-hydroxysuccinimide 2.26 (134mg, 
0.7mmol) and pyridine (60!lL, 57mg, 0.72mmol) stirring under N2. Stirring was 
continued overnight as the reaction solution was allowed to come to rt. Work-up gave 
1.4lf as abrown oil (quanatative yield): IH NMR (CDCb) cS 2.53 (dd, 1H, J::: 4.5, 
18.5Hz, HCHPh), 2.78 (dd, 1H, J::: 8.5, 18.0Hz, HCHPh) , 2.95 (dd, 1H, J = 10.0, 
15.0Hz, HCHC(O»), 3.20-3.28 (m, 2H, HCHC(O) and CHC(O», 6.95 (d, 2H, J = 
15.6Hz, ArID, 7.15-7.56 (m, lOH, ArH), 7.69 (d, 2H, J::: 15.5Hz, ArH). 
3· Benzyl-N-[ (benzenesulfonyl)oxy ]succinimide (l.41g)87a 
By Method B: benzene sulfonyl chloride (26!lL, 35mg, 0.2mmol) was added to a 
solution of 3-benzyl-N-hydroxysuccinimide 2.26 (40mg, 0.2mmol) and pyridine (32!lL, 
32mg, O.4mmol) in toluene (ImL) stirring under N2 at rt. Stired overnight. Work-up for 
a reaction carried out in toluene gave 1.41g as a white solid: mp 83-5°C (lit,87a mp 80-
2°C): IR (CDCI3) 'Umax 1814.9 and 1747.4 (C:::O), 1452.3, 1404.1 and 1197.7 and 
1180.4 (-OS02-) em-I; IH NMR (CDCI3) cS 2.47 (dd, IH, J::: 4.7, 18.4Hz, HCHPh) , 
2.72 (dd, 1H, J = 8.8, 18.1Hz, HCHPh), 2.93 (dd, IH, J = 8.3, 13.6Hz, HCHC(O», 
3.12-3.26 (m, 2H, HCHC(O» and CHC(O», 7.17 (d, 2H, J = 7.5Hz, ArH), 7.25-7.37 
(m, 3H, Ar7 (m, 3H, ArH), 7.59 (t, 2H, J = 7.8Hz, ArH), 7.75 (t, IH, J = 7.2Hz, ArH), 
7.99 (d, 2H, J = 7.3Hz, ArH): l3C NMR (CDCI3) 0 30.3, 36.1, 38.5, 127.4, 129.0, 
129.1, 129.4, 134.1, 135.5, 135.9, 167.7, 170.8: HRMS (+EI, M+) calcd. 345.0671, 
found 345.0671. 
3-Benzyl-N-[ 4-toluenesulfonyl)oxy ]succinimide (1.4Ih) 
By Method A: To a ice-cooled solution of 3-benzyl-N-hydroxysuccinimide 2.26 
(52mg, 0.25mmol) and iprNEt (48.1mL, 36mg, 0.28mmol, 1.1 equiv.) in CH2Ch (lmL) 
stirring in N2, TsCI was added slowly portion wise. The resulting yellow solution was 
stirred at 0-5°C for 0.5h and then the ice bath was removed and the solution allowed to 
come to rt while stirring was continued for 3h. The reactionsolution was diluted with 
CH2Ch (5mL), washed with 10% HCI (5mL), saturated aqueous NaHC03 (5mL) , and 
H20 (5mL). Subsequent work up in the usual manner gave a white solid (?mg, ?%): mp 
71-6°C (lit.87a mp 87-8°C): IR (KBr) 'Urnax cm- I 1793.7 and 1739.7 (C=O): IH NMR 
(CDC13) 0 2.44-2.52 (m, 4H, HCHPh and Cfu), 2.73 (dd, IH, J = 8.8, 18.3Hz, 
HCHPh), 2.94 (dd, IH, J= 9.5, 15.0Hz, HCHC(O», 3.16-3.25 (m, 2H, HCHC(O» and 
CHC(O», 7.17 (d, 2H, J = 6.5Hz, ArH), 7.26-7.37 (m, 3H, ArH), 7.84 (d, 2H, J = 
8.5Hz, ArH); l3C NMR (CDCI3) 021.8,30.3,36.0,38.5, 127.7, 128.9, 129.1, 129.3, 
130.0, 130.9, 135.9, 147.0, 167.8, 170.9: HRMS (+EI, M+) calcd. 359.0828, found 
359.082828. Anal. Calcd for CI8H17NOSS: C, 60.15; H, 4.77; N, 3.90; S, 8.90. Found 
C, 60.26; H, 4.80; N, 3.94; S, 8.68. 
3-Phenyl-N-[(4-toluenesulfonyl)oxy]succinimide (lAli) 
By Method A: a solution of TsCI (149mg, 0.78mmol, 1.5 equiv.) in CH2Ch (0.5 
mL) added to a solution of 3-phenyl-N-hydroxysuccinimide 2.32 (lOOmg, 0.52mmol) 
and i-PrNEt (lOOJlL, 74mg, 0.57mmol, 1.1 equiv.) in CH2Ch (2mL). Stirred at 0-5 °C 
for 20 min and then at rt for 30 min. Work up gave l.4li as a white solid (177mg, 
98%); mp 119°C (toluene, white crystals); IR (CHC13/NaCl) 'Urn ax 1801.4 and 1751.2 
(C=O), 1421.4 and 1182.3 (-OS02-) em-I; IH NMR (CDC13) 0 2.46 (s, 3H, CH3), 2.91 
(dd, IH, J = 4.4, 18.6Hz, HCHC(O», 3.31 (dd, IH, J = 9.8, 18.6Hz, HCHC(O», 4.09 
(dd, IH, J 4.4, 9.7Hz, CHC(O», 7.24-7.27 (m, 2H, ArH), 7.35-7.44 (m, 5H, ArH), 
7.93 (d, 2H, J = 7.8Hz, ArH): l3C NMR (CDC13) 0 21.8, 34.6, 43.1, 110.9, 127.4, 
128.4, 129.3, 129.4, 130.0, 137.0, 167.7, 169.4; HRMS (+EI, M+) calcd. 345.0671, 
found 345.0671. 
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3-Benzyl-N-[(2-napthylsulfonyl)oxy]succinimide (1.41j) 
By Method A: 2-napthylsulfonyl chloride (33mg, 0.15mmol, 1.1 equiv.) was added 
to a solution of 3-benzyl-N-hydroxysuccinimide 2.25 (30mg, 0.15mmol) and i-PrNEt 
(26~L, 21mg, 0.16mmol, 1.1 equiv.) in CH2Cl2 (5mL). Stirred at 0-5 °C for 0.5h and 
then at rt for 1h. Work up by diluting with CH2Ch and washing with H20, 10% HCI 
and 10% aqueous NaHC03 gave 1.41j as a white solid (57mg, 99%); IH NMR (CDC!)) 
62.50 (dd, IH, J = 4.4, 18.5Hz, HCHPh), 2.74 (dd, 1H, J = 9.1, 18.4Hz, HCHPh), 2.95 
(dd, IH, J = 8.8, 14.7Hz, HCHC(O) 3.16-3.27 (m, 2H, HCHC(O» and CHC(O), 7.15-
7.18 (m, 2H, ArH), 7.26-7.37 (m, 3H, ArH), 7.63-7.7.75 (m, 2H, ArH), 7.93-8.05 (m, 
2H, ArH), 8.56 (s, IH, ArH):13C NMR (CDCl)) 6 30.3,36.0,38.5, 121.3, 123.2, 127.4, 
128.0,128.1,128.9,129.0,12.1,129.6,129.7,130.2, 130.8,131.8,131.9,135.9,136.0, 
1648, 167.8, 170.9: HRMS (+EI, M+) calcd. 395.0828, found 395.0828. 
3-Benzyl-N -[ (3-nitrobenzenesulfonyl)oxy ]succinimide (1.41k) 
By Method A: a solution of 3-nitrobenzene sulfonyl chloride (120mg, 0.55mmol, 1.5 
equiv) was added to a solution of 3-benzyl-N-hydroxysuccinimide 2.25 (75mg, 
0.36mmol) and Et3N (55.7mL, 4Omg, 0.40mmol, 1.1equiv.) in CH2Cb (4mL). Stirred 
0-5°C Ih and then rt 4.5h. Work up as described gave a brown residue which was 
purified by flash Si02 chromatography eluting with 3:7 EtOAc/petroleum ether to give 
a brown oil (quantative yield): IR (CDC!) 'Umax 1813.0 and 1747.4 (C=O) cm- 1; IH 
NMR (CDCI) 6 2.51 (dd, IH, J = 4.4, 18.6Hz, HCHPh), 2.77 (dd, 1H, J = 8.8, 18.6Hz, 
HCHPh), 2.94 (dd, IH, J= 8.8, 13.7Hz, HCHC(O», 3.16 (dd, IH, J = 4.9, 14.2Hz, 
HCHC(O», 3.24-3.33 (m, lH, CHC(O», 7.17 (d, 2H, J = 7.3Hz, ArH), 7.23-7.34 (m, 
3H, ArH), 7.83 (t, lH, J = 7.8Hz, ArH), 8.24 (d, 1H, J = 8.3Hz, ArH), 8.55 (d, 1H, J = 
803Hz, ArH), 8.75 (s, IH, ArH); 13C NMR (CDCI) 6 30.3, 36.0, 38.5, 124.5, 127.6, 
129.1, 129.1, 129.7, 130.8, 134.5, 135.6, 136.6, 148.2, 167.5, 170.6: HRMS (+EI, M+) 
calcd. 390.0522, found 390.0522. 
Synthesis of 3-benzyl-N -[ (2-carbethoxy -ethanesulfonyl)oxy ]succinimide (1.411) 
1. Freshly distilled 2-bromopropionic acid 2.37 (l8mL, 30.6g, 0.2mol) was added 
dropwise to SOCh (20mL, 32.740g, 0.275mol, 1.4 equiv.) stirring at 30-40°C. After the 
addition was completed the resulting solution was refluxed for 2h. Excess SOCh was 
removed by distilllation at aspirator pressure to give a dark brown liquid which was 
then distilled at reduced pressure to give the intermediate 2-bromopropionoyl chloride 
as a colourless liquid (10.192g, 30%). This acid chloride was transferred with toluene 
washings (2mL) to a dropping funnel and was added dropwise to dry EtOH (4mL, 
3.140g, 0.068mol, 1.15 equiv.) stirring at 0-5°C (ice-salt bath). After the addition was 
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completed, stirring was continued at that same temperature for 2h at which point the 
ice-salt bath was removed and the reaction solution allowed to come to rt while being 
stirred for 2.75d. The reaction solution was poured into H20 (lOmL) and the organic 
layer that separated washed with the same volume of 10% aqueous NaHC03 and H20 
and worked up in the usual manner to give the ester 2.38 as a clear oil (6.629g, 18% 
overall): bp 22°C 10.02rnrnHg; IH NMR (CDCI3) 8 1.27 (t, 3H,J = 7.1Hz, CH2CH3), 
1.79 (d, 3H, J = 6.8Hz, CHCHJ.), 4.20 (q, 2H, J = 6.8, 7.4Hz, CHZCH3), 4.33 (q, lH, J 
= 6.8, 6.9Hz, CHCH3). 
2. A solution of ethyl 2-bromopropionate 2.38 (1.31g, 7mmol) and K2S03 (1.312g, 
8m mol) in 12%:88% EtOHlH20 (l7mL) was refluxed for 1.5h. The solvent was 
evaporated in vacuo to give a white solid. This crude salt 2.39 (1.271g, 80%) was dried 
in an oven set at 110°C for 2d and then used without further purification. 1 H NMR 
(D20) 8 1.25 (t, 3H,J = 7.3Hz, CH2CH1), 1.48 (d, 3H, J = 6.9Hz, CHCHJ.), 3.93 (q, IH, 
J = 6.8, 7JHz, CHCH3), 4.22 (q, 2H, J = 7.1, 7.3Hz, ClliCH3). 
3. A suspension of potassium ethyl 2-sulfopropionate 2.39 (1.271g, 6mmol) and 
PCls (1.250g, 6mmol) in POCh (l2mL) was stirred vigorously at 80°C for 2.5h under a 
N2 atmosphere. The reaction mixture was allowed to cool to rt and then filtered under a 
N2 atmosphere directly into a modified Claisen flask and short Vigreux column set up 
for distillation. The salt cake was washed with a small quantity of POCh and this 
washing and the yellow coloured filtrate were distilled at aspirator pressure to give a 
mixture of a small quantity of white solid, presumably unremoved NaC!, and brown 
residue. This mixture was distilled at reduced pressure to give 2.40 as a yellow coloured 
liquid with a characteristic piquant odour (122mg, 11 %): bp 52°C 10.02mmHg; IH 
NMR (CDCh) 8 1.35 (t, 3H,J = 7.1Hz, CH2CH3), 1.86 (d, 3H, J = 6.8Hz, CHCfu), 
4.30-4.38 (m, 2H, CH2CH3), 4.50 (q, IH, J = 6.8, 7.4Hz, CHCH3). 
4. By Method C: a solution of ethyl (2-chlorosulfonyl)propionate 2.40 (122mg, 
0.61mmol) in toluene (1.5mL) was added dropwise to a solution of 3-benzyl-N-
hydroxysuccinimide 2.26 (125mg, 0.61rnrnol) and pyridine (98.7JlL, 97mg, 1.2rnmol,2 
equiv.) in toluene (1.5mL) stirring in N2 at rt. The resulting white slurry was stirred at rt 
for 15min after which the tenperature was raised to 50°C during which the slurry 
cleared to give a brown coloured solution. Stirring was then continued for 18h. The 
reaction solution was evaporated to give a brown residue which was dissolved in EtOAc 
and wahed with 2N HCI. The aqueous layer was re-extracted with EtOAc and the 
organics combined and worked up in the usual manner to give a brown coloured residue 
(151mg, 67%). Purification of 101mg of this residue by flash Si02 chromatography 
eluting with 1: 1 EtOAc/petroleum ether gave 1.411 as a brown coloured residue (64mg, 
28%); IR (CDC13) 'Umax 1801.4 and 1747.4 (C=O), 1409.9 and 1190.0 (-S02-) cm- I ; 
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IH NMR (CDC13) {) 1.32 (t, 3H, J :=: 7.3Hz, CH2CH3), 1.85 (dd, 3H, J :=: 2.3, 7.3Hz, 
CHCH3), 2.55 (dd, IH, J:=: 3, 17.5Hz, HCHPh), 2.80 (dd, IH, J:=: 8.8, 18.3Hz, HCHPh), 
2.87-2.97 (m, IH, H2CCHCH2), 3.24-3.30 (m, 2H, CHCH2), 4.31 (q, 2H, J = 7.0, 
7.3Hz) 4.67 (q, IH, J = 6.0, 7.0Hz, CHCH3), 7.17-7.35 (m, 5H, ArH); l3C NMR 
(CDCI3) {) 13.4, 13.9, 30.5, 36.1, 36.3, 38.5, 38.6, 63.2, 65.3, 127.4, 128.5, 129.0, 
129.0, 129.2, 135.9, 164.3, 168.1, 171.0, 171.0; HRMS (+E1, M+) calcd. 369.0883, 
found 369.0882. 
3-Benzyl-N -[ (3-{ 3-benzyl-N-succinimidylsulfonate }benzenesulfonyl)oxy] 
succinimide (l.4ln) 
By Method A: 1,3-bis(chlorosulfonyl)benzene (32mg, 0.12mmol) was added slowy 
to a solution of 3-benzyl-N-hydroxysuccinimide 2.26 (45mg, 0.22mmol, 2 equiv.) and i-
PrNEt (42J..iL, 31mg, 0.24mmol, 2.2 equiv.) stirring under N2 at 0-5 DC. Stirring 
continued at 0-5 °C for 0.5h and then for 11h at rt. Work-up gave l.4ln as a white solid 
(22mg, 17%) after crystallisation from toluene/petroleum ether: mp 95-100 °C; 1R 
(CDC13) 'Umax 1813.0 and 1747.4 (C=O) cm-I; IH NMR (CDC13) {) 2.50 (dd, IH, J = 
4.4, 18.5Hz, HCHPh), 2.75 (dd, IH, J = 9.0, 18.3Hz, HCHPh), 2.94 (dd, IH, J = 8.6, 
l3.9Hz, HCHC(O», 3.17-3.27 (m, 2H, HCHC(O) and CHC(O», 7.l3-7.36 (m, 5H, 
ArH) , 7.86 (t, IH, J 8.lHz, ArH), 8.35 (d, 2H, J = 83Hz, ArH), 8.59 (s, IH, ArH); 
J3C NMR (CDC13) {) 30.4,36.0, 38.5, 127.4, 129.0, 130.1, 130.8, 135.5, l35.8, 136.1, 
167.6, 170.7; HRMS (FAB, MH+) calcd. 613.0951, found 613.0951. 
3-Benzyl-N-[(4'-{3-benzyl-N-
succinimidyl}sulfonatebiphenylsulfonyl)oxy ]succinimide (l.4lm) 
By Method C: 4,4-biphenyl disulfonyl chloride (173mg, 0.5mmol) was added slowly 
portionwise to a solution 3-benzyl-N-hydroxysuccinimide (202mg, Immol, 2 equiv.) 
and pyridine (160.1mL, 157mg, 2mmol, 4 equiv.) in toluene (8mL) stirring at 400 C in 
N2. The temperature was raised to 500 C and stirring continued for 2h. Solvent was 
evaporated and the resulting mixture consisting of a brown residue and a white solid 
was dissolved in the minimum amount of EtOAc and washed with H20. The aqueous 
layer was reextracted with EtOAc and the extracts combined and worked up in the usual 
manner to give a yellow solid. Purification by flash Si02 chromatography eluting with 
CH2Cb gave l.4lm as a brown oil (117mg, 34%): 1R (CDCb) 'Umax 18l3.0 and 
1747.4 (C=O) em-I; IH NMR (CDCI3) {) 2.50 (dd, IH, J = 4.4, 18.5Hz, HCHPh), 2.75 
(dd, IH, J = 9.0, 18.3Hz, HCHPh), 2.94 (dd, IH, J:=: 8.6, 13.9Hz, HCHC(O», 3.17-3.27 
(m, 2H, HCHC(O) and CHC(O», 7.13-7.36 (m, 5H, ArH), 7.86 (t, IH, J:=: 8.1Hz, ArH), 
8.35 (d, 2H, J = 8.3Hz, ArH), 8.59 (s, IH, ArH); 13C NMR (CDC13) {) 30.4,36.0, 38.5, 
127.4, 129.0, 130.1, l30.8, 135.5, 135.8, 136.1, 167.6, 170.7; HRMS (FAB, MH+) 
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calcd. 613.0951, found 613.0951. Anal. Calcd. for C34H2SN201OS2.1.5H20: C, 57.17; 
H, 3.95; N, 3.92. Found C, 56.96; H, 4.14; N, 3.93. 
THE SYNTHESIS OF 3·SUBSTITUTED N-[(ACYL)OXY] 
SUCCINIMIDES 
Method A: Et3N/iPrNEt and DMAP catalysed acylation. 
Acetic anhydride or the appropriate acid chloride (l equiv.) was added to a solution 
of 3-substituted N-hydroxysuccinimide (stated amount), DMAP (0.1 equiv.), and Et3N 
or i-PrNEt (l equiv.) in CH2C12 (stated volume) which had been stirring for 5min under 
N2 at r1. Stirring was then continued at rt overnight. The reaction solution was diluted 
with EtOAc and washed with 10% aqueous citric acid and H20 and then O.5N KHC03 
and H20 again. The organic phase was then worked up in the usual manner to give the 
title compounds. These were purified by crystallisation from the stated solvent system. 
MethodB: Et3N li-PrNEt catalysed acylation. 
The appropriate acid chloride (1.5 equiv.) was added to a solution of N-hydroxy 
imide (stated amount) and Et3NH or iPrNEt (1.1 equiv.) in CH2Cl2 stirring at 0-50 C 
(ice-salt bath). Stirring was continued at that temperature for the stated time, (typically 
at least 20min), then the ice-salt bath removed and the reaction mixture allowed to come 
to rt while stirring for the stated period (typically at least 0.5h). The reaction solution 
was diluted with CH2Cb and washed with H20, 10% HCI and saturated NaHC03. The 
organic phase was worked up in the usual manner to give the title compounds in high 
purity by 1 HNMR. 
Method C: TMSOTf catalysed acetylation. 
TMSOTf (0.02 equiv.) was added to a solution of N-hydroxy imide (stated amount) 
and AC20 (1.5 equiv.) in CH2C12 which had been stirring in N2 for lOmin at 0-50 C 
(ice-salt bath). The resulting solution was allowed to come to rt while stirring overnight. 
This was then treatedwith saturated aqueous NaHC03 and extracted with CH2C12. The 
organic extract was separated, washed with 10% aqueous NaHC03 and worked up in 
the usual manner to give the title compounds as crystalline solids. 
Method D: TMSOTf catalysed acylation with in situ mixed anhydride 
A solution of the appropriate acid (stated amount) in CH2Cb was treated with N-
methylmorpholine and ethyl chloroformate to give an in situ mixed anhydride. After 
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this solution was stirred for the stated period the N-hydroxysuccinimide (stated amount) 
was added followed by TMSOTf (0.02 equiv.) and the reaction stirred while being 
allowed to come to rt over the stated period. Saturated aqueous NaHC03 was added to 
the reaction mixture and the organic phase then separated and washed with saturated 
aqueous NH4CI and H2O. Work-up in the normal manner gave the title compound. 
Method E: DCC, HOBt mediated acid coupling 
HOBt (stated amount) and acid (stated amount) were added to an ice cooled solution 
of the N-hydroxysuccinimide (stated amount) in CH2Cl2 stirring under N2. The 
resulting solution was stirred for the stated period under N2 at O-S °c after which DCC 
(stated amount) was added and the resulting mixture stirred for the indicated period 
while the reaction mixture was allowed to come to rt. The reaction mixture was 
evaporated and the resulting product suspended in EtOAc (stated amount). This 
suspension was then filtered to remove the by-product DCU and the filter cake washed 
with a small quantity of EtOAc. The filtrate and washings were combined and washed 
with O.5N aqueous KHC03 and H20 and the organic phase worked up in the usual 
manner to give the title compound. 
3-Benzyl-N -[ (acetyl)oxy ]succinimide (1.410) 
By Method A: AC20 (SS.7JlL, 6Omg, 0.6mmol) was added to a solution of 3-benzyl-
N-hydroxysuccinimide 2.26 (lllmg, 0 6mmol), DMAP (8mg, 0.06mmoL 0.1 equiv.), 
and Et3N (82.2mL, 60mg, 0.6mmol) in CH2Cl2 (6mL) which had been stirring for Smin 
under N2 at rt. Work-up gave 1.410 as a brown residue (108mg, 79%): mp 107-90 C 
(EtOAc/petroleum ether, amber coloured crystals); IH NMR (CDCI3) 8 2.22 (s, 3H, 
C(O)Cfu), 2.43 (dd, IH, J = 3.4, 18.1Hz, HCHPh), 2.62-2.81 (m, 2H, HCHPh and 
HCHC(O», 3.16 (bs, 2H, HCHC(O) and CHC(O», 7.08-7.26 (m, SH, ArH).;. l3C NMR 
(CDC13) 8 17.S, 30.7, 36.3, 38.7, 127.2, 128.6, 128.9, 136.3, 16S.S, 168.S, 171.S; 
HRMS (+E1, M+) calcd. 247.084S, found 247.084S. 
By method C: TMSOTf (4JlL, Smg, 0.02mmol, 0.02 equiv.) was added to a solution 
of 3-benzyl-N-hydroxysuccinimide 2.26 (202mg, 0.99mmol) and AC20 (l40IlL, 
lSlmg, l.Smmol, I.S equiv.) in CH2C12 (6mL) that had been stirring at O-S °C under 
N2 for 10 min. Stirrind was continued as the reaction solutionwas allowed to come to rt 
overnight. Work-up as described above gave 1.410 as a brown coloured residue which 
on standing at rt over a period of one week solidified to afford 1.410 as a white 
crystalline solid (209mg, 86%). Physical data as given above. 
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3~Phenyl~N~[ (acetyl)oxy ]succinimide (1.41p) 
By Method B: AcCI (28IlL, 3lmg, 0.39mmol) was added to a solution of 3-phenyl-
N-hydroxysuccinimide 2.32 (SOmg, 0.26mmol) and i-PrNEt (49.9JlL, 37mg, 0.29mmol, 
1.1 equiv.) in CH2Clz (1mL). Work-up gave 1.41p as an off-white solid (4Smg, 74%): 
mp 74 oC (Et20/petroleum ether, colourless crystals); IR (CDCb) 'Umax 1789.8 and 
1743.5 (C=O) cm-I; IH NMR (CDCh) (32.37 (s, 3H, CH3), 2.89 (dd, IH, J ::: 404, 19.0, 
HCHC(O)), 3.33 (dd, JH, J ::: 9.8, 18.SHz, HCHC(O)), 4.12 (bs, IH, CHC(O)), 7.31-
7043 (m, SH, ArH); l3C NMR (CDCI3) (3 17.6, 3S.3, 43.S, 126.6, 127.S, 128.3, 129.3, 
129.6, 130.2, 16S.6, 168.3; HRMS (+EI, M+) calcd. 233.0688, found 233.0688. Anal. 
Ca1cd. for C12HUN04: C, 61.80; H, 4.7S; N, 6.01. Found: C, 62.10; H, 4.81; N, 6.2S. 
3~Benzyl-N-[(trans-cinnamoyl)oxy]succinimide (1.41q) 
By Method A: trans-cinnamoyl chloride (70mg, 0.42mmol, 1.0S equiv.) was added 
slowly portionwise to a solution of 3-benzyl-N-hydroxysuccinimide 2.26 (83mg, 
OAmmol), DMAP (4mg, 0.03mmol), and i-PrNEt (70AJlL, S2mg, OAmmol) in CH2Cl2 
(7mL) that had been stirring for Smin under N2 at rt. The resulting reaction solution was 
stirred for 14.Sh. Work-up gave 1.41q as a white soid (lOOmg, 7S%): mp 1OS-70 C 
(EtOAc/petroleum ether, white crystals); IH NMR (CDCI3) (3 2.S7 (bd, JH, J = 18.0Hz, 
HCHPh), 2.76-2.93 (m, 2H, HCHPh and HCHC(O)), 3.29 (bs, 2H, HCHC(O) and CH) 
6.S9 (d, IH, J = 16.1Hz, C(H):CHPh), 7.93 (d, 1H, J::: 16.1Hz, C(O)CH:C(H)Ph1. l3C 
NMR (CDCI3) (330.8,36.2,38.8, IlLS, 127.2, 127.8, 128.6, 128.9, 128.9 129.0, 131.S, 
13304,149.9,162.0,168.7,171.7; HRMS (+EI) (M+) ca1cd 33S.11S8, found 33S.11S8. 
Anal. Calcd for C2oH170~: C, 71.64; H, S.07; N, 4.18. Found: C, 71.12; H, S.12; N, 
4.10. 
By Method D: N-methylmorpholine (11SmL, 106mg, 1.0Smmol) and ethyl 
chloroformate (104mL, 118mg, 1.09mmol, 1.1 equiv.) were added to an ice cooled 
solution of cinnamic acid (1S6mg, 1. OSmmol , 1.0S equiv.) in CH2Cl2 (SmL). The 
resulting solution was stirred at O-S °C under N2 for 10 min. 3-Benzyl-N-
hydroxysuccinimide 2.26 (206mg, Immol) and TMSOTf (4mL, Smg, 0.02mmol) were 
then added and the resulting reaction solution allowed to warm to rt while stirring 
overnight. Work-up gave 1.41q as a white solid (289mg, 86%). Spectral data as above. 
3-Benzyl-N -[ (N -benzyloxycarbonyl-( L) -phenylalanyl)oxy]succinimide (1.41r) 
By Method E: HOBt (66mg, OA9mmol) and N-Cbz-(L)-phenylalanine (147mg, 
OA9mmol) were added to an ice-cooled solution of 3-benzyl-N-hydroxysucccnimide 
2.26 (1OImg, O.SOmmol) in CH2C12 (9mL) stirring under N2. This solution was stirred 
189 
at 0-5 DC under N2 for 15min after which DCC (114mg, 0.55mmol) was added and the 
solution allowed to warm to rt while being stirred for 43h. The reaction solution was 
evaporated and the resulting mixture of a brown residue and white solid was suspended 
in the minimum amount of EtOAc. This was then filtered to remove the by-product 
DCU and the filer cake washed with a small quantity of EtOAc. The filtrate and 
washings were combined and washed with 0.5N KHC03 and H20 and the organics 
worked-up in the normal manner to give a brown residue (l98g, 83%): 1 H NMR 
(CDCb) 82.56 (1H, dd, J = 3.9, 18.1 Hz, HCHPh), 2.78-2.93 (2H, m, HCHPh and 
HCHC(O», 3.29-3.43 (m, 2H, HCHC(O) and CH), 4.62-4.66 (m, 1H, C(O)CHNH), 
5.10 (s, 2H, OCH2Ph), 5.24 (d, lH, J = 6.3Hz, NH), 7.09-7.38 (m, lOH, ArH); l3C 
NMR 8 24.6,25.3,29.6,30.6,30.7,33.3,36.1,37.6,37.8, 38.1, 38.4, 38.7, 52.9, 54.6, 
54.8,67.0,67.3,77.2,127.0, 127.1, 127.3, 127.4, 128.0, 128.1, 128.2, 128.4, 128.5, 
128.7, 128.8, 128.9, 129.3, 129.5, 134.3, 135.6, 135.8, 136.0, 136.2, 136.6, 155.5, 
155.9,167.4,168.2,171.1,171.8,174.5,174.88; HRMS (+EI) calcd. 486.1792, found 
486.1791. 
THE SYNTHESIS OF 2NALKYLGLUTARIC ACIDS 
Method A: Michael Reaction Route 
DiethyI2-benzyl-2-cyanoethyl malonate (2.45)182a 
Acrylonitrile (2.4mL, 1.934g, 36mmol) was added slowly to a solution of diethyl 
benzyl malonate (8.7mL, 9.257g, 37mmol) and 30% methanolic KOH (201mg) in 
tBuOH (13mL) stirring inN2 at such a rate that the temperature of the reaction mixture 
did not exceed 40°C. Stirring was continued at rt for a further 4.5h. The reaction 
mixture was acidified (pH=l, Universal Indicator Paper) with glacial CH3C02H and 6N 
HCI then concentrated and extracted with Et20. The Et20 extract was washed with an 
equal volume of H20 and worked up in the usual manner to give an oily brown residue. 
This was then distilled under reduced pressure (lmmHg) to give three liquid fractions. 
The first (1.620g) and second (1.045g) fractions were collected in the ranges 124-50 oC 
and 150-70 °C and contained, by IH NMR, 21:4 and 14:11 unreacted diethyl benzyl 
malonate/diethyl benzyl-2-cyanoethyl malonate respectively. The third fraction was 
found to contain pure product and after standing at rt for 19d slowly crystallised to give 
2.45 as a white solid (5.616g, 50%): bp 170-96 DC/1mmHg (lit. 182a bp 175-80 
oCllmmHg); IH NMR (CDCI3) 8 1.27 (t, 6H, J = 7.3Hz, 2CH2CH3), 2.11 (t, 2H, J = 
7.8Hz, CH2CN), 2.44 (t, 2H, J = 7.8Hz, CfuCH2), 3.26 (s, 2H, PhCH2), 4.23 (q, 4H, J 
= 6.9, 7.3Hz, 2CH2CH3), 7.06-7.09 (m, 2H, ArID, 7.24-7.31 (m, 3H, ArH): l3C NMR 
(CDC]3) 8 13.0, 13.8, 28.6, 39.4, 57.5, 61.7, 119.0, 127.3, 128.4, 129.7, 134.8, 169.9: 
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HRMS (+E1, M+) calcd. 289.1315, found 289.1314. Anal. Calcd for C17H21N04: C, 
66.41; H, 6.62; N, 4.84. Found: C, 66.17; H, 6.50; N, 4.71. 
2-BenzyIglutaric acid (2.44b) 
A mixture of 2.45 (2.249g, 7mmol) and 68% HBr (l8mL) was refluxed for ld. The 
solution was then evaporated to give a mixture of a brown liquid and a white solid 
(presumably NH4Br). Sufficient H20 was added to dissolve the NH4Br and the 
resulting mixture was extracted with Et20. Work up in the usual manner gave 2.44b as 
a brown oil (l.174g, 72%): IH NMR (CDCI3) 01.78 (q, 2H, J = 7.3, 7.8Hz), 2.26-2.39 
(m, 2H), 2.67 (dd, IH, J = 7.3, 14.lHz), 2.80 (dd, 1H, J = 6.4, 13.2Hz), 2.94 (dd, 1H, J 
= 8.3, 13.6Hz), 7.26-7.39 (m, SH, ArH); l3C NMR (CDCI3) 0 25.9, 31.5, 37.8,46.2, 
126.5, 128.4, 128.8, 138.2. 
THE SYNTHESIS OF 3,3-DIALKYLGLUTARIC ACIDS 
4,4-DimethyI-3,5-dicyanoglutarimmide (2.48a) 185 
A solution of EtOH saturated with NH3 was prepared by bubbling NH3(g) through 
EtOH (200mL) at ca. -S DC for 6h. This solution was added to a mixture of ethyl 
cyanoacetate (l06mL 113g, 1mol) and acetone (37mL, 29.267g, 0.5mol) and the 
resulting mixture was stored in the freezer for 3d. Cold EtOH (200mL) was added and 
the mixture stirred thoroughly and returned to the freezer. After this period the reaction 
mixture was allowed to warm to rt and the yellow salt that had deposited over this 
period was collected by suction filtration and washed with a small quantity of Et20 to 
remove ethyl cyanoacetate and acetone and then air-dried. The resulting pale yellow 
solid was dissolved in boiling H20 and cone. HCI added until this solution was acid to 
Congo Red Paper after which an additional volume of cone. HCI (SOmL) was added. 
On cooling 2.48a crystallised as a white solid (40.87g, 42%); IR (KBr) 'Umax 3215.1 
(NH), 1712.7 and 1749.3 (C=O); IH NMR (DMSO-d6) 0 1.27 (s, 3H, CH3), 1.44 (s, 
3H, CH3), 4.88 (s, 2H, 2xCll), 12.23 (bs, lH, NH); l3C NMR (DMSO-d6) 19.9,26.0, 
39.1,46.9,114.6,164.7; HRMS (FAB, M+) calcd. 191.069S, found 191.0695. 
3,3-CycIohexyIglutaric acid (2.44d)253 
4,4-Cyc1ohexyl-3,S-dicyano-glutarimide 2.49b (2.020g, 9mmol) was dissolved in 
cone. H2S04 (5mL) with gentle warming. Water (SmL) was added slowy and the 
resultant solution heated to reflux becoming a black mixture containing a suspension of 
fine white solid. At this stage some foaming problems were experienced leaving 
material adhered to the insides of the reaction flask and reflux condenser. This was 
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washed back down into the reaction mixture with a small quantity of H20. Reflux was 
continued overnight during which period the described suspension dissolved to give a 
clear black solution. This was diluted carefully with H20 (lOmL) and extracted 
thoroughly with Et20. The Et20 extracts were combined and washed with H20 and 
then extracted with saturated aqueous NaHC03. The NaHC03 extracts were acidfied 
(pH:::: 1 , Universal Indicator Paper) with conc. HCI and then extracted with Et20. Work 
up in the usual manner gave 2.44d as a white solid (1.259g, 72%): mp 179-820C (lit.253 
mp 182-3 °C). 
3,3-Dimethylglutaric acid (2.44e)185 
Compound 2.48a (23.22g, 0.12mol) was dissolved in conc. H2S04 (62mL) with 
slight warming. Water (62mL) was then added slowly and the resulting mixture 
refluxed for 1.5d. The reaction mixture was diluted with H20 (50mL) and extracted 
with Et20. The organic extracts were combined and washed with H20 and then worked 
up in the normal manner to give a pale yellow solid (l5.19g, 78%); mp 99-102 °C 
(lit.1 85 mp 102-3 °C); IR (KBr) 'Urn ax 2881.5 (OH), 1689.5 (C=O) cm- I ; IH NMR 
(DMSO-d6) b 1.14 (s, 6H, 2xCH3), 2.38 (s, 4H, 2xCH2C(O)). 
THE SYNTHESIS OF SUBSTITUTED GLUTARIC ANHYDRIDES 
General Method 
A mixture of the glutaric acid (stated amount) and excess AcCI or AC20 (stated 
amount) was refluxed for the stated time. The solvent - a mixture of the excess AcCI or 
AC20 and AcOH which was formed during reaction - was removed by downward 
distillaton at aspirator pressure to give either liquids or more typically brown to black 
residues. These were distilled at reduced pressure, or recrystallised from the stated 
solvent system, as indicated, to give the title anhydride. 
2.Phenylglutaric anhydride (2.43a) 
A mixture of 2-phenylglutaric acid 2.44a (2.500g, 13mmol) and AcCI (5.200mL, 
61mmol, 4.7equiv.) was refluxed for 1h. The excess AcC} was evaporated and the 
resultant liquid was distilled at reduced pressure to give a pale yellow solid. 
Recrystallisation from toluene/petroleum ether gave 2.43a as a white solid (2.081g, 
84%); IR (CHCl)lNaCI) 'Urnax 1813.0 and 1762.8 (C=O) cm-I ; IHNMR (CDCh) b 2.28 
(m, 2H, CH2C(O)), 2.85 (m, 2H, CHCH2), 3.92 (dd, 1H, J = 6.3, 8.7Hz, Cm, 7.33 (m, 
5H, ArH); l3C NMR (CDC13) b 24.4, 29.4, 46.8, 127.8, 128.0, 128.9, 135.9, 166.5. 
2-Benzylglutaric anhydride (2.43b) 
A mixture of 2-benzylglutaric acid 2.44b (2.131g, 9.6rnrnol) and AC20 (5.978mL, 
6.468g, 0.063mol, 6.6 equiv.) was refluxed for 2d. Distillation of the reaction mixture at 
reduced pressure gave 2.43b as a pale yellow solid (1.354g, 69%): mp 80-1 DC 
(toluene/petroleum ether); IR (KEr) 'Urn ax 1801.4 and 1755.1 (C=O) cm-1; IH NMR 
(CDCI3) 8 1.64-1.78 (m, IH, HCHPh), 1.89-1.98 (m, IH, HCHPh), 2.55-2.67 (m, IH, 
CHHCHCH2), 2.76-2.91 (m, 3H, CHHCHCH2 and C(O)CH2), 3.44 (q, 1H, J = 8.8, 
18.1Hz, CHC(O)) 7.19-7.36 (m, 5H, ArH); 13C NMR (CDCI3) 821.2,29.9,36.1,42.3, 
127.1,128.8, 129.1, 137.2, 166.5, 168.7. 
3-Phenylglutaric anhydride (2.43c) 
A mixture of 3-phenylglutaric acid (764mg, 4rnrnol) and AC20 (1.900rnL, 2.056g, 
20mmol, 5 equiv.) was refluxed for 20.75h. The solvent was removed to give a brown 
mass. This was dissolved in toluene, activated carbon added and the mixture filtered 
with celite. The celite cake was washed with a small quantity of toluene and the filtrate 
and washings combined and evaporated to yield a pale yellow solid (629mg, 89%): mp 
101-3 DC: IH NMR (CDCI3) 82.87 (dd, 2H, J = 11.2, 17.6Hz, CH2C(O)), 3.11 (dd, 2H, 
J = 4.4, 17.6Hz, CH2C(O)), 3.38-3.48 (m, IH, CH), 7.18-7.43 (m, 5H, ArH); 13C NMR 
(CDCI3) 8 37.1, 41.0, 126.2, 128.1, 129.3,139.1,165.9. 
3,3-Cyclohexylglutaric anhydride (2.43d)253 
A mixture of 3,3-cyclohexylglutaric acid 2.44d (848mg, 4mmol) and AC20 
(0.793mL 858mg, 8mmol, 2equiv.) was refluxed for 2h 20min. The solvent was 
removed as per the general method to give a brown mass that was distilled at reduced 
pressure to give 2.43d as a white solid (691mg, (91 %): mp 68-9 DC (lit. 253 mp 73 DC 
(benzene/petroleum ether): bp 150 DC/5mrnHg (lit. 253 bp 213 DC/36mrnHg); IR (KEr) 
'Urnax 1807.2 and 1755.1 (C=O) cm-I; IH NMR (CDCI3) 81.43-1.53 (m, lOH,5xCH2), 
2.66 (s, 4H, 2xCH2C(O)); 13C NMR (CDCI3) 8 21.3,25.2,32.2,35.9,41.5, 166.3. 
3,3-Dimethylglutaric anhydride (2.43e) 
3,3-Dimethyl glutaric acid 2.44e (14.945g, 0.093mol) and AC20 (55rnL, 59.51Og, 
O.583mol, 6.3 equiv.) were placed in a 2-necked round bottom flask set up for 
downward distillation with a thermometer dipping into the reaction mixture. This was 
heated, with distillation of AcOH and AC20, until the temperature reached 180 DC. The 
resultant dark brown mass was allowed to cool to rt while stirring and then dissolved in 
the minimum amount of boiling toluene. Activated carbon was added, celite added and 
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the mixture filtered. On cooling to rt a white solid crystallised from the filtrate. This 
was reheated then recooled and petroleum ether was added upon which 2.44e 
precipitated as a white solid which was isolated by suction filtration. Yield 11.703g, 
(89%): mp 122-5 °C (lit.254 mp 122-3°C); IH NMR (CDC13) 81.15 (s, 6H, 2CH3), 2.61 
(s, 4H, 2xCH2C(0»: 13C NMR (CDCI3) 8129.1, 129.1, 130.0, 133.7, 139.8, 167.3. 
THE SYNTHESIS OF SUBSTITUTED N-
BENZYLOXYGLUTARIMIDES 
Method A: From anhydride 
A dispersion of O-benzyloxyamine (1 equiv.) and the respective anhydride (stated 
amount) in toluene or xylenes (stated volume) was refluxed with azeotropic removal of 
H20 for the stated time. The solvent was evaporated to yield either a crude solid or 
more typically a brown residue. Subsequent work up depended on this result. A solid 
was purified by recrystalllisation from the stated solvent system to give the title 
compounds as white solids. A residue was dissolved in the minimum of EtOAc (stated 
volume) and washed with an equal volume of 10% aqueous NaHC03 and H20. The 
organic phase was worked up in the usual manner to give the title compounds as solids. 
These were purified, if required, by recrystallisation from the stated solvent system. 
:Method B: From acid 
O-Benzyloxyamine (1.2 equiv.), Et3NH (5 equiv.) and HOBt (2.2 equiv.) were added 
in successsion to a solution of acid (stated amount) in CH2Ch (stated volume) stirring 
in N2 at 0-5 °C (ice-salt bath). Stirring W&'I) continued for ten min and then EDAC (2.08 
equiv.) was added. The resulting solution was allowed to come to rt while stirring 
overnight. The reaction solution was washed with H20, 10% HCI, and saturated 
aqueous NaHC03. Work up in the usual manner gave the desired product as a crude 
oily solid. This was purified by flash chromatography eluting with the stated solvent 
system. 
3-Benzyl-N-benzyloxyglutarimide (2.49b) 
By Method A: a dispersion of 2-benzylglutaric anhydride 2.43b (418mg, 2mmol) 
and O-benzyloxyamine (263mg, 2.lmmol, 1.05 equiv.) in xylenes (5roL) was heated 
until dissolution and refluxed with azeotropic removal of H20 overnight. Work-up gave 
a white solid (436mg, 69%): mp 91-4 °C (toluene/petroleum ether); IH NMR (CDCI3) 
8 1.51-1.59 (m, IH, HCHPh), 1.65-1.85 (m, IH, HCHPh), 2,45-2.57 (m, IH, 
CHHCHCH2), 2.64-2.81 (m, CHHCHCH2 and CH2C(O», 3,40 (dd, IH, J = 3.5, 
13.0Hz, CHC(O», 5.01 (s, 2H, OCfuPh), 7.16-7.52 (m, lOH, ArH); 13C NMR (CDCh) 
() 21.5,32.1,36.1,44.6, 77.95, 126.8, 128.3, 128.6, 129.1, 129.1, 130.0, 133.8, 137.9, 
168.1,170.3; HRMS (+CI, MH+) calcd. 310.14440, found 310.1443. 
4-Phenyl-N -benzyloxyglutarimide (2.49c) 
By Method A: a dispersion of 3-phenylglutaric anhydride 2.43c (286mg, l.5mrnol) 
and O-benzyloxyarnine (196mg, 1.6mmol, 1.07 equiv.) in toluene (l1rnl) refluxed with 
azeotropic removal of H20 for 19h. Work up gave 2.49c as a white solid (425mg, 
96%): mp 164-7 °C; IR 'Umax (KEr) 1743.5 and 1691.5 (C=O) em-I; IH NMR (CDC13) 
() 2.83-3.05 (m, 4H, 2xCH2C(O», 3.27-3.37 (m, IH, CH), 5.03 (s, 2H, OCH2Ph), 7.18 
(d, 2H, J = 8.3Hz, ArH), 7.26-7.40 (m, 6H, ArH), 7.51-7.55 (m, 2H, ArH); 13C NMR 
(CDC13) () 34.5, 40.2, 78.2, 126.2, 127.7, 128.4, 129.1, 129.1, 130.0, 133.7, 139.8, 
167.3; HRMS (+EI, mlz) 190.1 (M - OCH2Ph, 11), calcd. 289.1315, found 289.1314. 
4,4-Cyclohexyl-N-benzyloxyglutarimide (2.49d) 
A dispersion of 3,3-cyclohexylglutaric anhydride 2.43d (478g, 2.6mmol) and 0-
benzyloxyamine (338mg, 2.7mmol) in xylene (6ruL) was refluxed with azeotropic 
removal of H20 overnight. The solvent was evaporated in vacuo to give a white solid 
which was dissolved in the minimum amount of EtOAc and washed with 10% aqueous 
NaHC03. Work-up in the usual manner gave 2.49d as a purified white solid (618mg, 
83%): IR (KEr) 1741.6 and 1705.0 (C=O) em-I; IH NMR (CDCL3) () 1.33-1.58 (m, 
lOH, 5xCH2), 2.61 (s, 2H, CH2C(O», 5.03 (s, 2H, OCH2), 7.35-7.37 (m, 3H, ArH), 
7.51-7.54 (m, 2H, ArH); 13C NMR (CDCL3) () 21.4,25.5,32.2,35.8,44.4,78.0,128.4, 
129.1, 129.9,170.1; HRMS (+EI, M+) calcd. 287.1522, found 287.1522. 
4,4-Dimethyl-N -benzyloxyglutarimide (2.4ge) 
By Method A: a dispersion of 3,3-dimethyl glutaric anhydride 2.43e (3 oOrng , 
2.l1mmol) and O-benzyloxyamine (265mg, 2.15mmol, 1.02 equiv.) in xylene (4.3mL) 
was heated until dissolution and then refluxed with removal of H20 for 15h. The 
resultant solution was allowed to cool to rt and then refridgerated overnight during 
which 2.4ge crystallised as a white solid. This was isolated by withdrawing the solvent 
with a pasteur pipette. Yield (375mg, 72%): mp 112-4 oC; IR (KEr) 'Umax 1733.9 and 
1693.4 (C=O) em-I; 1 H NMR (CDCh) () 1.07 (s, 6H, 2xCfu), 2.56 (t, 2H, 
2xCH2C(O», 5.02 (s, 2H, OCH2Ph), 7.36-7.38 (m, 3H, ArH), 7.52-7.53 (m, 2H, ArH); 
13C NMR (CDCI3) () 27.5,29.4,46.7, 78.0, 128.4, 129.1, 129.9, 133.8, 167.6; HRMS 
(FAB, MH+) calcd. 248.1287, found 248.1287. Anal. Calcd. for CI4H17N03: C, 68.02; 
H, 6.88; N, 5.67. Found: C, 67.72; H, 6.96; N, 5.63. 
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By Method B: with O-Benzyloxyarnine (43mg, 0.35mmol, 1.2 equiv.) in CH2Cl2 
(2mL), Et3N (202~L, 147mg, 1.45mmol, 5 equiv.) and HOBt (88mg, 0.65mol, 2.2 
equiv.) were added in successsion to a solution of 3, 3-dimethylglutaric acid (46mg, 
0.29mmol) in CH2Ch (4mL). EDAC (115mg, 0.60mmol, 2.08 equiv.) was added. Work 
up gave an oily white solid which was purified by flash Si02 chromatography eluting 
with 1:4 EtOAc/petroleum ether to give 2.4ge as a white solid (10 mg, 13%). Physical 
data as above. 
THE SYNTHESIS OF SUBSTITUTED N -HYDROXY 
GLUTARIMIDES 
Method A: From 3-substitutedN -benzyloxysuccinimide 
A solution of the respective substituted N-(benzyloxy)succinimide (stated amount) in 
the stated solvent (stated volume) was hydrogenated in the presence of the indicated 
palladium catalyst (stated amount) for the stated time. The reaction mixture was filtered 
through celite and Na2S04 and this cake washed with a small quantity of solvent. The 
filtrate and washings were combined and evaporated to give the title N-
hydroxysucccinimides. These were purified, if required, by either chromatagraphy or 
recrystallisation using the stated solvent system. 
Method B: From 2-substituted succinic acid anhydride 
The respective anhydride (stated amount) was added to a solution of hydroxylamine 
hydrochloride (1.2 equiv.) and K2C03 (0.6-1equiv.) in distilled H20 (stated volume). 
This mixture was refluxed for the stated time. The hot solution was acidified (pH= 1, 
Universal Indicator Paper) with 10% or conc. HCI, allowed to cool to rt, and then 
extracted with EtOAc. The combined extracts were worked up in the usual manner to 
give the titleN-hydroxysuccinimide. 
3-Phenyl-N-hydroxyglutarimide (2.42a) 
By Method B: 2-phenylglutaric anhydride 2.43a (500mg, 2.6mmol) was added to a 
solution of hydroxylamine hydrochloride (220mg, 3.2mmol, 1.2 equiv.) and K2C03 
(218mg, 1.6mmol, 0.6 equiv.) in distilled H20 (7.5mL). This mixture was refluxed for 
5h. Acidification with 10% HCI and subsequent work up gave a pale yellow oil 
(420mg, 77%). This oil was heated to 160°C for lh at ca. 2mmHg. Decolourisation of 
the resultant oil with charcoal gave 2.42a as a pale yellow oil (218mg, 56%): IR 
(CHCI3/NaCl) 'Umax 1768.6 and 1643.2 (C=O) cm- I ; IH NMR (DMSO-d6) (52.27 (m, 
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2H, CH2C(O», 2.86 (m, 2H, CHCfu), 4.07 (dd, 1H, J = 4.9, 11.2Hz, CH), 7.29 (m, 5H, 
ArH), 10.35 (bs, 1H, NOH); 13C NMR (CDCl3) 8 24.8,31.5,48.3, 126.9, 127.6, 128.3, 
138.9,168.6,170.0; HRMS (+EI, M+) caIed. 205.0739, found 205.0739. 
3.Benzyl·N·hydroxyglutarimide (2.42b) 
By Method A: a solution of 3-benzyl-N-benzyloxyglutarirnide 2.49b (l98mg, 
0.64mmol) in THF (5mL) was hydrogenated in the presence of 10% palladium on 
carbon (66mg) for 14h. Work-up gave 2.42b as a white solid (l16mg, 83%); mp 62-5 
oC; IR (CDC13) 'Umax 3350.1 (OH) , 1739.7 and 1681.8 (C=O) cm- I ; IH NMR (CDC13) 
8 1.61-1.75 (m, 1H, HCHPh), 1.83-1.93 (m, 1H, HCHPh) , 2.55-2.67 (m, 1H, 
CHHCHCH2), 2.72-2.94 (m, 3H, CHHCHCH2 and C(O)CH2), 3.45 (dd, IH, J = 2.9, 
14.2Hz, CHC(O»), 7.18-7.34 (m, 5H, ArID; 13C NMR (CDCl3) 8 21.5,31.0,36.0,43.6, 
126.9, 128.7, 129.1, 137.6, 166.9, 169.2; HRMS (+EI) caIed. 219.0896, found 
219.0895. 
4· Phenyl-N .hydroxyglutarimide (2.42c) 
By Method A: a solution of 4-phenyl-N-benzyloxyglutarimide 2.49c (347mg, 
1.2mmol) in THF (6mL) was hydrogenated in the presence of 10% palladium on carbon 
for 17.25h. Work-up gave 2.42c as a brown residue (221mg, 90%); 1 H NMR 
(CDC13IDMSO-d6) 82.90-3.06 (m, 4H, 2xCH2), 3.37-3.49 (m, 1H, CH), 7.23-7.39 (m 
5H, ArH) , 10.03 (bs, 1H, NOH):13C NMR (CDC13IDMSO-d6) 8 33.9, 39.2, 125.8, 
126.9,128.4, 139.8, 167.2. 
4,4·Cyclohexyl-N·hydroxyglutarimide (2.42d) 
By Method A: a solution of 4, 4-Cyclohexyl-N-(benzyloxy)glutarimide 2.49d 
(618mg, 2.2mmol) in THF (5mL) was hydrogenated for 72h in the presence of 10% 
palladium on carbon (206mg). Work-up gave 2.42d as a white solid (371mg, 86%) 
which was purified by crystallisation from toluene/petroleum ether to give a white solid 
(305mg, 82%): mp 99-102 oC; IR (CDCI3) 'Umax 3352.1 (OH) , 1735.8 and 1678 (C=O) 
cm- I ; l3C NMR (CDCI3) 8 21.3,25.5, 35.9,43.4, 167.2: HRMS (+EI, M+) calcd. 
197.1053, found 197.1052. 
4,4·Dimethyl-N .hydroxyglutarimide (2.42e) 
By Method A: a solution of 3,3-dimethyl-N-(benzyloxy)glutarimide 2.4ge (95mg, 
0.38mmol) in THF (5mL) was hydrogenated in the presence of 10% Pd/C (43mg) for 
7h. Work up as described gave a brown oil which on standing at rt crystallised. 
Recrystallisation from toluene/petroleum ether gave a purified white solid (35mg, 
59%): mp 56-9 °C; IR (KBr) umax 3496.7 (OH), 1734.9 and 1676.0 (C=O) cm- I; IH 
NMR (CDCb) 0 1.17 (s, 6H, 2xCH3), 2.67 (s, 4H, 2xCH2C(0»; l3C NMR (CDCI3) 0 
27.7,29,9,45.6, 166.5; HRMS (+EI, M+) calcd. 157.0739, found 157.0739. 
THE SYNTHESIS OF SUBSTITUTED N-[(ACYL AND 
ALKYL) OXY] GLUTARIMIDES 
3-Phenyl-N-[(methanesulfonyl)oxy]glutarimide (2.Ia) 
Methane sulfonyl chloride (34mL, 50mg, 0.44mmol, 1.5 equiv.) was added to an ice-
cooled solution of 3-phenyl-N-hydroxyglutarimide 2.42a (60mg, 0.29mmol) and i-
PrNEt (55IlL, 41mg, 0.32mmol) in CH2Cl2 (2mL) stirring under N2. The resulting 
solution was stirrd at 0-5 °C for 20min followed by 30min at rt. Work-up gave 2.Ia as a 
pale yellow oil (25mg, 30%): IR (CHCblNaCI) umax 1793.7 and 1724.2 (C=O), 1375.2 
and 1215.1 (-S02- ) cm- I ; IH NMR (CDCI3) 02.28-2.34 (m, 2H, CHCH2), 2.87-2.93 
(m, 2H, CH2CH2), 3.43 (s, 3H, OS02CH3), 4.05 (dd, IH, J = 5.3, 9.2Hz, CH), 7.23-
7.40 (m, 5H, ArH); l3C NMR (CDCb) 25.0, 31.5, 40.7, 49.5, 128.0, 128.1, 129.0, 
129.1,166.6,168.3; HRMS (+EI) calcd. 283.0515, found 283.0514. 
3-Phenyl-N-[ (acetyl)oxy ]glutarimide (2.Ib) 
Acetyl chloride (52mL, 57mg, 0.73mmol, 1.5 equiv.) was added to an ice-cooled 
solution of 3-phenyl-N-hydroxyglutarimide 2.42a (lOOmg, 0.49mmol) and i-PrNEt 
(94IlL, 70mg, 0.54mmol, 1. 1 equiv.). The resulting solution was stined for 20min under 
N2 at 0-5 oC and allowed to warm to rt while stirring for a further 0.5h. Work-up gave 
2.Ib as a pale yellow oil (34mg, 28% yield): IH NMR (CDCb) 02.30 (m, 5H, CHCH2 
and CH3), 2.85 (m, 2H, CH2C(0», 4.06 (m, IH, CH), 7.32 (m, 5H, ArH); l3C NMR 
(CDCb) 0 25.0, 31.5, 40.7, 49.5, 128.0, 128.1, 129.1, 136.4, 166.6, 168.3; IR 
(CHCblNaCl) umax 1813.3 and 1751.2 (C=O) cm- 1; HRMS (+EI, M+) calcd. 
247.0845, found 247.0845. 
3-Benzyl-N -[ (methanesulfonyl)oxy ]glutarimide (2.Ic) 
Methane sulfonyl chloride (39.3IlL, 58mg, 0.51mmol, 1.5 equiv.) was added to an 
ice-cooled solution of 3-benzyl-N-hydroxyglutarimide 2.42b (74mg, 0.34mmol) and 
Et3N (51.8!lL, 38mg, 0.37mmol) in CH2Cb (5mL) stitTing under N2. Stirred at 0-5 °C 
for 0.5h and then at rt overnight. Work-up gave a brown coloured residue which was 
purified by flash Si02 chromatography to give 2.Ic as a white solid (79mg, 79%): mp 
86-7 °C; IR (CDCI3) 'Utnax 1762.8 and 1720.0 (C=O), 1388.7 and 1247.9 (-S02-) cm-I; 
198 
IH NMR (CDCI3) 0 1.67-1.81 (m, IH, HCHPh), 1.89-1.98 (m, IH, HCHPh), 2.63-3.01 
(m, 4H, CHCH2 and CH2C(0», 3.42 (s, 3H, ArCH3), 3.47 (dd, IH, J = 4.2, 14.0 Hz, 
CH), 7.19-7.36 (m, 5H, ArH); l3C NMR (CDCb) 021.2, 32.0, 35.9,40.7,44.8, 127.0, 
128.8,129.1,137.4,166.7,169.1; HRMS (+EI, M+) calcd. 297.0671, found 297.0671. 
AnaL Calcd. for C13HlSNOSS: C, 52.51; H, 5.09; N, 4.71; S, 10.76. Found: C, 52.51; 
H, 5.30; N, 4.68; S, 10.71. 
4-Phenyl-N -[ (methanesulfonyl)oxy ]glutarimide (2.ld) 
Methane sulfonylchloride (l3.2mL, 20mg, O.l7mmol) was added to a solution of 4-
phenyl-N-hydroxyglutarimide 2.42c (35mg, 0.17mmol) and pyridine (27.7mL, 27mg, 
0.34mmol, 2 equiv.) in CH2C12 (3mL) and the resulting solution stirred overnight under 
N2 at rt. The reaction solution was washed with H20, 10% aqueous HCl and saturated 
aqueous NaHC03. The organic phase was worked-up in the normal manner to give 2.ld 
as a brown solid which was purified by trituration with ice-cold petroleum ether. Yield 
46mg (94%): mp 101-3 DC; IR (CDCI3) 1759.0 and 1720.0 (C=O), 1379.0 and 1226.6 (-
S02-) em-I; IH NMR (CDCb) 0 2.99-3.18 (m, 4H, 2xCH2C(0», 3.43 (s, 3H, 
OS02CH3), 3.46 -3.56 (lH, m, CH), 7.22-7.42 (m, 5H, ArH); l3C NMR 0 34.2, 40.1, 
40.7, 126.3, 128.0, 129.2,139.2, 166.0; HRMS (+EI) calcd. 283.0515, found 283.0515. 
4,4-Cyclohexyl-N-[(methanesulfonyl)oxy]glutarimide (2.le) 
Methane sulfonyl chloride (41.8IlL, 62mg, 0.54mmol, 1.5 equiv.) was added to an 
ice-cooled solution of 4,4-cyc1ohexyl-N-hydroxyglutarimide 2.42d (70mg, 0.36mmol) 
and Et3NH (55.2J.1L, 40mg, 0.40mmol, 1.1 equiv.) in CH2Cl2 (3mL). Stirred at 0-5 DC 
for 20min then at rt overnight. Brown residue obtained on work up which was purified 
by flash chromatography eluting with 2:3 EtOAc/petroleum ether to give 2.le as a 
white solid (5Img, 52%): mp 80-81 DC; IR (CDCl]) 1)max 1759.0 and 1724.2 (C=O) 
cm-1; IH NMR (CDCl]) 0 1.50 (bs, 10H, 5CH2), 2.76 (s, 4H, 2CfuC(0», 3.42 (s, 3H, 
CH3); 13C NMR (CDCI3) 021.4,25.4,32.5,35.7,40.7,44.2, 166.3; HRMS (+EI, M+) 
ca1cd. 275.0828, found 275.0828. Anal. Calcd for Cl1H17NOSS: C, 47.99; H, 6.23; N, 
5.09; S, 11.62. Found: C, 48.12; H, 6.31; N, 5.10; S, 11.71. 
4,4-Dimethyl-N -[ (methanesulfonyl)oxy ]glutarimide (2.1t) 
Methane sulfonyl chloride (49.5mL, 73mg, 0.64mmol) was added to a solution of 
4,4-dimethyl-N -hydroxyglutarimide 2.42e (lOOmg, 0.64mmol) and pyridine (104~, 
101mg, 1.28mmol, 2 equiv.) in toluene (4mL) which had been stirring at 40 DC under 
N2. The temperature was elevated to 50°C and the reaction solution stirred for 3d at 
this temperature. The reactio solution was evaporated to give a brownresidue that was 
dissolved in the minimum anount of EtOAc and washed with H20, 10% aqueous HC1, 
and saturated aqueous N aHC03 and the organic phase worked up in the normal manner 
to give 2.1f as a white solid (quantative yield): mp 86-88 DC; IR (CDCh) umax 1764.7 
and 1724.2 (C=O), 1386.7 and 1232.4 (-S02-) em-I; IH NMR (CDC13) d 1.17 (s, 6H, 
2xCH3), 2.70 (s, 4H, 2xCfuC(O)), 3.42 (s, 3H, OS02CH3); 13C NMR (CDCl3) d 27.4, 
29.7,40.6,46.4,166.3; HRMS (+EI) calcd. 235.0515, found 235.0515. 
6.3 CHAPTER 4 EXPERIMENTAL 
(S)-phenylalaninol (4.19) 
Method A: LiALH4 reduction of (S)·Phenylalanine 
To a suspension of LiAIH4 (1.723g, 0.045mol, 1.5 equiv.) in THF (100mL) (L)-
phenylalanine (5.lg, 0.03mol) was added portionwise and the resulting mixture refluxed 
gently for 6h. The reaction mixture was allowed to cool to rt after the which IN 
aqueous NaOH (5mL) was added and the reaction mixture refluxed for a further 0.5h. 
The reaction mixture was again allowed to cool to rt and diluted with 0.5N NaOH (ca 
100mL). The aqueous and organic layers were then left to separate but due to an 
emulsion this mixture was filtered through celite. The aqueous and organic phases of 
the filtrate were then separated, the aqueous phase extracted with EtOAc and the 
organic extracts combined and worked up in the usual manner to give an oily white 
solid (454mg, 10%): IH NMR (CDCI3) 8 1.89 (bs, IH, NH), 2.53 (dd, IH, J = 8.8, 
13.5Hz, HCHPh), 2.79 (dd, IH, J = 5.0, 13.5Hz, HCHPh), 3.09-3.17 (m, IH, CH), 3.38 
(dd, IH, J = 7.0, 1O.5Hz, HCHOH), 3.64 (dd, IH, J = 3.8, lO.5Hz, HCHOH), 7.18-7.31 
(m, 5H, ArH). 
Method B: Borane reduction of (S)-Phenylalanine 
Freshly distilled BF3.0Et (0.76OmL, 877mg, 6.2mmol) was added over a period of 
40 min to a white slurry of (S)-Phenylalanine (l.OOlg, 6.1mmol) in THF (3.2mL) 
stirring in N2 at rt. The mixture was heated uptil reflux. Reflux was continued for 2h, 
resulting in a colourless, homogeneous solution. BH3.SMe2 (0.670mL, 529mg, 7mmol, 
1.15 equiv.) was then added via a dropping funnel to the refluxing solution followed by 
a THF (I mL) washing of the funnel over a period of 2.7 5h and reflux was continued for 
4.5h. The solution was allowed to cool to rt while stirring for 12.25h. The reaction 
solution was again heated to reflux and this was maintained for 0.5h after which 
additional BH3.SMe2 (0.2mL, 158mg, 2.1mmol) was added dropwise and the resulting 
solution refluxed for a further 4.25h. THF (lmL) and 5N aqueous NaoH (4mL) were 
added in succession and the resulting mixture consisiting of an upper white phase and a 
clear lower phase was refluxed overnight. The reaction mixture was allowed to coo] to 
iT and then filtered. The residual solids were washed with a 1:1 TIIFIH20 (2mL) rinsing 
of the reaction flask and THF (2mL). The filtrate and washings were combined and 
evaporated to give a white slurry which was extracted with CH2Ch. Work up in the 
usual manner gave 4.19 as a white solid (603mg, 65%). More product (232mg, 25%) 
was obtained on a second extraction procedure. Total yield 835mg (91 %): mp 90-2 °C 
(EtOAc, fine white needles) (lit. 240 mp 88.5-91 OC); IH NMR (CDCI3) 82.16 (bs, IH, 
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NH), 2.51 (dd, 1H, J = 8.8, 13.6Hz, HCHPh), 2.79 (dd, 1H, J = 5.2, 13.5Hz, HCHPh), 
3.07-3.15 (m, 1H, CPh), 3.07-3.15 (m, IH, CH), 3.39 (dd, IH, J = 7.1, 10.Hz, 
HCHOH), 3.63 (dd, IH, J 3.9, 1O.7Hz, HCHOH), 7.18-7.34 (m, 5H, ArH); l3C NMR 
(CDC13) () 40.8, 54.2, 66.3, 126.4, 128.6, 129.2, 138.6; HRMS (+EI, M+) 149.0 (57), 
120.1 (47),103.1 (10),91.1 (20),77.0 (8), 60.1 (M - PhCH2, 100). 
(S)-4-Benzyl-2-oxazolidinone (4.17)240 
A mixture of (S)-phenylalaninol 4.19 (407mg, 3mmol), K2C03 (38mg, 0.3rnmol, 0.1 
equiv.) and diethyl carbonate (0.679mL, 662mg, 6mmol, 2 equiv.) was heated in an oil 
bath set at 136°C for 4h. The resuling mixture consisting of a white solid suspended in 
a yellow solution was allowed to cool to rt and then diluted with CH2Ch and washed 
with H20. The organic phase was worked up in the usual manner to give 4.17 as a 
white solid (468mg, 98%): mp 85-7 °C (EtOAc/petroleum ether, white plates) (lit.240 
mp 84.5-86.5 DC); IH NMR (CDCI3) () 2.81-2.94 (m, 2H, CH2Ph), 4.05-4.16 (m, 2H, 
HCHO and CH), 4.39-4.46 (m, IH, HCHO), 6.04 (bs, 1H, NH), 7.15-7.19 (m, 2H, 
ArH), 7.24-7.36 (m, 3H, ArH); l3C NMR (CDCh) () 41.3, 53.7, 69.5, 127.1, 128.9, 
129.0, 135.9,159.6: HRMS (+EI, M+) ca1cd. 177.0790, found 177.0790. 
N-3-Phenylpropionyl-(S)-4-benzyl-2-oxazolidinone (4.15)239a 
n-BuLi (l.3M in hexane) (14.9mL, 19mmol, 1.05 equiv.) was added dropwise to a 
solution of (S)-4-benzyl-2-oxazolidinone 4.17 (3.245g, 18mmol) in THF (l3mL) 
stirring in N2 at -78°C. The resulting dark red solution was stirred for 1h after which a 
solution of 3-phenylpropionyl chloride (3.360g, 20mmol, 1.11 equiv.) in THF (6mL) 
was added slowly dropwise. The resulting amber reaction solution was allowed to corne 
to rt while stirring was continued overnight. Brine (20mL) was added and the solvent 
evaporated to give an immiscible mixture consisting of a brown oily residue and 
aqueous layer. This was extracted with CH2C12 to give a brown residue that was 
purified by flash chromatography eluting with 1:4 EtOAc/petroleum ether to give 4.15 
as a white solid (4.623g, 83%): mp 105-6 °C (lit.239a mp 92-5 DC); IR (CDC13) 'Umax 
1782.1 and 1701.1 (C=O) em-I; IH NMR () 2.75 (dd, 1H, J = 9.5, 13.4Hz, CHHCHPh), 
2.95-3.10 (m, 2H, CHHCHPh and CH2HCHPh), 3.19-3.38 (m, 3H, CH2HCHPh and 
CH2C(O»), 4.13-4.21 (m, 2H, CH20), 4.62-4.70 (m, 1H, NCH), 7.16-7.35 (m, lOH, 
ArH); l3C NMR (CDC13) () 30.2, 37.1,37.8, 55.1, 66.2, 126.2, 127.3, 128.4, 128.6, 
128.9, 129.4, 135.2, 140.4, 153.4, 172.4; HRMS (+EI, M+) ca1cd. 309.1366, found 
309.1365. 
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N -[3-Ethoxycarbonyl-(2R)-benzyl-1-oxopropylJ-(S)-4-benzyl-2-oxazolidinone 
(4.21) 
A 1.8M solution of LDA in THFlhexanes (0. 64mL, 1. 15mmol, 1.26 equiv.) was 
added slowly dropwise to a solution of (S)-4-benzyl-2-oxazolidinone (280mg, 
0.91mmol) in THF (5mL) stirring under a N2 atmosphere at -78°C (dry ice-acetone 
bath). The resulting solution was stirred for Ih at -78°C after which a solution of ethyl 
bromo acetate (2l2~L, 319mg, 1.91mmol) in THF (ImL) was added slowly dropwise. 
The bath was packed with dry ice and the temperature allowed to come to rt while 
stirring was continued overnight. Brine (6mL) was added and the bulk of the THF 
evaporated to give a white slurry which was extracted with EtOAc. Work up of the 
extract in the usual manner gave a brown residue which was purified by flash Si02 
chromatography eluting with 1:4 EtOAc/petroleum ether to give 4.21 as a brown 
residue (177mg, 49%): mp 60-2 °C (EtOAc/petroleum ether); IH NMR (CDCh) 02.45 
(dd, IH, J = 4.2, 17.2Hz, NCHHCHPh), 2.62-2.77 (m, 2H, NCHHCHPh and 
C(O)CHHCHPh), 2.89-3.06 (m, 2H, C(O)CHHCHPh and HCHC(O)), 3.32 (dd, lH, J = 
3.2, 13.4Hz, HCHC(O)), 3.94 (t, IH, J = 8.3Hz, HCHO), 4.05-4.12 (m, 3H, HCHO and 
OCH2CH3), 4.49-4.60 (m, 2H, NCH and C(O)CH), 713-7.37 (m, 10H, ArH); l3C NMR 
(CDCI3) 0 14.1, 35.5, 37.5, 38.3, 41.0, 55.6, 60.7, 65.9, 126.8, 127.2, 128.5, 128.9, 
129.2, 129.5, 135.6, 137.8, 152.9, 171.8, 175.1; HRMS (+EI) calcd. 395.1734, found. 
395.1733. 
N -[3-tert-Butoxycarbonyl-(2R)-benzyl-1-oxopropylJ-(S) -( 4S) -benzyl-2-
oxazolidinone (4.23) 
LDA 1.8 M solution in THFlhexanes (2.4mL, 4.3mmol, 1.2 equiv.) was slowly 
added dropwise to a solution of 4-(S)-benzyl-2-oxazolidinone 4.15 (1.116g, 3.6mmol) 
in THF (lOmL) stirring in N2 at -78°C (dry ice-acetone bath). The resulting solution 
was stirred for Ih after which a solution of tert-butyl bromo acetate (l.458mL, 1.761g, 
9mmol, 2.5 equiv.) in THF (2mL) was added slowly dropwise. The bath was packed 
with dry ice and the temperature allowed to come to rt while stirring was continued 
overnight. Brine (l2mL) was added and the bulk of the THF evaporated to give an 
immiscible solution consisting of a brown residue and an aqueous phase. This was 
extracted with EtOAc (30mL) then washed with brine (30mL) and worked up in the 
usual manner to give a brown residue (94mg). Purification by flash Si02 
chromatography eluting with 1:4 EtOAclpetroleum ether gave 4.23 as a pale yellow 
solid (675mg, 44%): mp 105-7 °C (EtOAc/petroleum ether, crystals); IH NMR 
(CDCb) 0 1.40 (s, 9H, O(CH3h), 2.37 (dd, 1H, J = 4.2, 16.8Hz, NHCHHCHPh), 2.64 
(dd, 1H, J = 9.0, 12.9Hz, NHCHHCHPh), 2.73 (dd, 1H, J = 10.0, 13.4Hz, 
C(O)CHHCHPh), 2.84 (dd, lH, J = 10.7, 17.lHz, C(O)CHHCHPh), 3.01 (dd, J = 6.3, 
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12.7Hz, CHHCHC(O», 3.30 (dd, IH, J 3.4, 13.7Hz, CHHCHC(O», 3.92 (t, IH, J = 
8.3Hz, HCHO), 4.07 (dd, IH, J = 2.4, 8.8Hz, HCHO), 4.44-4.57 (m, 2H, NCH and 
CHC(O», 7.13-7.37 (m, lOH, ArH); 13c NMR 15 (CDCI3) 28.0,36.8,37.6,38.3,41.2, 
55.6, 65.9, 80.8, 126.7, 127.2, 128.4, 128.9, 129.3, 129.5, 135.7, 138.0, 152.9, 171.2, 
175.4; HRMS (+EI) calcd. 423.2047 found. 423.2046. 
(+ )-(R)-Ethyl-3-Benzylsuccinate (4.25) 
30% H202 (36f.LL, OAmmol, 4 equiv.) was added dropwise to a solution of (4S)-(-)-4-
benzyl-N-[(2R)-benzy 1-3-( ethoxycarbony l)propiony 1]-2-oxazolidinone 4.21 (35mg, 
0.09mmol) in 4:1 THFIH20 (4mL). LiOH.H20 (6mg, 0.14mmol, 1.6 equiv.) was added 
and the reslting mixture was stirred for Ih after the LiOH.H20 had dissolved. Aqueous 
1.345M Na2S03 (265f.LL, O.4mmol, 4 equiv.) was added and the bulk of the THF 
evaporated to give a mixture consisting of a brown residue and an aqueous phase. This 
mixture was extracted with CH2Cl2 to remove the chiral oxazolidinone auxiliary 4.17 
and the aqueous layer was acidified with 2N HCI and then extracted with EtOAc. The 
EtOAc extracts were worked up in the usual manner to give (R)-ethyl-3-benzylsuccinate 
4.25 as a brown residue (17mg, 81%): [a]24D = 20.30 (c = 1.6, EtOAc); IR 'Umax 
(CDCl3) 1728.1 (C=O) cm- I; IH NMR (CDCI3) 15 1.22 (t, 3, J = 7.z, OCH2CH3), 2040 
(dd, IH, J 4.4, 17. 1Hz, HCHPh), 2.59-2.82 (m, 2H, HCHPh and HCHC(O», 3.10-
3.19 (m, 2H, HCHC(O) and CHC(O», 4.10 (q, 2H, J = 6.8, 7.3Hz, OCH2CH3), 7.17-
7.33 (m, 5H, ArH); l3c NMR (CDC13) 15 14.0, 34.7, 37.3,42.8, 60.8, 126.8, 128.9, 
129.0, 137.9, 171.7, 180.2; HRMS (+EI) ca1cd. 236.1049, found 236.1049. 
(-)-(R)-3-Benzyl-N-benzyloxysuccinimide «R)-2.25) 
A solution of (R)-ethyl 2-benzylsuccinate 4.25 (l40mg, 0.59mmol) in CH2Cl2 (7mL) 
was added to a solution of 0 -benzyloxyamine hydrochloride (94mg, 0.59mmol) and 
Et3N (104f.LL, 76mg, 0.75mmol, 1.27 equiv.) in CH2Cl2 (4mL) which had been stirring 
for 0.25h under N2 at 0-5 °c (ice-salt bath). HOBt (80mg, 0.59mmol) and then DCC 
(l23mg, 0.59mmol) were added successively and the resulting solution stirred 
overnight while the temperature was allowed to come to rt. The reaction slurry was 
evaporated to give a white solid that was suspended in EtOAc (8mL) and this mixture 
was filtered to remove the DCU byproduct. The reaction flask was rinsed with EtOAC 
(2mL) and this was used to wash the DCU filter cake. The filtrate and the washings 
were combined and evaporated to give a brown residue (294mg) containing a 2: 1 
mixture, by IH NMR, of 3-ethoxycarbonyl-(3R)-benzylpropionyl N-benzyloxy amide 
4.26 and (3R)-benzyl-N-benzyloxysuccinimide (R)-2.25. 
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A solution of this residue (294mg) and p-TsOH.1H20 (57mg, 0.30mmol, 0.5 equiv.) 
in 1,2-DCE (lOmL) was refluxed with azeotropic removal of EtOH for 20h. The solvent 
was evaporated to give a brown residue (0.335g) which was submitted to flash Si02 
chromatography eluting with 1:4 EtOAc/petroleum ether to give (R)-3-benzyl-N-
benzyloxysuccinimide (R)-2.25 as a white solid (lOlmg, overall yield 58%): mp 86-88 
°C; [a]21D = -67.80 (c = 4.5, EtOAc); IH NMR (CDC13) 0 2.28 (dd, 1H, ] = 4.4, 
18.1Hz, HCHPh), 2.53 (dd, 1H, ] = 8.8, 18.1Hz, HCHPh), 2.70 (dd, 1H, ]= 8.3, 
13.7Hz, HCHC(O», 2.92-3.00 (m, 1H, CHC(O», 3.06 (dd, 1H,] =:: 4.2, 13.4Hz, 
HCHC(O», 7.06 (d, 2H,] = 6.8Hz, ArID, 7.17-7.38 (m, 8H, ArH); 13C NMR 0 30.5, 
36.2,38.3,78.5,127.2,128.5, 128.9,129.1,129.4, 130.0,133.2, 136.3, 170.4, 173.3. 
(-)-(R)-3-Benzyl-N-hydroxysuccinimide «R)-2.26) 
A solution of (-)-(R)-3-benzyl-N -hydroxysuccinimide (R)-2.25 (lOlmg, 0.34mmol) 
in EtOAc (4mL) was hydrogenated in the presence of 10% palladium on carbon (33mg) 
for 7h. The reaction mixture was filtered through celite and Na2S04. This filter cake 
was washed with a small quantity of EtOAc and the filtrate and the washings were 
combined and evaporated to give (R)-2.26 as a white solid (64mg, 91%): mp 142-3 °C; 
[a]24D = -78.00 (c = 3.0, EtOAc); IH NMR (CDC13IDMSO-d6) 0 2.35-2.45 (m, 1H, 
HCHPh), 2.60-2.71 (m, IH, HCHPh), 2.82-2.92 (m, 1H, HCHC(O», 3.08-3.15 (m, 1H, 
HCHC(O», 3.21-3.27 (m, IH, CH), 7.17-7.39 (m, 5H, ArH); 13C NMR 
(CDCI3IDMSO-d6) 030.3,36.0,38.1,126.8,128.6,128.8,136.6,171.1,174.0. 
(R)-3-Benzyl-N-[(trans-styrylsulfonyl)oxy]succinimide «R)-1.41t) 
Trans-Styrylsulfonyl chloride (90mg, 0.44mmol, 1.5 equiv.) was added to a solution 
of (-)-(R)-3-benzyl-N-hydroxysuccinirnide (R)-2.26 (59mg, 0.29mmol) and pyridine 
(47!lL, 46mg, 0.58mmol, 2 equiv.) in CH2Ch (5mL) which had been stirring under N2 
at rt. The resulting solution was then stirred overnight. The reaction solution was then 
diluted with CH2Cb (5mL) and then washed with H20, 10% HCI and saturated 
aqueous NaHC03. The organic phase was worked up in the normal manner to give (R)-
1.4lf as a brown oil (quantative yield): IH NMR (CDCI3) 0 2.53 (dd, 1H, ] = 4.4, 
18.6Hz, HCHPh), 2.78 (dd, 1H, ] =:: 8.5, 183Hz, HCHPh), 2.95 (dd, 1H,] =:: 10.0, 15.4, 
HCHC(O», 3.20-3.30 (m, 2H, HCHC(O) and CHCeO», 6.94 (d, 1H, ] = 15.6Hz, 
C:CHPh), 7.15-7.35 (m, 5H, ArH), 7.68 (d, lH, ] =:: 15.6Hz, HC:C ); HRMS (+EI) 
calcd. 371.0828, found 371.0828. 
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N -3-Carbomethoxy-propionyl-(S)-4-benzyl-2-oxazolidinone (4.32) 
n-BuLi (1.6M in hexane) (540JlL, 0.86mmol, 1.02 equiv.) was added dropwise over 
15min to a solution of (S)-4-benzyl-2-oxazolidinone 4.17 (l50mg, 0.85mmol) in THF 
(3mL) stirring under N2 at -78°C. A solution of 3-carbomethoxy-propionyl chloride 
(140mg, 0.93mmol, 1.1 equiv.) in THF (lmL) was added in one portion and the 
resulting reaction solution was stirred overnight while being allowed to come to rt. The 
reaction solution was quenched with saturated aqueous NI4CI and the resulting mixture 
evaporated and then extracted with CH2Ch. The organic extracts were washed with IN 
aqueous NaOH and then worked up in the normal manner to give a brown residue 
(198mg, 80%); IR (KBr) umax 1782.1, 1735.8 and 1703.0 (C=O) cm- I ; IH NMR 
(CDC13) 0 2.69-2.83 (m, 3H, HCHPh and CH2CH2C02CH3), 3.24-3.31 (m, 3H, 
HCHPh and C(O)CH2,CH2), 3.72 (s, OCH3), 4.16-4.26 (m, 2H, CHCH20), 4.64-4.72 
(m, IH, NCH), 7.20-7.37 (m, 5H, ArH); l3C NMR (CDCb) 0 28.0, 30.8, 37.7, 51.8, 
55.1,66.3,127.3,128.9,129.4,135.1,153.4,171.8,172.8. 
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6.4 CHAPTER 5 EXPERIMENTAL 
4-Nitro-benzyl alcohol (5.10) 
An alkaline solution of NaBH4 was prepared by dissolving NaBH4 (950mg, 
25mmol, 038 equiv.) in 2N NaOH (1.33mL) and H20 (12mL). This alkaline solution 
was added to a yellow solution of 4-nitrobenzaldehyde 5.9 (lOg, 66mmol) in CH30H 
(65mL) at such a rate that the internal reaction temperature was maintained below 25 
DC. The reaction solution turned orange almost immediately and when a sample 
withdTawn from the reaction mixture was treated with 3N H2S04 H2(g) evolved 
indicating the reaction was complete. The reaction mixture was then evaporated to give 
a yellow oil which was diluted with H20 (60mL) and extracted with Et20 (2 x 60mL). 
The Et20 extracts were worked-up in the normal manner to give a pale yellow solid 
(6.628g, 66%): mp 92-4 DC; IH NMR (DMSO-d6) 04.74 (d, 2H, J = 5.4Hz, CfuOH), 
5.65 (t, lH, J = 5.9Hz, CH20H), 7.66 (d, 2H, J = 8.8Hz, ArH), 8.24 (d, 2H, J = 73Hz, 
ArID; l3C NMR (DMSO-d6) 061.9, 123.0, 126.7, 146.1, 150.5. 
4-Hydroxymethyl aniline (5.8) 
A solution of 4-nitro-benzyl alcohol 6.10 (200mg, 1.3mmol) in EtOH (3mL) was 
hydrogenated inthe presence of Pt02 (l5mg) for 28h. The reaction mixture was filtered 
through celite and the filtrate was evaporated to give a brown residue that solidified 
overnight to afford 6.8 as a brown solid (l29mg, 78%): mp 43°C (lit.245a mp 63-4 DC); 
IH NMR (CDCI3) 02.96 (bs, 2H, NH2), 4.54 (s, 2H, CH20H), 6.67 (d, 2H, J = 83Hz), 
7.15 (d, 2H, J = 83Hz); l3C NMR (CDC13) 0 65.1,115.1,128.7,131.1,145.9; HRMS 
(+EI) calcd. 123.0685, found 123.0684. 
4,4-Dimethyl-N -[ (4-hydroxymethyl)phenyl]glutarimide (5.15) 
EDAC (260mg, 1. 36mmol, 2.09 equiv.) was added to a solution of 3,3-
dimethyl glutaric acid 2.44e (104mg, 0.65mmol), 4-hydroxymethylaniline 5.8 (97mg, 
0.78mmol, 1.2 equiv.) and HOBt (193mg, 1.43mmol, 2.2 equiv.) and Et3N (453mL, 
329mg, 3.25mmol, 5 equiv.) in CH2Cb (lOmL) stirring under N2 at 0-5 DC. Stirring 
was continued overnight as the reaction mixture was allowed to warm to rt. The 
reaction mixture was then washed with H20 (lOmL), and the aqueous phase extracted 
with CH2Cb. The organics were combined and washed with 10% aqueous HCI and 
then worked up in the normal manner to give a brown residue which was purified by 
flash Si02 chromatography, eluting with 7: 13 EtOAc/petroleum ether to give 5.15 as a 
brown residue (20mg, 12%): IR (CDCI3) umax 1732.0 and 1683.7 (C=O) cm- I ; IH 
NMR (CDC13) 01.21 (s, 6H, 2xCH3), 2.67 (s, 2xCH2C(O), 4.70 (s, 2H, OCH2Ph), 7.07 
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(d, 2H, J= 7.8Hz, ArH), 7.45 (d, 2H, J= 8.3Hz, ArH); 13CNMR (CDCb) 827.7,29.3, 
46.5,64.7, 127.7, 128.4, 134.1, 141.4, 172.0; HRMS (+EI) ca1cd. 247.1209, found 
247.1208. 
4-Phenyl-N -[ (4-hydroxyrnethyI}phenyl]glutarimide (5.16) 
Aniline 5.8 (108mg, 0.89mmol), HOBt (214mg, 1.6mmol, 2.2 equiv.) and Et3N 
(502mL, 364mg, 3.6mmol, 5 equiv.) were added in succession to a solution of 3-
phenyl glutaric acid (150mg, 0.72mmol) in CH2C12 (lOmL) stirring under N2 at 0-5 DC. 
EDAC (288mg, 1.5 mmol, 2.08 equiv.) was added to the above solution and stirring 
was continued overnight whilethe reaction solution was allowed to come to rt. The 
reaction solution was washed with H20 and 2N HCI and the organic phase worked up 
in the normal manner to give crude 5.16 as an orange solid (l38mg, 64% mass 
recovery): mp 68 DC (EtOAc/petroleum ether); IR (CDCl}) 'Umax 1735.8 and 1687.6 
(C=O); IH NMR (CDCl}) 83.00 (dd, 2H, J = 11.0, 16.6Hz, CH2C(O)), 3.16 (dd, 2H, J 
4.4, 17.1Hz, CH2C(O)), 3.53-3.61 (m, lH, CH), 4.74 (s, 2H, CH20H), 7.10 (d, 2H, J 
= 8.3Hz, ArH), 7.23-7.49 (m, 7H, ArH); HRMS (+EI) calcd. 295.1209 found 295.1208. 
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Appendix 
DATA OBTAINED 
DETERMINATION 
SUCCINIMIDE (1.410) 
231 
FROM CRYSTAL STRUCTURE 
OF 3-BENZYL-N-[(ACETYL)OXY] 
05 
Figure A.l Labelled drawing of 1.410 
Atom X Y Z U(eq) 
01 7989(4) 692(4) 3430(2) 38 
02 6068(4) -837(4) 4275(2) 42 
05 9951(4) 2018(4) 4888(2) 46 
011 6554(5) 2638(4) 3261(3) 68 
N1 7958(8) 720(5) 4408(3) 30 
C1 7256(5) 1869(6) 2895(3) 36 
C2 6958(5) -100(5) 4766(3) 30 
C3 7260(5) 169(5) 5844(3) 29 
C4 8676(5) 960(5) 6054(3) 30 
C5 8985(5) 1356(5) 5089(3) 30 
C6 7182(6) -1234(5) 6415(3) 38 
C7 7376(5) -946(5) 7495(3) 31 
C8 6366(6) -227(5) 7880(3) 38 
C9 6556(7) 40(5) 8864(4) 47 
ClO 7720(11) -408(6) 9477(4) 45 
C11 8793(7) -1122(6) 9108(4) 49 
C12 8605(6) -1374(6) 8112(3) 40 
C13 7280(7) 1618(7) 1868(3) 53 
Table A.l Atomic coordinates [x 104] (standard deviation) and equivalent 
displacement parameters [A2 x 103] for 1.410. U(eq) is defined as one third of the trace 
of the orthogonalized Uij tensor. 
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01-N1 1.383(5) 01-C1 1.419(5) 
02-C2 1.202(5) 05-C5 1.201(5) 
011-C1 1.171(5) N1-C2 1.403(7) 
NI-C5 1.368(7) C1-C13 1.470(6) 
C2-C3 1.507(6) C3-C4 1.534(6) 
C3-C6 1.527(6) C4-C5 1.495(6) 
C6-C7 1.517(6) C7-C8 1.387(6) 
C7-C12 1.387(7) C8-C9 1.382(6) 
C9-ClO 1.344(10) ClO-C11 1.418(9) 
C1l-Cl2 1.396(7) 
Table A.2 Bond lengths for 1.410 
N1-01-C1 113.8(4) 01-NI-C2 120.2(5) 
01-N1-C5 123.0(6) C2-N1-C5 116.1(4) 
01-C1-011 120.0(4) 01-C1-CI3 107.2(4) 
011-C1-C13 130.8(5) 02-C2-Nl 124.6(5) 
02-C2-C3 130.0(5) N1-C2-C3 105.4( 4) 
C2-C3-C4 104.9(3) C2-C3-C6 111.8(4) 
C4-C3-C6 115.8(4) C3-C4-C5 106.1(3) 
05-C5-N1 123.2(5) 05-C5-C4 130.4(4) 
N1-C5-C4 106.3(4) C3-C6-C7 111.8(4) 
C6-C7-C8 121.4(5) C6-C7-CI2 119.7(5) 
C8-C7-CI2 118.9(4) C7-C8-C9 121.0(5) 
C8-C9-ClO 121.0(6) C9-ClO-C11 119.6(5) 
C lO-C 11-C 12 119.2(6) C7-C12-C11 120.3(5) 
Table A.3 Bond Angles [0] (standard deviation) for 1.410 
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Atom Ull U22 U33 U23 U13 U12 
01 45(2) 49(2) 23(2) 4(1) 11(2) 10(2) 
02 36(2) 51(2) 39(2) -9(2) 5(2) -9(2) 
05 45(2) 51(2) 44(2) -2(2) 18(20 -10(2) 
011 92(4) 63(2) 49(2) 10(2) 13(2) 22(3) 
Nl 28(3) 40(3) 23(2) 1(2) 9(2) -6(3) 
C1 41(3) 50(3) 17(2) 4(2) 7(2) 23(3) 
C2 26(3) 29(3) 40(3) 2(2) 14(2) 1(2) 
C3 33(3) 31(2) 28(2) -4(2) 14(2) 2(2) 
C4 33(3) 30(2) 27(2) -4(2) 5(2) 5(2) 
C5 32(3) 28(2) 31(2) -2(2) 8(2) 3(2) 
C6 50(4) 28(3) 38(3) -1(2) 17(3) -6(2) 
C7 41(3) 27(2) 27(2) 5(2) 9(2) -3(2) 
C8 46(3) 30(3) 40(3) 4(2) 12(2) 1(2) 
C9 72(4) 32(3) 41(30 -3(2) 23(3) -1(3) 
ClO 75(8) 34(3) 28(3) -7(2) 14(4) -8(4) 
Cll 52(4) 43(3) 44(3) 7(3) -9(3) -13(3) 
C12 42(3) 38(3) 40(3) -2(2) 7(2) 1(3) 
C13 57(4) 68(4) 36(3) 14(3) 15(3) 3(4) 
Table A.4 Anisotropic displacement parameters [A.2 x 103] for 1.410. The anisotropic 
displacement factor exponent takes the form: -27t2 [(ha*)2U 11 + ... + 2hka*b*U 12] 
Atom X Y Z U(eq) 
H3 6548 842 5989 35 
H4A 8625 1829 6438 36 
H4B 9401 327 6406 36 
H6A 7902 -1903 6299 45 
H6B 6279 -1694 6187 45 
H8 5546 80 7470 46 
H9 5868 538 9105 56 
HlO 7821 -251 10140 54 
Hll 9611 -1419 9524 59 
H12 9307 -1830 7861 48 
H13A 8015 2187 1689 79 
H13B 6396 1900 1476 79 
H13C 7444 602 1767 79 
Table A.S Hydrogen coordinates [x 104] and isotropic displacement parameters [A2 x 
103] for 1.410 
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CRYSTAL STRUCTURE DETERMINATION OF 3-PHENYL-N-
[(ACETYL)OXY]SUCCINIMIDE (1.41p) 
Figure A.2 Labelled drawing of 1.41p showing 50% thermal ellipsoid probability for 
non-hydrogen atoms, with hydrogens as small spheres of arbitrary size 
Single-crystal data collection was performed at 293K on a Siemens P4 diffractometer 
using graphite-monochromatised Mo-Ka radiation (A = 0.71073A). The crystal used 
was a rectangular prism with dimensions 0.23 x 0.30 x 0.63 mm. Compound 3 
C12HIIN04 (Mr = 233.22) crystallised from diethyl ether-petroleum ether in the 
monoclinic system, space group C2/c, a = 19.542(3), b = 5.7830(10), c = 20.626(4) A, 
R 0 3 . -3 
a = y = 90°, f-' = 107.570(10)°, V = 2222.2(7) A, Z = 8, Deale = 1.394 Mg m . 
Absorption coefficient 0.106mm-J , 8 range for data collection 2.07 - 24.99, index 
ranges -22 ~ h ~ 8, 0 ~ k ~ 6, -24 ~ I ~ 23, data/restraints/parameters 194610/155, 
goodness of fit on F was 0.817, final R indices [1>20'(1)] RJ = 0.0404, WR2 = 0.0752, 
R indices (all data) RJ = 0.0853, wR2 = 0.0845, largest difference peak and hole 0.187 
and -0. 16gek3. 
The unit cell parameters were obtained by least-squares refinement of the setting 
angles of 42 reflections with 6.894° ~ 28 ~ 24.910° from a Siemens P4 diffractometer. 
A unique data set was measured at 293K within 28max = 57° limit (Omega scans). Of 
the 2908 reflections obtained, 1946 were unique (Rint = 0.0473) and were used in the 
full-matrix least-squares refinement.A.l The intensities of 3 standard reflections, 
measured every 97 relections throughout the data collection, showed only 1.55% decay. 
The structure was solved by direct methods.A.2 Hydrogen atoms were fixed in idealised 
positions. All non-hydrogen atoms were refined with anisotropic atomic displacement 
parameters. Neutral scattering factors and anomalous dispersion corrections for non-
hydrogen atoms were taken from Thers and Hamilton.A.3 
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Atom X Y Z U(ea) 
01 613(1) 7595(3) 4080(1) 43(1) 
02 248(1) 7382(3) 5279(1) 40(1) 
05 1992(1) 5656(3) 4316(1) 37(1) 
011 1230(1) 10772(3) 4552(1) 43(1) 
Nl 1011(1) 6460(4) 4665(1) 30(1) 
Cl 774(1) 9944(4) 4099(1) 30(1) 
C2. 772(1) 6399(4) 5228(1) 31(1) 
C3 1290(1) 4806(4) 5728(1) 30(1) 
C4 1951(1) 4712(4) 5463(1) 29(1) 
C5 1689(1) 5608(4) 4745(1) 29(1) 
C6 1426(1) 5593(4) 6459(1) 25(1) 
C7 1750(1) 7667(4) 6683(1) 32(1) 
C8 1867(1 ) 8363(4) 7343(1) 34(1) 
C9 1665(1) 6950(5) 7793(1) 36(1) 
CI0 1331(1) 4880(5) 7581(1) 39(1) 
Cll 1208(1) 4198(5) 6905(1) 34(1) 
C12 289(1) 11080(5) 3487(1) 40(1) 
Table A.6 Atomic coordinates [x 104] and equivalent isotropic displacement 
parameters [A2 x 103] for 1.41 p. U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor. 
01l-C1 1.180(3) 01-N1 1.388(2) 
01-Cl 1.393(3) 05-C5 1.205(3) 
02-C2 1.203(3) NI-C2 1.376(3) 
N1-C2 1.377(3) CI2-Cl 1.483(3) 
C5-C4 1.505(3) C4-C3 1.548(3) 
C3-C6 1.520(3) C3-C2 1.520(3) 
C6-C7 1.370(3) C6-C11 1.384(3) 
Cll-CI0 1.398(3) ClO-C9 1.371(4) 
C9-C8 1.379(3) C8-C7 1.372(3) 
Table A.7 Selected bond lengths [A] for 1.41p 
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N1-01-C1 112.0(2) C2-NI-C5 116.7(2) 
C2-N1-01 120.1(2) C5-N1-01 122.6(2) 
01l-Cl-01 121.9(2) 011-CI-C12 129.0(2) 
01C1-C12 109.1(2) 05-C5-N1 124.9(2) 
05-C5-C4 129.4(2) Nl-C5-C4 105.6(2) 
C5-C4-C3 105.3(2) C6-C3-C2 111.9(2) 
C6-C3-C4 116.5(2) C2-C3-C4 103.8(2) 
02-C2-N1 125.2(2) 02-C2-C3 129.6(2) 
N1-C2-C3 105.2(2) C7-C6-C11 119.3(2) 
C7-C6-C3 121.4(2) C11-C6-C3 119.2(2) 
C6-Cll-ClO 120.3(3) C9-C10-C11 119.1(3) 
C10-C9-C8 120.6(2) C7-C8-C9 119.8(2) 
C6-C7-C8 120.9(2) 
Table A.S Selected bond angles [0] for 1.41p 
Atom Uu U22 U33 U23 UB U12 
01 38(1) 33(1) 25(1) 1(1) 0(1) -3(1) 
02 29(1) 54(1) 38(1) 4(1) 11(1) 8(1) 
05 30(1) 23(2) 34(1) -6(1) 19(1) -5(1) 
011 35(1) 35(1) 54(1) -5(1) 3(1) -5(1) 
N1 29(1) 33(1) 25(1) 5(1) 6(1) 3(1) 
C1 29(1) 33(2) 31(1) 0(1) 13(1) -2(1) 
C2 23(1) 34(2) 33(1) -3(1) 7(1) -3(1) 
C3 31(1) 27(2) 31(1) 2(1) 9(1) -1(1) 
C4 28(1) 32(2) 30(1) -4(1) 8(1) 1(1) 
C5 30(1) 23(2) 34(1) -8(1) 7(1) -5(1) 
C6 22(1) 28(1) 24(1) 4(1) 5(1) 6(1) 
C7 30(1) 33(2) 34(1) 3(1) 10(1) -2(12) 
C8 30(2) 32(2) 39(2) -3(1) 7(1) 1(1) 
C9 31(2) 49(2) 2791) -2(1) 10(1) 7(1) 
ClO 36(2) 48(2) 3692) 10(1) 16(1) 1(2) 
Cl1 30(2) 32(2) 39(2) -3(1) 7(1) 1(1) 
C12 30(1) 33(2) 34(1) 3(1) 10(1) -2(1) 
Table A.9 Anisotropic displacement parameters [A2 x 103] for 1.41p. The anisotropic 
displacement factor exponent takes the form: -2n2 [ (ha*)2U 11 + ... + 2hka*b*U 12] 
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Atom X Y Z U(eq) 
H3 1076(1) 3258(4) 5682(1) 36 
H4A 2336(1) 5676(4) 5739(1) 36 
H4B 2126(1) 3139(4) 5472(1) 36 
H7 1893(1) 8615(4) 6384(1) 39 
H8 2081(1) 9785(4) 7488(1) 41 
H9 1757(1) 7406(5) 8243(1) 43 
HlO 1187(1) 3942(5) 7882(1) 47 
Hll 979(1) 2800(5) 6755(1) 41 
H12A -191(2) 11087(22) 3517(4) 48 
H12B 301(6) 10247(14) 3088(1) 48 
H12C 445(5) 12642(9) 3460(4) 48 
Table A.10 Hydrogen coordinates [x 104] and isotropic displacement parameters 
(Axl03) for 1.41p 
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DATA OBTAINED FROM CRYSTAL STRUCTURE 
DETERMINATION OF 3-BENZYL-N-[(TRANS-CINNAMOYL) 
OXY]SUCCINIMIDE (1.41£1) 
Figure A.3 Labelled drawing of 1.41q 
Atom X Y Z U(eq) 
01 1608(1) 5045(6) 1(1) 50 
02 1982(1) 5138(7) 1255(1) 59 
05 1876(1) 908(6) -377(1) 57 
011 818(1) 3915(6) 129(1) 57 
N1 1857(1) 3276(7) 370(1) 47 
C1 1032(2) 5266(9) -92(2) 41 
C2 2051(2) 3518(10) 991(2) 51 
C3 2362(2) 1383(8) 1241(2) 51 
C4 2339(2) -29(9) 687(2) 48 
C5 2003(2) 1344(9) 149(2) 46 
C6 2939(2) 1941(9) 1672(2) 61 
C7 3293(2) -24(9) 1941(2) 47 
C8 3202(2 1411(10) 2359(2) 61 
C9 3533(2) -3173(10) 2604(2) 48 
C10 3991(2) -3693(8) 2437(2) 54 
C11 4084(2) 2286(9) 2022(2) 60 
C12 3746(2) -5639(10) 1774(2) 57 
C13 822(2) 7236(8) 445(2) 42 
C14 302(2) 7865(9) 556(2) 49 
C15 36(2) 9834(8) -892(2) 41 
Table A.ll Atomic coordinates [x 104] (standard deviation) and equivalent isotropic 
displacement parameters [A2 x 103] for 1.41q. U(eq) is defined as one third of the trace 
of the orthogonalized Uij tensor. 
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Atom X Y Z U(eq) 
C16 271(2) 11210(8) -1211(2) 48 
C17 -9(2) 13023(9) 1523(2) 58 
C18 539(2) 13536(9) -1522(2) 62 
C19 -766(2) 12219(10) -1211(2) 60 
C20 -504(2) 10388(9) -904(2) 51 
Table A.ll (cont.) Atomic coordinates [x 1()4] (standard deviation) and equivalent 
isotropic displacement parameters [A2 x 103] for 1.41q. U(eq) is defined as one third of 
the trace of the orthogonalized Uij tensor. 
Ol-N1 1.380(4) Ol-C1 1.419(5) 
02-C2 1.201(6) 05-C5 1.204(5) 
011-C1 1.198(5) N1-C2 1.388(6) 
N1-C5 1.376(6) C1-C13 1.436(6) 
C2-C3 1.513(7) C3-C4 1.549(6) 
C3-C6 1.508(6) C4-C5 1.508(6) 
C6-C7 1.485(7) C7-C8 1.376(6) 
C7-C12 1.392(6) C8-C9 1.349(7) 
C9-C10 1.399(6) ClO-Cll 1.381(6) 
Cll-C12 1.342(7) C13-C14 1.320(5) 
C14-C15 1.451(6) C15-C16 1.391(6) 
C15-C20 1.413(6) C16-C17 1.365(6) 
C17-C18 1.392(6) C18-C19 ] .347(7) 
C19-C20 1.357(7) 
Table A.12 Bond lengths [A] (standard deviation) for 1.41q 
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N1-01-C1 113.0(3) 01-N1-C2 121.9(3) 
01-N1-C5 116.8(4) C2-NI-C5 120.5(4) 
01-C1-011 118.7(4) Ol-CI-C13 108.7(4) 
01l-CI-CI3 132.5(4) 02-C2-Nl 125.2(5) 
02-C2-C3 129.4(4) NI-C2-C3 105.7(4) 
C2-C3-C4 105.7(4) C2-C3-C6 109.4(4) 
C4-C3-C6 115.5(4) C3-C4-C5 105.2(4) 
05-C5-Nl 124.7(5) 05-C5-C4 128.8(5) 
NI-C5-C4 106.5(4) C3-C6-C7 114.8(5) 
C6-C7-C8 123.7 C6-C7-CI2 120.3(4) 
C8-C7-CI2 115.9(4) C7-C8-C9 122.8(4) 
C8-C9-ClO 120.9(4) C9-CIO-Cl1 116.2(4) 
ClO-C11-C12 122.3(4) C7-C12-C11 121.8(5) 
C1-CI3-C14 119.6(4) C13-C14-C16 125.8(5) 
C14-C15-C16 125.0(4) C14-CI5-C20 117.7(4) 
CI6-CI5-C20 117.3(4) CI5-CI6-CI7 121.5(4) 
C16-C17-CI9 119.9(5) CI7-C18-C19 118.9(5) 
C 18-C 19-C20 122.7(5) C 15-C20-C 19 119.7(5) 
Table A.13 Bond Angles [0] (standard deviation) for 1.41q 
Atom Ul1 U22 U33 U23 U13 U12 
01 3292) 71(3) 49(2) 22(2) 16(1) 6(2) 
02 59(2) 69(3) 52(2) 3(2) 24(2) 15(2) 
05 51(2) 82(3) 39(2) -1(2) 16(1) -13(2) 
011 43(2) 75(3) 56(2) 11(2) 21(2) -3(2) 
N1 37(3) 68(3) 36(2) 13(2) 1492) 10(2) 
C1 37(3) 53(3) 34(2) 0(2) 13(2) -8(2) 
C2 35(3 78(4) 44(3) 2(3) 18(2) 2(3) 
C3 44(3) 58(4) 49(3) 9(2) 15(2) 4(3) 
C4 45(3) 55(3) 43(2) 1(2) 14(2) -0(2) 
C5 29(3) 65(4) 47(3) -2(3) 19(2) -11(2) 
C6 28(3) 63(4) 37(2) 3(2) 10(2) -4(2) 
C7 39(3) 63(4) 32(2) 1(2) 5(2) 7(3) 
C8 33(3) 105(5) 45(3) 12(3) 14(2) 13(3) 
C9 49(3) 89(5) 51(3) 22(3) 15(2) -6(3) 
Table A.14 Anisotropic displacement parameters [A2 x 103] for 1.41q. The anisotropic 
displacement factor exponent takes the form: -2n2 [(ha*)2U 11 + ... + 2hka*b*U 12] 
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Atom U11 U22 U33 U23 U13 U12 
ClO 53(3) 50(3) 49(3) 5(3) 7(2) 9(3) 
C11 50(3) 79(4) 56(3) 8(3) 25(3) 17(3) 
C12 49(3) 81(4) 44(3) 98(3) 20(2) 10(3) 
C13 28(3) 63(4) 37(2) 3(2) 10(2) -4(2) 
C14 41(3) 72(4) 35(2) -5(2) 15(2) -7(3) 
C15 49(3) 36(3) 30(2) -3(2) 4(2) 1(2) 
C16 40(3) 56(4) 45(3) 2(3) 10(2) -4(3) 
C17 50(3) 55(4) 60(3) 12(3) 7(2) -6(3) 
C18 58(4) 48(4) 59(3) 0(3) -4(3) 5(3) 
C19 52(3) 67(4) 54(3) -15(3) 11(3) 13(3) 
C20 45(3) 69(4) 42(2) -1(3) 20(2) 3(3) 
Table A.14 (cont.) Anisotropic displacement parameters [A2 x 103] for 1.4Iq. The 
anisotropic displacement factor exponent takes the form: -2n2 [ (ha*)2U 11 + ... + 
2hka *b *U 12] 
Atom X Y Z U(eq) 
H3 2161 583 1462 61 
H4A 2712 -296 686 58 
H4B 2160 -1455 688 58 
H6A 3127 2832 1461 73 
H6B 2904 2851 1994 73 
H8 2900 -1121 2478 73 
H9 3456 -4054 2887 77 
HlO 4219 -4916 2596 65 
H11 4393 -2543 1911 72 
H12 3817 295 1483 68 
H13 1052 8063 -593 50 
H14 85 6967 -41 59 
H16 626 10888 -1212 58 
H17 155 13914 -1736 70 
H18 -732 14767 -1733 74 
H19 -1118 12581 -1207 72 
H2O 626 10888 -1212 58 
Table A.IS Hydrogen coordinates [x 104] and isotropic displacement parameters [A2 x 
103] for 1.4Iq 
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